Control of the EBV growth transformation programme: the importance of the Bamhi W repeats by Kao, Kuan-Yu
 1 
 
 
 
 
 
 
 
 
CONTROL OF THE EBV GROWTH TRANSFORMATION PROGRAMME:   
THE IMPORTANCE OF THE BAMHI W REPEATS 
 
 
 
 
 
 
 
by 
 
KUAN-YU KAO 
 
 
 
 
 
 
 
 
A thesis submitted to  
The University of Birmingham 
for the degree of  
DOCTOR OF PHILOSOPHY 
 
 
 
 
 
 
Cancer Research UK Institute for Cancer Studies 
Medical School 
Faculty of Medicine & Dentistry 
The University of Birmingham 
October 2010 
 
 
 
 
 
 
 
 
 
University of Birmingham Research Archive 
 
e-theses repository 
 
 
This unpublished thesis/dissertation is copyright of the author and/or third parties. 
The intellectual property rights of the author or third parties in respect of this work 
are as defined by The Copyright Designs and Patents Act 1988 or as modified by 
any successor legislation.   
 
Any use made of information contained in this thesis/dissertation must be in 
accordance with that legislation and must be properly acknowledged.  Further 
distribution or reproduction in any format is prohibited without the permission of 
the copyright holder.  
 
 
 
 2 
Abstract 
Epstein-Barr virus (EBV), a human gammaherpesvirus, possesses a unique set of latent 
genes whose constitutive expression in B cells leads to cell growth transformation. The 
initiation of this B-cell growth transformation programme depends on the activation of a 
viral promoter, Wp, present in each tandemly arrayed BamHI W repeat of the EBV genome. 
In order to examine the role of the BamHI W region in B cell infection and growth 
transformation, we constructed a series of recombinant EBVs carrying different numbers of 
BamHI W repeats and carried out B cell infection experiments. We concluded that EBV 
requires at least 2 copies of BamHI W repeats to be able to activate transcription and 
transformation in resting B cells in vitro. At least 5 copies of BamHI W were required for 
optimal transcription and transformation; while increasing the number beyond 5 copies had 
no further effect. Experiments to try to rescue the impaired virus indicated that the 
expression of sufficient levels of EBNA-LP and EBNA2 from Wp are the key determinants 
of virus-driven B cell transformation. We believe that EBV has evolved to contain multiple 
copies of BamHI W repeats to ensure high levels of Wp-initiated transcripts immediately 
post infection. 
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Chapter 1. Introduction 
 
1.1 Epstein-Barr virus (EBV) history 
EBV was discovered as a result of the pioneering work in the 1950s, by Denis Burkitt, a 
surgeon working in East Africa (Burkitt, 1958). Burkitt spent many years mapping the 
distribution of a fast-growing tumour which affected the jaws of young African children. 
This tumour was previously undescribed, but is now classified as a lymphoma. Burkitt 
noted that this tumour was most common in children living in areas where malaria was 
holoendemic and speculated that an infectious arthropod-borne agent may be involved in its 
etiology (Burkitt, 1962b, Burkitt, 1962a). A collaboration was set up between Burkitt and 
pathologist Tony Epstein, where BL biopsy samples were transported from Uganda to 
England.  Epstein and his PhD student, Yvonne Barr, established cell lines from the biopsy 
samples and, by electron microscopy, identified the presence of herpesvirus-like particles in 
some of the cells (Epstein et al., 1964, Epstein and Barr, 1964). The absence of biological 
activities associated with the then known human herpesviruses identified EBV as a new 
member of the herpesvirus family (Epstein et al., 1965, Henle and Henle, 1966b, Henle and 
Henle, 1966a). 
 
More than 95% of adults worldwide are infected with EBV (Henle et al., 1969, Henie et al., 
1974). In the majority of cases, a harmless life-long infection is established in the B cells, 
with periodic shedding of the virus into the saliva and then spread through saliva. 
Importantly EBV from BL cells was shown to transform resting B lymphocytes in vitro 
 18 
leading to the outgrowth of B lymphoblastoid cell lines (LCLs), thus establishing EBV as a 
B lymphotropic transforming virus (Henle et al., 1967).  
 
1.2 Classification of Herpesviruses 
Like other herperviruses, EBV has a toroid-shaped protein core wrapped with a 184 
kilobase pair linear, double-stranded DNA, encased by a nucleocapsid with 162 capsomers, 
a protein tegument between the nucleocapsid and the envelope, and an outer envelope with 
external glycoprotein spikes (Epstein et al., 1965, Pope et al., 1968). EBV (also named as 
HHV4) is a member of the Herpesviridae. There are three sub-families of the 
Herpesviridae, -alpha, beta and gamma herpesviruses, which were originally classified by 
their biologic properties, such as host range, duration of reproduction cycle, cytopathology 
and characteristics of latent infection. This classification has now been amended on the 
basis of genome organisation and homology. 
Alphaherpesvirinae 
The members of this subfamily were classified on the basis of a variable host range, 
relatively short reproductive cycle, rapid spread in culture, efficient destruction of infected 
cells, and the capacity to establish primarily latent infections. The subfamily contains the 
genera Simplexvirus (prototype: HSV-1), Varicellovirus (prototype: VZV), Mardivirus 
(prototype: GaHV-2), and Iltovirus (prototype: GaHV-1). Simplexviruses and 
Varicelloviruses have mammalian hosts, and GaHV-1 and GaHV-2 have avian hosts.  
Betaherpesvirinae 
Unlike Alphaherpesvirinae, the characteristics of the members of this family are a restricted 
host range; all the members of this family are restricted to mammalian hosts. The 
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reproductive cycle is long and the infection progresses slowly in culture. The virus can be 
maintained in latent form in secretory glands, lymphoreticular cells, kidneys and other 
tissues. This subfamily contains the genera Cytomegalovirus (prototype: HCMV), 
Muromegalovirus (prototype: MCMV), Roseolovirus (prototype: HHV-6), and the 
proposed Proboscivirus (prototype: EIHV-1). 
Gammaherpesvirinae 
The experimental host range of the members of the subfamily Gammaherpesvirinae is 
limited to the family or order to which the natural host belongs. Most of these viruses are 
characterised by the establishment of lifelong infection in their host, association with 
cellular transformation and the development of malignancies (Simas and Efstathiou, 1998). 
In vitro, all members replicate in lymphocytes, and some also cause lytic infections in some 
types of epitheloid and fibroblastic cells. Viruses in this group are usually specific for either 
T or B lymphocytes. Members of the Gammaherpesvirinae subfamily are divided into two 
genera: gamma-1 herpesviruses, or Lymphocryptovirus (LCV) which are B-lymphotropic 
viruses, e.g., Epstein-Barr virus and genetically related viruses of old world primates, and 
the gamma-2 herpes viruses, or rhadinoviruses (RVs), e.g., herpes virus saimiri (HVS) of 
new world monkeys and HHV-8 of humans (Simas and Efstathiou, 1998).  Many old world 
and some new world primate species have endemic LCV, in contrast, RVs are endemic not 
only in most primate species but also in some subprimate mammalian species, for example, 
MHV68 and related viruses of wild mice (Kieff and Rickinson, 2007). EBV is the only 
human LCV, and Kaposi’s sarcoma associated herpesvirus (KSHV/HHV8) is the only 
human RV. 
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1.3 Herpesviruses genomes 
Herpesviruses genomes can be divided into six groups, A-F (Figure 1.1.) The class A 
genome consists of a unique sequence flanked by terminal repeats (TR). It is represented 
among Betaherpesvirinae (HHV6 and HHV7) and one member of the 
Gammaherpesvirinae (EHV2). Class B genomes have directly repeated (DR) sequences at 
the termini, but these consist of variable copy numbers of a tandemly repeated sequence of 
0.8-2.3 kbp. This arrangement characterises most Gammaherpesvirinae in the Rhadinovirus 
genus, such as HVS and HHV8. Group C genomes, exemplified by EBV represent another 
derivative of class B, in which an internal set of direct repeat is present but is unrelated to 
the terminal set.  Class D genomes, exemplified by VZV contain two unique regions (UL 
and US), one internal repeat region (IR) and one terminal repeat (TR). In Class E, 
exemplified by HSV1, sequences from both termini are repeated in an inverted orientation 
and juxtaposed internally dividing the genomes into two components, each of which 
consists of unique sequences flanked by inverted repeats. In Class F exemplified by tupaia 
herpesvirus, the terminal sequences are not identical and are not repeated either directly or 
in an inverted orientation.  
 
1.4 The EBV genome 
EBV was the first herpesvirus to have its complete genome cloned and sequenced 
(Dambaugh et al., 1980, Arrand et al., 1981, Baer et al., 1984). This was done using BamHI 
restriction fragments from the B95.8 EBV strain, derived from an infectious mononucleosis 
(IM) patient isolate and passaged in marmoset B cells in vitro. Figure 1.2 shows a 
schematic of the circular EBV genome. Open reading frames (ORFs) are named relative to 
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the BamHI fragment, direction of transcription and position relative to other ORFs. 
Promoters are also named according to their location in a particular BamHI fragment. For 
example, BHRF1 is the first rightward ORF located on the BamHI H fragment and Wp is 
the promoter in the BamHI W fragment.  
 
EBV contains several repeat regions within its genome. The terminal repeats (TRs) are 
tandem, 500kb direct repeats of the same sequence at both termini of the linear genome, 
which mediate circularisation of the viral DNA into episomes (Kintner and Sugden, 1979). 
The precise number of TRs is determined during virus replication and this provides a useful 
indicator of cell clonality, as latently infected progeny cells will retain the same number of 
TRs as the parental cells (Raab-Traub and Flynn, 1986). The large internal repeat 1 (IR1) 
within the EBV genome comprises 3 to 12 tandem reiterations of a 3kb, direct repeat, 
which comprises numerous repeats of a 3072bp BamHI W region containing one of the 
EBNA promoters, Wp. The number of BamHI W repeats, and therefore the number of Wp 
copies, also varies between EBV strains. 
 
All EBV strains have essentially the same genome organisation and most parts of the 
genomes are highly conserved. However, there are two EBV types circulating in most 
populations, type 1 and type 2, reflecting linked polymorphisms in the latent genes 
encoding EBV nuclear antigens (EBNAs)-LP, 2, 3A, 3B and 3C (Sixbey et al., 1989, 
Sample et al., 1990). Epidemiologically, type 1 strains are far more common in most 
populations but in equatorial Africa and New Guinea, type 2 appears to be more prevalent 
although type 1 strains are still in the majority.  
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1.5 In vivo EBV infection 
1.5.1 Primary infection 
EBV is naturally transmitted via the salivary route and infection results in life-long EBV 
persistence. Primary EBV infection usually occurs asymptomatically during early 
childhood (Henle and Henle, 1970). However, if infection is delayed until adolescence, as 
is often the case in the Western world, a self-limiting lymphoproliferative disease termed 
infectious mononucleosis (IM) can ensue (Henle et al., 1968). Symptoms can range from 
mild transient fever to several weeks of pharyngitis, lymphodenopathy and general malaise, 
which are mainly caused by the activation and proliferation of the host CD8+ T cells in 
response to viral infection.  
 
1.5.2 Lytic infection at Oropharyngeal sites 
Figure 1.3 outlines the sites of EBV infection and the type of infection (latent or lytic) 
established within each cell population. Primary infection normally takes place in the 
muscosal tissues of the oropharynx, but the initial target cell for infection, either an 
epithelial cell or a B cell, is still not clear. One theory suggests that EBV first infects 
oropharyngeal epithelial cells, which then undergo lytic cycle to generate virions which can 
infect B cells. Certainly high levels of infectious virus have been detected in throat washing 
of IM patients (Gerber et al., 1972, Yao et al., 1985) and the presence of the virus has been 
reported in desquamated oropharyngeal epithelial cells of such patients (Sixbey et al., 1984). 
In addition, a recent report described the presence of EBV DNA, mRNA and protein in a 
small subset of tonsillar epithelial cells from healthy, EBV-positive donors (Pegtel et al., 
2004). Oral hairy leukoplakia in immunocompromised patients is characterised by 
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productive EBV replication within the upper-layer epithelial cells undergoing terminal 
differentiation, apoptosis and desquamation, strongly suggesting that EBV replication in 
vivo is dependent upon the differentiation state of the epithelial cells (Becker et al., 1991, 
Walling et al., 2004). In addition, EBV replication has been reported in normal tongue 
epithelium, suggesting the tongue may be a source of EBV secreted into saliva (Walling et 
al., 2001).  Alternatively, it is suggested that B cells may be directly infected, and crypt 
structures in the tonsil formed by invaginations of the tonsillar lymphoepithelium might 
allow direct access of EBV-containing saliva to B cells in lymphoid tissue below (Perry et 
al., 1988). Thus patients with B-cell-deficient, X-linked agammaglobulinemia show no 
evidence of even transient EBV infection in the throat implying that acquisition of EBV by 
the naïve host depends on initial B-cell infection (Faulkner et al., 1999). A recent finding 
that epithelial cell infection is rendered more than 1000 times more efficient if the virus is 
first bound to the surface of a resting B cell (Shannon-Lowe et al., 2006), suggests EBV 
might access epithelium not through an intermediate round of replication in B cells but 
through binding to the resting B cell surface and using this surface as a transfer vehicle. 
Therefore binding of orally transmitted EBV to B cells within the lymphoepithelium of the 
oropharynx may be important for EBV entry into permissive epithelium.  
 
1.5.3 Latent infection: Colonization of the B cell system 
Orally transmitted virus establishes replicative foci within the oropharynx, and at the same 
time, the virus begins to colonise the B cell system. However, the events involved in virus 
colonisation of the B cell system during primary infection are still poorly understood. Viral 
transcripts associated with growth transformation are detectable in peripheral blood 
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mononuclear cells (PBMCs) and tonsils of infectious mononucleosis (IM) patients, 
indicating that primary infection is associated with a transient virus-driven expansion of the 
infected B-cell pool through a growth transforming programme (Tierney et al., 1994, 
Niedobitek et al., 1997a). 
 
The human circulating B-cell pool contains 3 main populations: (1) antigen-inexperienced 
naïve cells (IgD+CD27-), (2) isotype-switched memory cells (IgD-CD27+), and (3) 
nonswitched memory cells (IgD+CD27+). In the blood of healthy virus carriers and IM 
patients, EBV-infected cells were found to be sequestered in the IgD- and in the 
CD27+fractions, consistent with selective colonization of the IgD-CD27+ memory cells 
(Hochberg et al., 2004b, Babcock et al., 1998, Joseph et al., 2000).   
 
This has given rise to a model for EBV colonization of the B-cell pool in which virus first 
targets naïve B cells as a growth-transforming infection (Latency III, see later) that, 
mimicking antigen stimulation, drives these cells down the physiologic, GC-dependent 
route into memory. In GC B cells, a more restricted EBV gene expression pattern is 
detected (Latency II, see later), in which only EBNA1, LMP1 and LMP2A proteins are 
expressed. The clonal expansion in the germinal centre increases the size of the pool of 
EBV-infected B cells. These GC B cells will then differentiate into resting memory B cells, 
which are the long-term reservoir of EBV. In this process, antigen activates B cells to 
become blasts that enter primary follicles, proliferate, and alter their Ig genes through 
isotype switching and hypermutation (Thorley-Lawson, 2001). As memory B cells are 
resting and long-lived, EBV can persist in these cells for a long time without needing to 
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express any viral genes (Latency 0). This allows virus to persist in memory B cells as an 
immunologically silent infection in the face of the host T cell response. Limiting dilution 
RT-PCR analysis for study at the single-cell level has shown that more than 90% of EBV-
infected resting memory cells express no protein-coding latent gene transcripts whatsoever, 
and that the genome maintenance protein EBNA1 is occasionally detected, presumably to 
preserve the EBV episome when the cells divide as part of the normal physiologic turnover 
of memory B cells (Hochberg et al., 2004a). 
 
Although the above model is supported by numerous studies, there are some arguments. In 
vitro, naïve and memory B cells are equally susceptible to EBV infection (Ehlin-
Henriksson et al., 2003) and also in acute IM patients, EBV-infected B cells in tonsillar 
tissue are almost all in exrafollicular areas and are rarely detected in GCs. A different 
model of B-cell colonization, envisaging a GC-independent route into memory, is based 
largely on evidence from IM tonsil sections (Kuppers, 2003). There the EBV-infected cells 
population in extrafollicular areas is dominated by clones with stable memory Ig genotypes 
without ongoing hypermutation (Anagnostopoulos et al., 1995, Niedobitek et al., 1997a, 
Kurth et al., 2000). This model proposes that, instead of infecting naïve B cells, EBV can 
directly infect memory B cells during infectious mononucleosis in the oropharynx. 
Recently, Chaganti and colleagues have showed that EBV was detectable in the 
nonswitched memory pool both in IM patients undergoing primary infection and in most 
long-term virus carriers by qPCR. In IM tonsillar cells, viral loads were concentrated in B 
cells with the CD38 marker of GC origin but lacking the other GC markers, CD10 and 
CD77 (Chaganti et al., 2008). These findings suggest that EBV infection in IM tonsils 
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involves extrafollicular B cells expressing CD38 as an activation antigen and not as a 
marker of ectopic GC activity.  
 
Virus replication in the oropharynx and virus–driven proliferation and expansion of the B 
cell pool initiate a T cell response and EBV-specific CD8+ CTLs are induced into rapid 
proliferation. Despite the strong CTL response, the virus establishes a lifelong persistence 
and remains detectable at very low levels both as infectious virus in throat washings and as 
a latent infection (largely latency 0, see later) in the B cell pool (Yao et al., 1985, Miller et 
al., 1973, Nilsson et al., 1971). 
 
1.5.4 T cell responses to EBV 
The immune response to EBV in acute IM patients represents one of the extreme examples 
of a highly activated response to a virus. The ability to follow acute EBV disease in IM 
patients alongside chronic infection in healthy carriers has allowed in-depth study of the T 
cell response to EBV infection (Hislop and Sabbah, 2008). The most important feature of 
the immune response in IM patients is the dramatic expansion of CD8+ T cells seen in the 
peripheral circulation, where up to 80% of the PBMC are CD8+ T cells. These expanded 
CD8+ populations are specific for both latent and lytic cycle antigens. Although lytic-
specific CD8+ T cells have been shown to dominate the population, expanded CD8+ 
populations with latent specificities typically to EBNA3-derived epitope are also detectable 
(Callan et al., 1998, Catalina et al., 2001, Hislop et al., 2002, Hislop et al., 2005, Steven et 
al., 1996). Following the resolution of acute IM disease, there is a rapid contraction of the 
majority of the EBV-specific CD8+ T cell population (Catalina et al., 2001, Hislop et al., 
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2002, Hislop and Sabbah, 2008). A similar picture is seen when analyzing the specificity of 
EBV-specific CD8+ T cell memory responses in healthy donors, although the relative 
frequency of these T cells is generally much lower than seen in IM patients (Bihl et al., 
2006, Benninger-Doring et al., 1999, Saulquin et al., 2000).  
 
No CD4+ T cell expansion has been detected even during the early stages of EBV acute 
infection (Maini et al., 2000). However, EBV specific CD4+ T cell memory response are 
detectable in virus carriers. Responses to a wide range of latent and lytic proteins exist, but 
the frequencies are lower than CD8+ T cell’s.  
 
1.6 EBV associated malignancies 
1.6.1 Post-transplant lymphoproliferative disease (PTLD) (Latency III) 
Patients receiving organ or bone marrow transplantation are usually treated with 
immunosuppressive drugs to avoid graft rejection. The link between immunosuppressive 
therapy and lymphoma risk is now well documented from epidemiologic studies on large 
cohorts of transplant recipients (Craig et al., 1993) and immunosuppressed transplant 
patients have been shown to be at increased risk of developing a particular spectrum of 
EBV-associated B lymphoproliferative lesions/lymphomas termed PTLD (Penn, 1979).  
The association of EBV with PTLD is well recognised (Thomas et al., 1990). Patients 
developing PTLD tend to present with fever, lymphadenopathy or nonspecific symptoms 
and only occasionally, with acute systemic disease. Usually this disease arises within the 
first year after transplantation and presents as multifocal lesions within either lymphoid 
tissue, the central nervous system (CNS), the liver or the transplanted organ (Nalesnik, 
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1998). PTLD often derives from EBV-infected donor B cells present with the graft itself. 
Therefore, PTLD risk can be markedly reduced by protocols that also deplete the graft of B 
cells (Hale and Waldmann, 1998). In addition, measuring and monitoring increases in EBV 
loads in the PBMCs of transplant patients may serve as a useful diagnostic tool to predict 
the likelihood of PTLD onset (Savoie et al., 1994, Rooney et al., 1995, Bai et al., 1997, 
Rowe et al., 1997, Lucas et al., 1998, Kimura et al., 1999, Baldanti et al., 2000). Most early 
onset PTLD tumours display a broad pattern of EBV latent gene expression, with 
expression of EBNA1, EBNA2 and LMP1, consistent with in vivo outgrowth of EBV 
infected cells in the absence of CTL responses (Young et al., 1989, Thomas et al., 1990, 
Rea et al., 1994, Delecluse et al., 1995, Oudejans et al., 1995).  
 
There is therefore a strong parallel between viral gene expression in PTLD (Young et al., 
1989, Gratama et al., 1991) and that seen in in vitro infected LCLs. Indeed studies on LCLs 
have been the key to defining the growth transformation Latency III pattern of infection. As 
shown in Figure 1.4, latency III, infected cells express all six nuclear antigens, EBNAs 1, 2, 
-LP, 3A, 3B and 3C from Wp- or Cp-initiated transcripts and the membrane proteins LMPs 
1, 2A and 2B transcripts initiating from their own promoters. In addition, the most 
abundant EBV-encoded RNAs, the EBERs and the highly spliced Bam A rightward 
transcripts (Brooks et al., 1993) are also transcribed.  
 
These viral gene products cause the resting B lymphocytes to enter cycle and continuously 
proliferate. Most infected B cells enter the first round of cell DNA synthesis 48-72 hours 
post-infection (Alfieri et al., 1991, Moss et al., 1981, Moss et al., 1986). Such EBV infected 
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lymphoblasts in many ways are similar to lymphocytes proliferating in response to antigen, 
mitogen or IL4 in vitro; both show high level expression of activation and adhesion 
markers, secretion of immunoglobulin (Ig) and the acquisition of efficient antigen-
processing function (Wang et al., 1988, Wang et al., 1990a, Peng and Lundgren, 1992, 
Peng and Lundgren, 1993, Rowe et al., 1995). 
 
Other PTLDs clearly show a more restricted pattern of gene expression, with only EBNA1 
protein detectable (Delecluse et al., 1995, Oudejans et al., 1995). It is possible that this 
latter group of tumours, which tend on average to be later onset post-transplant, have 
acquired genetic abnormalities over time and are less reliant on EBV for growth 
transformation. 
 
1.6.2 Burkitt lymphoma (BL) (Latency I) 
Burkitt lymphoma (BL) occurs in three epidemiologically distinct forms, endemic, sporadic 
and AIDS-associated forms. Endemic BL was first described by Denis Burkitt as a sarcoma 
of the jaw (Burkitt, 1958). BL is the most common cancer of childhood in equatorial Africa 
and Papua New Guinea where malaria is holoendemic (Burkitt, 1962b, Pope et al., 1967). 
These tumours normally present in the jaw but can also arise in the orbit, central nervous 
system, ovaries and abdomen (Magrath, 1990). The endemic form of BL shows the 
strongest and most consistent association with EBV. In virtually, every tumour analyzed to 
date, all the malignant cells are EBV genome-positive and each tumour carries a 
monoclonal EBV episome (Magrath, 1990). The association between EBV and sporadic BL 
is less consistent. Sporadic BL is histologically identical to eBL occurs at a lower incidence 
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worldwide and in the west, only 15-20% of these tumours are EBV-positive (Magrath, 
1990).  A third form of BL has been recognised in human immunodeficiency virus -positive 
individuals (Carbone et al., 1998, Gaidano et al., 1998). AIDS-BL is identical histologically 
and has similar sites of presentation to the sporadic tumour but occurrs predominantly in 
adults and only around 30% of AIDS-BLs are EBV-positive.  
 
Irrespective of endemic/sporadic/AIDS classification and irrespective of EBV genome 
status, all BL presents with one of three reciprocal translocations involving chromosome 8 
at the c-myc locus at 8q24 and either the immunoglobulin heavy (IgH) chain locus on 
chromosome 14 (termed the “common” translocation seen in up to 80% tumours) or one of 
the light chain loci on chromosomes 2 or 22 (termed the “variant” translocations) (Dalla-
Favera et al., 1982, Magrath, 1990, Taub et al., 1982). Translocations of the c-myc gene 
release the gene from its usual regular controls and bring it under the control of the long-
range enhancer within Ig loci. This translocation likely occurs as an accident of Ig gene 
rearrangement during class switching in the germinal centre B cells (Goossens et al., 1998), 
and leads to unusually high and deregulated expression of c-myc protein. Myc proteins are 
transcription factors that regulate cell growth, differentiation and apoptosis. Deregulated c-
myc expression very likely contributes to the high rate of cell proliferation seen in BL 
tumours. To address the question whether c-myc activation might abrogate the requirement 
of EBNA2 and LMP function (both are essential for transformation of primary B cells by 
EBV in vitro), Polack and colleagues introduced an activated c-myc gene with a conditional 
EBNA2 gene in the virus genome in an LCL cell and showed that overexpression of c-myc 
is able to induce continuous B cell proliferation independently of EBNA2 and LMP1 and 
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give cells a BL phenotype (Polack et al., 1996). In addition to the translocations of the c-
myc locus, BL cells often show other genetic alterations which may contribute to BL 
pathogenesis (Lindstrom and Wiman, 2002). The majority of BL cell lines and 30% of BL 
tumours contain mutations within p53, often within the core domain, which affect the 
transcription activation function of p53 (Farrell et al., 1991, Gaidano et al., 1991, Vousden 
et al., 1993, Wiman et al., 1991).  
 
The ability to grow BL cell lines derived from biopsy material in vitro has provided useful 
tools for the study of EBV latency. In vitro most BL cell lines retain the original biopsy cell 
phenotype and grow as single cells expressing EBNA1 only (Latency I, see later). These 
BL cell lines have a completely different growth pattern and cellular phenotype to Latency 
III lymphoblastoid cell lines (LCL), in particular they lack expression of activation, 
adhesion markers (Gregory et al., 1988, Gregory et al., 1987) and many components of the 
HLA class I antigen processing pathway, which in vivo is used as a strategy to escape 
immune detection by CD8+ T cells (Frisan et al., 1996, Khanna et al., 1994, Masucci, 
1990). However, in later passage, some latency I lines spontaneously switch to a Latency 
III form of infection with full latent protein expression and the cells begin to grow in 
clumps as a result of expression of activation and adhesion marker (Gregory et al., 1990, 
Rowe et al., 1987). 
 
Latency I is a more restricted from of latency. As shown in Figure 1.4, in Latency I infected 
cells, Cp, Wp and the LMPs promoters remain silent and there is activation of an 
alternative promoter, Qp, located downstream in the BamHI Q fragment (Nonkwelo et al., 
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1996, Schaefer et al., 1995b). Qp-initiated transcription leads to the production of the a Q-
U-K spliced transcript encoding only EBNA1. In addition, the non-coding EBER RNAs 
and BARTs are also detectable in Latency I (Brooks et al., 1993, Rowe et al., 1987).  
 
Recently, a second form of restricted virus latency has been identified in a subset (~15%) of 
eBL in Africa (Kelly et al., 2002). In these BLs, Wp is the dominant promoter, Qp is silent 
and EBNA1, 3A, 3B, 3C and LP are all expressed in the absence of EBNA2 or the LMPs in 
a form of Latency termed Wp-restricted Latency (see Figure 1.4) The EBNA2 gene and the 
unique exons of EBNA-LP have been deleted in these cells and the absence of EBNA2 is 
thought to be the key determinant of the inactivity of Cp and LMP promoters.  
 
The mechanism of how EBV contributes to BL pathogenesis is still not fully understood. 
EBV may initially expand the population of cells at risk for translocation or increase the 
survival or proliferation of a translocation-positive clone. The most popular theory at 
present is that EBV may contribute to BL development by protecting the cells from 
apoptosis. EBV-positive and negative subclones of EBV-positive BL cell lines can be 
generated in vitro and used as a useful tool to study the influence of EBV on BL cell 
growth. In particular, the EBV-negative subclones can be reinfected with the virus in vitro 
(Shimizu et al., 1994) It was found that the presence of EBV is associated with improved 
growth in low serum, anchorage-independent growth in soft agar and tumourigenicity in 
nude mice (Shimizu et al., 1994). EBV-positive clones were also significantly more 
resistant to IFN-α-induced apoptosis (Nanbo et al., 2002). It was reported that transfecting 
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EBERs into the BL cell lines can confer apoptosis resistance (Nanbo et al., 2002, Takada 
and Nanbo, 2001).  
 
1.6.3 Hodgkin lymphoma (HL) (Latency II) 
Hodgkin lymphoma is a tumour with a malignant population of mononuclear Hodgkin and 
multinuclear Reed–Sternberg (H-RS) cells greatly outnumbered by a reactive non-
malignant cell infiltrate. Classical HL can be divided into four subtypes: nodular sclerosis 
(ns), mixed cellularity (mc), and rarer forms called lymphocyte-rich (lr) and lymphocyte-
depleted (ld). HL is seen worldwide and there are differences in age and subtype 
distribution. In Europe and the United States, HL shows a high peak in young adults 
dominated by ns-HL and mc-HL while ns-HL contributes to the lower disease incidence 
seen at other ages. Monoclonal EBV has been detected in H-RS cells and has been 
subsequently estimated to occur in 60-80% of mc and ld HL types, 20-40% of ns HL types, 
a fraction of lr HL cases but only rarely if ever in the pathogenetically distinct ld HL 
(Anagnostopoulos et al., 2000, Anagnostopoulos et al., 1989, Boiocchi et al., 1993, Weiss 
et al., 1989, Weiss et al., 1987). 
 
EBV present in H-RS cells consistently displays a Latency II pattern of gene expression 
(Deacon et al., 1993, Grasser et al., 1994, Herbst et al., 1991, Niedobitek et al., 1997b, 
Pallesen et al., 1991). As shown in Figure 1.4, in Latency II infected cells, Cp and Wp are 
silent, EBNA1 transcripts initiate from Qp, LMP1 and LMP2 transcripts initiate from their 
own promoters and in addition, the EBERs and BARTs are also transcribed (Brooks et al., 
1992, Brooks et al., 1993, Deacon et al., 1993, Kerr et al., 1992). Elevated levels of LMP1 
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and LMP2 suggest a significant pathogenic role for these proteins in the development of 
EBV positive HL. Studies show that LMP2A can mimic signalling through the BCR 
complex, leading to activation of the downstream PI3 Kinase /AKT and extracellular 
signal-regulated kinase (ERK) pathways (Cahir-McFarland et al., 2004). Therefore, 
LMP2A expression could promote survival of even surface Ig-negative GC cells by 
allowing them to bypass the requirement of high affinity antigen binding for selection into 
memory (Kuppers, 2002, Kuppers, 2003) and LMP1 signalling can in turn bypass the need 
for CD40 ligand mediated T cell help. Thus, EBV infection may play a critical role early in 
the pathogenesis of HL by allowing crippled GC cells to survive. In addition, it is possible 
that LMP1 and LMP2 proteins act to prevent apoptosis of crippled HL progenitor GC cells 
by mimicking cellular activation signals, delivered by CD40 and BCR pathways 
respectively, that are normally required to rescue GC cells into memory. 
 
The contribution of EBV to the pathogenesis of classical HL is yet to be fully understood. 
EBV is monoclonal in HR-S cells, implying that HL arises from a single EBV-positive 
precursor (Anagnostopoulos et al., 1989). One recent report about EBV’s role in HL 
pathogenesis showed that EBV infection of Hodgkin lymphoma cells results in the 
induction of autotaxin, a secreted tumour-associated factor with lysophospholipase-D 
activity. Up-regulation of autotaxin increased the generation of lysophosphatidic acid 
(Skandalos et al.) and led to the enhanced growth and survival of Hodgkin lymphoma cells, 
whereas specific down-regulation of autotaxin decreased LPA levels and reduced cell 
growth and viability (Baumforth et al., 2005). 
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1.6.4 Other EBV-associated malignancies 
Nasopharyngeal carcinoma (Latency I/II) 
Nasopharyngeal carcinoma (NPC) is a tumour of epithelial origin that occurs with 
extremely high incidence in China and Southeast Asia, up to 100 times higher than in 
Western countries. In all these high incidence areas, most tumours preferentially affect 
males (male-to-female ratio 2-3:1). 100% of poorly/non-differentiated NPC tumours are 
EBV-positive (Andersson-Anvret et al., 1977). Detection of EBV DNA within the NPC 
tumour cells themselves was the first evidence that the virus could infect epithelial cells 
(Wolf et al., 1973, zur Hausen et al., 1970). Terminal repeat analysis showed that EBV is 
monoclonal in the NPC cells (Raab-Traub and Flynn, 1986).  
 
EBV in NPC displays a Latency I/II form of infection, intermediate between those 
displayed by BL (Latency I) and by HL (Latency II). EBV gene expression in NPC is 
generally limited to EBNA1 (from Qp), variable levels of LMP1 and LMP2 and EBER 
RNAs are also transcribed (Raab-Traub, 2002). In epithelial cells, LMP1 is expressed from 
a different promoter to that in B cells; this promoter is not dependent on EBNA2 and may 
therefore allow LMP1 expression in the absence of EBNA2 (Sadler and Raab-Traub, 
1995a).  
 
The LMP1 mRNA is usually difficult to amplify from the tumour biopsies and the LMP1 
protein is only detectable in a minority (35%) of Chinese NPC samples. By contrast, 
LMP2A RNA is easy to amplify and LMP2A protein can be detected in approximately 
50% of tumours by histochemical staining (Heussinger et al., 2004). Due to the limited 
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sensitivity of the available antibodies for detecting LMP2, the expression of LMP2 may be 
underestimated. The fact that patients with NPC reproducibly show serum antibody 
response against LMP2A or B suggests that the protein is regularly expressed in tumour 
cells. From an understanding of its many effects, LMP1 is inferred to be the key viral 
protein in NPC pathogenesis. For example, in cultured epithelial cells, LMP1 induces 
epidermal growth factor receptor and matrix metalloproteinase 9, and downregulates E-
cadherin, all of which may contribute to metastasis and tumour invasion in vivo (Fahraeus 
et al., 1992, Miller et al., 1995, Takeshita et al., 1999). 
 
Gastric carcinoma 
EBV is detected in the tissue of about 10% of gastric carcinoma cases throughout the world. 
In each case, 100% of carcinoma cells are infected with EBV (Shibata and Weiss, 1992). 
The EBV-positive gastric tumours express EBER, the Qp-initiated EBNA1 mRNA, BARTs 
and in about 50% cases, the LMP2 transcript, but never LMP1 (zur Hausen et al., 2004). In 
rare cases it has been possible to immortalize primary gastric epithelial cells by EBV 
infection and a similar form of latency is established in these cells as in EBV positive 
tumours which show accelerated malignant properties (Nishikawa et al., 1999, Yoshiyama 
et al., 1997). This suggests that EBV contributes to the maintenance of the malignant 
phenotype of EBV positive gastric carcinoma. 
 
T/NK lymphomas 
In rare cases, EBV can access the non-B-lymphocyte compartment in vivo and the infection 
carries a significant oncogenic risk. This happens in the case of T/NK cell lymphomas. Two 
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groups of T/NK lymphomas with different clinical presentations have been recognized. 
Nasal lymphoma of T or NK cells is a specific extra-nodal lymphoma which presents in the 
nasal cavity. The other group of T/NK lymphomas are peripheral T-cell lymphomas and 
most frequently following acute primary EBV infection manifest as virus-associated 
haemophagocytic syndrome (VAHS) or in the setting of chronic active EBV infection with 
VAHS-like symptoms. EBV infections of T and NK cells lead to latency II infections and 
not the fully growth transforming program used by the virus in B cells. However detectable 
levels of LMP1 protein are restricted to a few tumour cells (Minarovits et al., 1994). 
 
1.7 EBV lytic infection studied in vitro 
Given the link between epithelial cells and EBV replication in vivo, there have been efforts 
to establish in vitro replication models in epithelial cell cultures. However, in vitro 
infection of primary epithelial and T cells with free virus is very inefficient because these 
CD21-negative cells are largely resistant to infection in vitro and infection does not result 
in transformation (Fingeroth et al., 1999, Imai et al., 1998, Shapiro et al., 1982, Sixbey et 
al., 1983, Yoshiyama et al., 1997). However, recent work with tonsillar epithelial cultures, 
where there is spontaneous differentiation, shows that productive EBV infection can be 
achieved experimentally in at least some cells, but this has not yet been studied rigorously. 
Alternatively, Shannon-Lowe and her colleagues developed a system where EBV is 
efficiently delivered into epithelial cells by a process involving transfer from the surface of 
virus-loaded resting B cells (Shannon-Lowe et al., 2006). In contrast to B-cell infection, 
high levels of EBERs and LMP1 and 2A transcripts were detected in the first 48 hour post-
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infection. Furthermore, EBNA1 was exclusively expressed from Qp-derived mRNA and 
Wp and Cp remained silent at all time points after infection (Shannon-Lowe et al., 2009). 
 
In vitro most studies of lytic cycle have used B cell lines (BL or LCLs), which either 
spontaneously enter lytic cycle in a small percentage of cells (~5%) or where to varying 
extents, lytic cycle can be induced by treatment with phorbol ester, calcium ionophore, 
5′azacytidine or sodium butyrate or by vector-mediated BZLF1 expression or by sIg cross-
linking (Ben-Sasson and Klein, 1981, Saemundsen et al., 1980, Hudewentz et al., 1980, zur 
Hausen et al., 1979, Luka et al., 1979, Davies et al., 1991, Baumann et al., 1998, Qualtiere 
and Pearson, 1980, Ragona et al., 1980). In the best characterised system involving anti-Ig 
induction of the Latency I Akata-BL cell line, EBV gene expression follows a sequential 
order and completion of the EBV lytic cycle takes 48-72 hours (Takada and Ono, 1989).  
 
Lytic cycle is initiated by expression of two immediate early genes, BZLF1 (also known as 
Zta or Zebra protein) and BRLF1, which then transactivate the early genes including 
BALF2, BHRF1 and BMRF1 leading to viral DNA synthesis. Late viral genes including 
BLLF1 (encodes for envelope glycoprotein gp350/220), BCRF1 (viral homologue of 
interleukin-10) and BALF4 (encodes for viral gp110) are then expressed and lead to 
synthesis of the viral structure proteins. Production of new virus starts with synthesis of 
viral DNA and packaging into capsids in the host cell nucleus followed by budding through 
the nuclear membrane resulting in cytoplasmic vesicles containing enveloped virus. These 
vesicles then fuse with the plasma membrane of the host cell to release the new virus 
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particles by exocytosis (Rickinson and Kieff, 2007). This process also leads to death of the 
host cell. 
 
1.8 EBV latent infection studies in vitro 
Virus binding and entry 
The ability of EBV to infect target B cells efficiently is determined by the combined 
interaction of the abundant viral glycoprotein gp350/220 (Peng-Pilon et al., 1995) with the 
receptor CD21 on the B cells (Fingeroth et al., 1984, Nemerow et al., 1985) and the viral 
envelope protein complex gp42/gH/gL with major histocompatability (MHC) class II 
molecules on the B cells (Li et al., 1997).  Both interactions are known to be required for 
efficient B cell infection and are dispensable for the much less efficient entry of EBV into 
other cell types, such as epithelial cells (Borza and Hutt-Fletcher, 2002, Li et al., 1995). 
EBV enters B cells by endocytosis, involving fusion of the viral envelope with the host cell 
plasma membrane and this is triggered by cross-linking of CD21 molecules (Nemerow and 
Cooper, 1984, Tanner et al., 1987). EBV genome delivery to the nucleus is a key rate-
limiting step to B cell transformation. For EBV infection of resting B cells, only 10-15 % 
of total bound viruses deliver their genomes to the cell nucleus and importantly, a single 
viral genome in the nucleus is capable of driving B cell proliferation (Henderson et al., 
1977, Hurley and Thorley-Lawson, 1988, Shannon-Lowe et al., 2005, Sugden and Mark, 
1977). 
 
The EBV genome, which is linear in the virion, circularises soon after virus entry to 
produce the covalently closed extrachromosomal episome (Adams and Lindahl, 1975, 
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Alfieri et al., 1991, Hurley and Thorley-Lawson, 1988). This circularisation takes place 
within 12 to 16 hours of infection. Episomes are maintained by the host cell DNA 
polymerase (Adams, 1987) and amplification of the EBV genome relative to the cell 
genome occurs after transformation, such that most latently infected cells harbour 
numerous episomes (Sugden et al., 1979).  
 
Viral gene transcription 
After the initial events of viral infection involving viral binding by adsorption to CD21, 
internalisation of the viral episome within the infected cell nucleus, the BamHI W promoter, 
Wp, present in each BamHI W repeat of the EBV genome, is selectively activated 
immediately post-infection, within 12 to 16 hours (Alfieri et al., 1991, Allday et al., 1989, 
Moss et al., 1981, Rooney et al., 1992). This activation leads to selective expression of 
EBNA-LP and EBNA2, detectable within 12-24 hours post-infection. EBNA-LP is 
hyperexpressed at this time whereas EBNA2 gradually rises to LCL-like levels. Differential 
splicing of Wp-initiated mRNAs leads to the expression of both EBNA-LP and EBNA 2 
(Rogers et al., 1990, Wang et al., 1987b).  
 
Figure 1.5, adapted from (Qu and Rowe, 1992), shows a schematic of the splicing patterns 
of Wp- and Cp-initiated transcripts. The N-terminus of EBNA-LP is encoded by multiple 
W1 and W2 exons within the BamHI W repeats, while the C-terminus is encoded by two 
unique BamHI Y exons, Y1 and Y2. As the W repeat exons are located within the 5′ 
untranslated region (UTR) of all EBNA transcripts, alternative splicing of the first 40nt 
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exon W0 to an alternative splice acceptor W1′ 5bp into the 66nt W1 exon is required to 
create a translation initiation codon specific for the production of EBNA-LP. These Wp-
transcripts splice into the next downstream 132nt W2 exon and then through multiple 
repeats of W1 and W2 exons and eventually into the Y1 and Y2 exons. 
 
EBNA2 is encoded further downstream in the BYFR1 ORF spanning across the BamHI Y 
and BamHI H fragment junctions. Wp-initiated transcripts productive for EBNA2 splice 
from W0 to W1, thereby ablating the translation initiation codon for EBNA-LP, then into 
W2, through multiple W1 and W2 exons, and finally into the Y1Y2Y3H (Alfieri et al., 1991, 
Sample et al., 1986, Speck and Strominger, 1985). 
  
EBNA-LP and EBNA2 reach the level that is maintained in transformed B cells (LCL) by 
24 to 32 hours after infection (Alfieri et al., 1994). EBNA2, either alone or acting together 
with EBNA-LP, activates the alternative promoter Cp, detectable 48-72 hours post-
infection (Alfieri et al., 1991, Jin and Speck, 1992, Sung et al., 1991). Cp then becomes the 
dominant promoter and Wp-initiated transcripts begin to wane (Woisetschlaeger et al., 
1991, Woisetschlaeger et al., 1990). The Cp-initiated transcripts, in which the C1 and C2 
exons replace the W0 exon, are highly spliced to generate mRNAs and encoded all six 
EBNAs. Some of these Cp-initiated transcripts exploit another splice donor upstream of 
EBNA2 to splice to the downstream U exon and then into the EBNA3 and EBNA1 
encoding exons. An internal ribosome entry site has recently been identified in the U exon 
which would permit efficient translation of these downstream EBNAs (Isaksson et al., 
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2003). Thus by alternative RNA splicing, the Cp-initiated transcripts are capable of 
encoding EBNAs 1, 2, -LP, 3A, 3B, and 3C (Bodescot and Perricaudet, 1986, Sample et al., 
1986, Speck and Strominger, 1985). EBNA 3A, 3B, 3C and 1 proteins are detectable 20-32 
hours after infection and reach LCL levels after 48-72 hours. In addition to EBNA2, it has 
also been reported that EBNA1 can also increase Cp and LMP1 promoter activity by 
binding to the oriP enhancer and thereby increasing transcription of the latent antigens 
(Reisman and Sugden, 1986). By contrast, EBNA3 may limit EBNAs transcription by 
competing with EBNA2 for binding to RBP-Jκ, the anchor for EBNA2 on the Cp enhancer 
to inhibit EBNA2 mediated transactivation (Johannsen et al., 1996, Waltzer et al., 1996). 
 
Subsequently, EBNA2 and EBNA-LP activate the LMP promoters (LMP1, 2A and 2B) 72-
96 hours post-infection (Abbot et al., 1990, Sung et al., 1991, Wang et al., 1990b, Zimber-
Strobl et al., 1991). The most abundant EBV-encoded RNAs (the EBERs) the BamHI A 
rightward transcripts are also expressed following these early events (Alfieri et al., 1991, 
Chen et al., 2005b). 
 
Expression of the full range of Latency III viral proteins triggers cells to enter the cell cycle 
and proliferate. EBNA2, either alone or acting with EBNA-LP, exerts many effects on 
cellular and viral gene expression leading to a G0 to G1 cell cycle transition as marked by 
the induction of cyclin D2 (Sinclair et al., 1994). Among EBV upregulated cell genes, c-
myc and CD21 RNA and c-myc protein expression are up at 16 to 24 hours after infection 
(Alfieri et al., 1991). Accompanying this is a change in cellular phenotype from a resting B 
cell to a proliferating LCL; cells begin to enlarge and clump together in culture, expressing 
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adhesion molecules and activation markers (Hurley and Thorley-Lawson, 1988). By 48 
hours after infection, 15% of cells are in S phase and at 72 hours a substantial fraction of 
infected cells have divided (Rickinson and Kieff, 2007). 
 
1.9 Regulation of latent promoters involved in Latency I, II, and III 
1.9.1 Wp 
The BamHI W promoter, Wp is present in each BamHI W repeat of the EBV genome and 
is selectively activated within 12-16 hours post-infection (Alfieri et al., 1991, Allday et al., 
1989, Moss et al., 1981, Rooney et al., 1992). Wp may be designed to function particularly 
well in the quiescent environment of a resting B cell due to its presence in multiple copies 
(Woisetschlaeger et al., 1990). The ladder of EBNA-LP species seen in the early stages of 
EBV infection supports the notion that transcription initiates from multiple copies of Wp 
(Finke et al., 1987, Rooney et al., 1989).  
 
The factors that determine Wp activation in B cells are poorly understood. It was initially 
suggested that EBV binding to its cellular receptor, CD21 on B cells triggers an NF- B-
dependent intracellular pathway and mediates transcriptional activation of Wp (Sugano et 
al., 1997). As shown in Figure 1.6, there are three positive regulatory regions or upstream 
activating sequences (UAS) located upstream of Wp, UAS1, UAS2 and UAS3 (Bell et al., 
1998, Ricksten et al., 1988). UAS2 and UAS3 were found to be lineage-independent in 
their activity, while UAS1 activity is preferentially in B cells (Bell et al., 1998). UAS2 
contains two binding sites for the ubiquitous transcription factor Yin-Yang 1 (YY1) and 
shows lineage-independent activity in reporter assays. By contrast UAS1 contains two 
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binding sites for the B cell-specific activator proteins (BSAP) protein, plus sites for the 
ubiquitous regulatory factor X (RFX) and the cAMP response element (CRE)-binding 
protein (CREB), and has B cell-specific activity (Bell et al., 1998, Kirby et al., 2000, 
Tierney et al., 2000a)  (Figure 1.6).  
 
Figure 1.6  Schematic diagram of Wp promoter and transcription factor binding sites 
 
      
 
Experiments using recombinant EBVs carrying two tandemly-arranged copies of Wp 
deleted either for UAS1 and/or UAS2 showed that UAS2 was completely dispensable for 
Wp activation and subsequent B cell transformation, whereas UAS1 was absolutely 
essential for both activities (Tierney et al., 2007). This was in agreement with earlier 
studies which showed that deletion of -369 to -169bp upstream of Wp, a region overlapping 
UAS1, in a recombinant virus, was unfavourable for B-cell transformation (Yoo et al., 
2002). In addition, recombinant virus carrying two Wp copies in which both BSAP sites are 
inactivated, like the UAS1 knockout, showed greatly reduced Wp activity in resting B cells 
and did not transform B cells. It inferred that EBV ensures the B-cell specificity of its 
growth-transforming function by exploiting BSAP/Pax5 as a lineage-specific activator of 
the transforming programme (Tierney et al., 2007). 
Wp 
+1 
YY1 YY1 RFX BSAP CREB BSAP 
UAS2 UAS1 UAS3 
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1.9.2 Cp 
As shown in Figure 1.7, the upstream regulatory regions of Cp are important for promoter 
activity and both viral and cellular proteins have been implicated in Cp regulation. In 
reporter assays, EBNA1 binding to oriP can activate transcription from Cp; multiple 
EBNA1 homodimers bind to the EBNA1-dependent enhancer within FR of oriP, and 
activate Cp several kilobases downstream (Zetterberg et al., 2004, Nilsson et al., 1993, 
Puglielli et al., 1996, Reisman and Sugden, 1986, Sugden and Warren, 1989). EBNA2 is 
also a transcriptional activator of Cp. The EBNA2-response element in Cp contains binding 
sites for the cellular transcription factors CBF1 (Cp binding factor 1)/RBP-Jκ and CBF2 
both of which are required for EBNA2-mediated activation of Cp in reporter assays 
(Fuentes-Panana and Ling, 1998, Jin and Speck, 1992, Ling et al., 1993, Henkel et al., 1994, 
Waltzer et al., 1994, Fuentes-Panana et al., 2000, Grossman et al., 1994).  CBF2 was 
identified as the AUF1/hnRNP D protein which is regulated by the cyclic AMP-protein 
kinase A (cAMP/PKA) signalling pathway, and this pathway contributes to the regulation 
of Cp activity (Fuentes-Panana et al., 2000). 
 
The Cp promoter is also regulated by the EBNA3 proteins, which can obstruct EBNA2-
mediated transactivation of Cp by preferentially binding to RBP-Jκ (Robertson et al., 1995). 
Also important for Cp activity are a CCAAT box which binds nuclear factor Y (NF-Y), 
promoter-proximal GC-rich elements that interact with Sp1, and a C/EBP-binding  site 
(Borestrom et al., 2003, Nilsson et al., 2001, Puglielli et al., 1996). 
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Figure 1.7 Schematic diagram of Cp promoter and transcription factor binding sites 
 
 
 
Although Cp is the promoter of choice in most LCLs, it is in fact dispensable for B cell 
immortalisation in vitro. Recombinant virus with a deletion of the key Cp regulatory 
regions (including the GRE and EBNA2 response element) and the C1 and C2 exons 
transformed B cells with wild-type efficiency (Swaminathan, 1996). Wp was instead 
adopted as the EBNA promoter and appeared to compensate entirely for the lack of Cp.  
Deletion of a 200bp section, comprising the entire EBNA2-response element, generated 
LCLs with substantially diminished Cp activity, but in which the immortalising capacity of 
the virus remained intact (Yoo and Speck, 2000, Yoo et al., 1997).  
 
1.9.3 Qp 
Qp located in the BamHI Q fragment is an alternative EBNA1 promoter that allows 
selective EBNA1 expression in the absence of the other EBNAs. Unlike the Cp and LMP1 
promoters, it is not dependent on EBNA2 for activity. Qp is a TATAA-less promoter 
whose architecture is similar to the promoters of housekeeping genes and it is active in a 
wide range of cell types, including non-lymphoid cells (Schaefer et al., 1995a). As shown 
in Figure 1.8, the key elements for Qp regulation are clustered in an 80bp sequence around 
the transcription start site (Schaefer et al., 1991). Two binding sites for E2F, which overlap 
RBP-Jκ CBF
Cp 
+1 
Sp1 C/EBP NF-Y Sp1 
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the EBNA1 binding sites were identified in vitro studies (Sung et al., 1994), but in vivo 
footprinting failed to confirm this (Salamon et al., 2001).   
 
Figure 1.8 Schematic diagram of Qp promoter and transcription factor binding sites 
 
 
 
Qp is positively regulated by interferon regulatory factors (IRFs) which associate with an 
interferon stimulated response element (ISRE) just upstream of the transcriptional start site 
(Nonkwelo et al., 1997, Schaefer et al., 1997, Zhang and Pagano, 1997). IRF2 binding to 
Qp activates the promoter and is the principal factor bound when Qp is active in Latency I 
BL lines (Schaefer et al., 1997). Two STAT binding sites adjacent to the ISRE have been 
described and STAT proteins have been shown to activate Qp (Chen et al., 1999a). A Sp1-
like site, which may bind Sp1 also identified by in vivo footprinting upstream of the Qp 
transcription start site (Salamon et al., 2001). EBNA1 expression from Qp is autoregulated 
by binding of EBNA1 to two low-affinity sites just downstream of the Qp start site, which 
inhibits transcription initiation (Sample et al., 1992, Schaefer et al., 1997).   
 
 
 
EBNA1 EBNA1 
Qp    
+1 
E2F? E2F? 
Sp1 ISRE 
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1.9.4 LMP1 promoters 
The LMP1 promoter (ED-L1) is responsive to transactivation by EBNA2 via binding to 
RBP-Jκ (Fahraeus et al., 1990).  As shown in Figure 1.9, there are two binding sites for 
RBP-Jκ in the LMP1 transcription regulatory sequence (LRS) but only the promoter 
proximal site is involved in transcriptional activation (Johannsen et al., 1995, Laux et al., 
1994b).  The cAMP response element (CRE) in the ED-L1 promoter has been shown to be 
one of the critical sites for LMP1 transactivation. Both EBNA2-dependent and -
independent transactivation of LMP1 require an intact CRE in LRS upstream of the 
transcription initiation site of ED-L1 promoter. Mutations in this site lead to a drastic 
decrease in promoter activity in reporter assays (Fahraeus et al., 1994). Downstream of the 
RBP-Jκ site, there is an E-box which may bind a repressor complex (Sjoblom-Hallen et al., 
1999), an octamer motif which binds a POU-domain protein (Sjoblom et al., 1995) and a 
purine-rich PU box sequence which binds PU.1/Spi-1 and Spi-B (Johannsen et al., 1995, 
Laux et al., 1994a, Sjoblom et al., 1995). PU.1 is a B cell-specific factor which has a role in 
EBNA2 activation of LMP1p as well as that of RBP-Jκ (Johannsen et al., 1995, Sjoblom et 
al., 1995). In different experimental situations, reportedly ED-L1 promoter can also be 
activated by EBNA1 binding to oriP (Gahn and Sugden, 1995), by EBNA3C expression 
(Allday et al., 1993) and by signals from the protein kinase A and C pathways (Fahraeus et 
al., 1994, Rowe et al., 1992). 
 
In epithelial cells, on the other hand, where EBNA2 is not expressed, transcription of 
LMP1 mRNA can also initiate from TRL1p, a TATA-less promoter situated in the first 
terminal repeat (Gilligan et al., 1990, Sadler and Raab-Traub, 1995a). TRL1p contains two 
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GC boxes (Sadler and Raab-Traub, 1995a), I and II and by binding to the GC boxes, the 
cellular Sp family proteins including Sp1 and Sp3 function as transcriptional activators and 
regulate this promoter (Tsai et al., 1999). 
 
Figure 1.9 Schematic diagram of LMP promoters and transcription factor binding sites 
 
 
 
 
 
1.9.5 LMP2 promoters 
The LMP-2A promoter is located approximately 3.2 kb downstream (leftward) of the LMP-
1 transcription start site. As shown in Figure 1.9, the regulatory sequence of LMP2A 
promoter, TP1p, contains two RBP-Jκ binding sites, and in vivo footprinting revealed 
binding of RBP-Jκ to its recognition sequence in B cell lines actively using TP1p, whereas 
no typical RBP-Jκ footprints could be observed in cells where TP1p was silent (Salamon et 
al., 2003). In addition to the two RBP-Jκ binding sites, two other sites (L2BF2 and L2BF3) 
were also found in the promoter proximal to the RBP-Jκ binding sites (Hofelmayr et al., 
1999). LMP2B is expressed from a promoter, termed TP2p in the same bidirectional 
ED-L1 
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promoter region as LMP1. Details are uncertain about specific factors controlling LMP2B 
expression.  
 
1.10 Latent gene products 
1.10.1 EBNA-LP 
EBNA-leader protein (EBNA-LP or EBNA 5), alongside EBNA 2, is one of the first EBV 
proteins expressed during B cell infection (Alfieri et al., 1991). EBNA-LP is encoded by 
the repeating W1 and W2 exons in the BamHI W fragments and the unique Y1 and Y2 
exons in the BamHI Y fragment (Bodescot et al., 1984, Dillner et al., 1986, Sample et al., 
1986, Speck et al., 1986), which generates a protein with a 66 amino acid repeat region and 
a unique 45 amino acid carboxy terminus. The size of the protein varies between 20-130kd 
in virus isolates, depending on the number of W1 and W2 repeats present and is seen on 
western blotting as a ladder of bands at 6-8kd intervals (Dillner et al., 1986, Finke et al., 
1987, Wang et al., 1987b).  
 
EBNA-LP functions to co-activate EBNA2-dependent activity of the EBNA2-responsive 
promoters, Cp and LMP1 (Harada and Kieff, 1997, Nitsche et al., 1997). While genetic 
analyses have mapped this co-activation function to the repeat region of the protein, the 
unique C-terminal domain appears to modulate EBNA-LP activity (Harada and Kieff, 1997, 
Peng et al., 2000b, Kitay and Rowe, 1996, McCann et al., 2001). EBNA-LP and EBNA 2 
together induce a G0 to G1 transition as measured by upregulation of cyclin D2 mRNA 
(Sinclair et al., 1994).  
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EBNA-LP is phosphorylated on serine residues at least once in each W2 repeat in vivo 
during the late G2 stage of the cell cycle (Kitay and Rowe, 1996, Petti et al., 1990). It has 
been shown that casein II kinase, p34cdc2 and DNA-PK are all capable of phosphorylating 
EBNA-LP in vitro (Han et al., 2001, Yokoyama et al., 2001). Phosphorylation of serine 
residue 36 in W2 is thought to be essential for EBNA-LP function (McCann et al., 2001, 
Peng et al., 2000b). EBNA-LP is highly associated with the nuclear matrix fraction. By 
immune microscopy, EBNA-LP has been detected in ND10 bodies and some spread 
throughout the nucleus (Wang et al., 1987b, Petti et al., 1990, Szekely et al., 1996). 
 
Most studies of EBNA-LP using recombinant viruses focused on the carboxyl-terminal two 
exons because mutations in the repeating exons are more difficult to construct. EBV 
recombinants expressing a truncated EBNA-LP lacking the unique C-terminus have 
impaired transforming capabilities and the resulting LCLs grow slowly, showing that the 
unique region is important, but not essential for transformation (Hammerschmidt and 
Sugden, 1989, Mannick et al., 1991). Recombinant virus carrying only two copies of 
BamHI W fragments, producing EBNA-LP with only two repeat regions have impaired 
transforming capabilities (Tierney et al., 2007). Therefore, the length of the EBNA-LP 
determined by the number of repeat regions may be important.  
 
Mannick et al immunoprecipated EBNA-LP from cell extracts, and found that EBNA-LP 
associated with members of the heat shock protein 70 family (HSP73 and HSP72) 
(Mannick et al., 1995), which colocalised with EBNA-LP in ND10 bodies (Szekely et al., 
1995). Recently, it has been shown that overexpressing HSP 72 up-regulates EBNA-LP 
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coactivation with EBNA2 (Peng et al., 2007). Sp100 has also been implicated in EBNA-LP 
coactivation, whereas HA95 and PKA are implicated in negative regulation of EBNA2 -and 
EBNA-LP- mediated transcription (Han et al., 2002, Ling et al., 2005).  
 
1.10.2 EBNA2 
EBNA2 is one of the first viral proteins to be expressed after EBV infection of B cells in 
vitro (Alfieri et al., 1991, Woisetschlaeger et al., 1990, Woisetschlaeger et al., 1991) and is 
essential for the B cell immortalising ability of EBV (Hammerschmidt and Sugden, 1989, 
Skare et al., 1985) as exemplified by the non-transforming phenotype of the EBNA2-
deleted virus P3HR1 (Miller et al., 1974, Menezes et al., 1975, Bornkamm et al., 1982, 
Rabson et al., 1982). Reintroduction of EBNA2 into P3HR1 cells restored the 
transformation capacity of the virus (Hammerschmidt and Sugden, 1989). Experiments 
using conditional EBNA2 also showed that EBNA2 is not only essential for initiation of, 
but also for maintenance of B cell immortalization (Kempkes et al., 1995a). 
 
The essential role of EBNA2 in B cell transformation is due to its ability to act as a potent 
transcriptional activator (Cohen and Kieff, 1991), upregulating transcription of several viral 
and cellular genes containing EBNA2-response elements in their promoters. Viral targets 
include the EBNA promoter, Cp (Jin and Speck, 1992, Sung et al., 1991) and the LMP1 
and LMP2A promoters (Figure 1.4) (Abbot et al., 1990, Fahraeus et al., 1990, Ghosh and 
Kieff, 1990, Zimber-Strobl et al., 1993, Wang et al., 1990b). The importance of EBNA2 in 
transactivating LMP1 and LMP2 gene expression in B cells is highlighted by the absence 
of the LMP proteins in BL lines in which the EBNA2 gene has been deleted (Abbot et al., 
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1990, Kelly et al., 2002, Zimber-Strobl et al., 1991). In its capacity as a transcriptional 
activator, EBNA2 has a C-terminal acidic activation domain that recruits transcription 
factors to promoters, including TFIIB, TAF40, and TFIIH (Cohen and Kieff, 1991, Tong et 
al., 1995a, Tong et al., 1995b). Interestingly, the EBNA2 transactivation domain closely 
resembles the herpes simplex virus VP16 acidic domain which also recruits transcription 
factors (Cohen, 1992). EBNA2 can interact with the histone acetyltransferases (HATs) 
p300, CBP and PCAF (Wang et al., 2000), and such associations may be central to 
EBNA2-mediated transactivation.  
 
EBNA2, either alone or acting with EBNA-LP, exerts many effects on cellular and viral 
gene expression leading to a G0 to G1 cell cycle transition as marked by the induction of 
cyclin D2 (Sinclair et al., 1994). The mechanism of activation and the range of cellular 
targets involved are still not fully understood. However it is known that in experimental 
models EBNA2 up-regulates cellular genes including the proto-oncogene c-myc, B cell 
activation marker CD23, the viral receptor CD21, chemokine receptor CCR7, and proto-
oncogene cfgr (Burgstahler et al., 1995, Cordier et al., 1990, Knutson, 1990, Wang et al., 
1991, Wang et al., 1987a). More recently, microarray analysis has identified numerous 
cellular genes upregulated in LCLs in response to EBNA2 expression (Zhao et al., 2006). 
 
EBNA2 does not bind directly to DNA but interacts with RBP-Jκ, a cellular sequence-
specific DNA binding protein that typically acts as a transcriptional repressor (Hsieh and 
Hayward, 1995, Waltzer et al., 1995); this interaction between EBNA2 and RBP-Jκ is 
essential for B lymphocyte immortalisation (Zimber-Strobl et al., 1994, Yalamanchili et al., 
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1994, Grossman et al., 1994, Ling et al., 1994, Henkel et al., 1994). Recombinant viruses 
carrying an EBNA2 gene lacking the interaction domain are not able to transform B cells 
(Yalamanchili et al., 1994). At least one consensus RBP-Jκ binding site is found in almost 
all the EBNA2-responsive elements in the promoters of EBNA2-transactivated viral and 
cellular genes. EBNA2 is thought to convert RBP-Jκ from a repressor into an activator to 
upregulate its target genes in B cells; EBNA2 binding to RBP-Jκ can mask the repression 
domain of RBP-Jκ and bring the transactivation domain within range of the Cp TATAA 
box (Hsieh and Hayward, 1995, Kao et al., 1998, Ling et al., 1993). Other elements 
important for EBNA2-reponsiveness include the PU.1 and CRE binding site in the LMP1 
promoter (Johannsen et al., 1995, Sjoblom et al., 1995) and the AUF1 binding sites in the 
Cp and CD21 promoters (Fuentes-Panana et al., 2000). 
 
In activating transcription through RBP-Jκ, EBNA2 mimics a constitutive Notch receptor. 
The WWP sequence in EBNA2 is similar to the WFP sequence in the Notch receptor 
intracellular domain that normally mediates tight association with RBP-Jκ in tissue 
development (Tamura et al., 1995). Notch binds RBP-Jκ in the nucleus through the same 
site as EBNA2, and also transactivates genes by interacting with RBP-Jκ and converting it 
into an activator (Schroeter et al., 1998, Struhl and Adachi, 1998, Hsieh et al., 1996). In BL 
cells, Notch can transactivate viral EBNA2 target promoters in transient transfection assays 
(Hofelmayr et al., 1999), and in an LCL Notch can transiently substitute for EBNA2 in 
maintaining proliferation (Hofelmayr et al., 2001).  
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1.10.3 BHRF1 
EBV encodes two homologues of the cellular anti-apoptotic Bcl2 protein, BALF1 and 
BHRF1 (Henderson et al., 1993, Horner et al., 1995, Marshall et al., 1999), which are 
expressed soon after EBV infection of B cells (within 24 hours). Single BHRF1- or BALF1- 
mutants were capable of generating LCLs at high virus doses however, a recombinant virus 
in which both genes were inactivated was unable to transform infected B cells, which died 
by apoptosis (Altmann and Hammerschmidt, 2005). These results suggest that BHRF1 and 
BALF1 can partially compensate for each other. Importantly when pre-activated B blasts 
were infected with the double knockout clonal LCLs were obtained. These studies indicated 
that either BALF1 or BHRF1 is essential to establish LCLs but are dispensable for their 
continued proliferation. Interestingly, it was also suggested that this EBV anti-apoptotic 
gene could provide a survival advantage to the infected cells favouring their developing 
into memory B cells in vivo. 
 
Recently, it has been reported the BHRF1 gene expression in newly infected B cells is 
temporally linked to Wp activation and the presence of W/BHRF1-spliced transcripts. Low-
level BHRF1 transcripts and protein remain detectable in these cells long-term, 
independently of any lytic cycle entry (Kelly et al., 2009). Stable transfection of the 
BHRF1 gene into P3HR-1 cells rescued the cells from the apoptosis induced by dominant 
negative EBNA1 expression and moreover, knockdown of BHRF1 expression in P3HR-1 
cells resulted in increased cell death. These results indicate that EBV is essential for the 
survival of P3HR-1 cells and that BHRF1 functions as a survival factor (Watanabe et al., 
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2010). This work suggested that BHRF1, in the context of Wp-restricted BL, may 
contribute to virus-associated lymphomagenesis in vivo. 
 
1.10.4 EBNA1 
EBNA1 is a nuclear protein encoded by the BKRF1 ORF.  EBNA1 transcripts are initiated 
from Cp or Wp in Latency III cells (Y3-U-K spliced transcript) and Qp in Latency I/II cells 
(Q-U-K spliced transcript). EBNA1 from the B95.8 EBV strain consists of 641 amino acids 
with an apparent size of 76kd. EBNA1 protein has four components: (a) an Arg-rich amino 
terminal 89 aa region, (b) a Gly-Ala repeat 239 aa domain, (c) an Arg-rich short 58 aa 
domain, (d) a long hydrophilic carboxy terminus (Hennessy and Kieff, 1983).  
 
EBNA1 was first identified as a protein that binds to chromosomes during mitosis, and is 
unique among the EBNAs in this regard (Reedman and Klein, 1973, Ohno et al., 1977). 
The chromosome-binding functions of EBNA1 are mediated through its interaction with a 
cis-acting element, termed oriP within the EBV genome (Yates et al., 1984, Yates et al., 
1985). OriP has at least two components with binding sites for EBNA1: a family of 20 
copies of a 30bp repeat, FR, and a dyad symmetry, DS, consisting of four copies of the 
30bp repeat, two in tandem and two in a larger dyad symmetry (Ohno et al., 1977, Petti et 
al., 1990, Reedman and Klein, 1973). The chromosome-binding function of EBNA1 is 
essential for EBV episome maintenance, allowing the viral genome to be replicated once 
per cell cycle by the host cell replication machinery, alongside the cellular genome and 
allows faithful partitioning to daughter cells (Adams, 1987, Lee et al., 1999, Yates et al., 
1985, Harrison et al., 1994, Harris et al., 1985).  
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Binding of EBNA1 to the FR may also enhance transcription from viral promoters Cp, Wp, 
LMP1 and LMP2B (Gahn and Sugden, 1995, Puglielli et al., 1996, Reisman and Sugden, 
1986, Sugden and Warren, 1989). Conversely EBNA1 binding to two low affinity sites 
downstream of the Qp promoter mediates negative regulation of Qp and presumably serves 
to limit EBNA1 expression in Latency I/II infections (Sample et al., 1992, Sung et al., 
1994). EBNA1 function may also contribute to the growth transformation properties of 
EBV. It was reported that EBNA1 is required for survival in BL cells, and inhibition of 
EBNA1 decreases survival of the cells by inducing apoptosis (Kennedy et al., 2003). In 
addition, delivery of a dominant-negative EBNA1 into EBV-positive BL cells can inhibit 
their growth (Nasimuzzaman et al., 2005). Furthermore, experiments using siRNAs against 
EBNA1 could also inhibit the growth and survival of an EBV-positive cell line (Yin and 
Flemington, 2006). By using an EBNA1-deficient EBV mutant virus, one group has 
reported that EBNA1 is not essential to establish LCLs but promotes the efficiency of this 
process significantly (Humme et al., 2003). 
 
1.10.5 The EBNA3 family 
The EBNA3 family consists of three proteins, EBNA3A, -3B and -3C which are large 
multifunctional proteins of sizes 145kDa, 165kDa and 155 kDa, respectively. The EBNA3 
genes are tandemly placed in the genome, and are transcribed from the far-upstream Cp or 
Wp. Use of recombinant viruses has shown that EBNA3A and 3C are essential for B 
lymphocyte growth transformation, while EBNA3B is not (Maruo et al., 2003, Maruo et al., 
2006, Tomkinson and Kieff, 1992b, Tomkinson et al., 1993). The EBNA3 proteins differ 
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between type 1 and type2 viruses, however, use of recombinant viruses has shown that 
type1 and type2 EBNA3 have similar effect on B-lymphocyte growth transformation 
(Tomkinson and Kieff, 1992a). The EBNA3 proteins are thought to function as 
transcriptional regulators of viral and cellular genes. Like EBNA2, EBNA3 proteins can 
interact with RBP-Jκ, and even bind more strongly than EBNA2 does (Johannsen et al., 
1996, Robertson et al., 1995, Robertson et al., 1996, Krauer et al., 1996, Zhao et al., 1996). 
This has led to the idea that the EBNA3s may modulate EBNA2 activation of RBP-Jκ 
repressed promoters by competing for RBP-Jκ binding (Waltzer et al., 1996). EBNA3A 
overexpression decreased EBNA2 association with RBP-Jκ, decreased c-myc expression, 
and caused G0/G1 growth arrest with prolonged viability (Cooper et al., 2003). It has been 
shown that EBNA3C can repress transcription from Cp through interactions with RBP-Jκ 
and a histone deacetylase (HDAC) (Bain et al., 1996, Radkov et al., 1997). In addition, 
EBNA3C is involved in transcriptional activation, and can cooperate with EBNA2 to 
coactivate the LMP1 promoter (Allday et al., 1993, Marshall and Sample, 1995). This 
ability to co-activate the LMP1 promoter with EBNA2 occurs independently of RBP-Jκ 
binding but instead is dependent on a PU.1 site within the promoter (Zhao and Sample, 
2000, Lin et al., 2002). EBNA3C has also been shown to co-operate with oncogenic Ras in 
the immortalisation of primary rodent fibroblasts (Parker et al., 1996). 
 
1.10.6 LMP1 
LMP1 is a 66kDa integral membrane protein encoded by the BNLF1 ORF, and consists of 
a short N-terminal cytoplasmic tail of 17aa residues, six hydrophobic transmembrane 
segments and a long C-terminal cytoplasmic region of 200aa residues (Fennewald et al., 
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1984). In LCLs, LMP1 is principally encoded by a 2.8 kb mRNA that initiates from the 
LMP1 promoter, ED-L1 and which requires transactivation by EBNA2 (Fennewald et al., 
1984, Ghosh and Kieff, 1990, Hudson et al., 1985, Abbot et al., 1990, Wang et al., 1990b, 
Fahraeus et al., 1990). However in epithelial cells, a different promoter, TRL1P is used to 
drive LMP1 expression, giving rise to a 3.5 kb LMP1 mRNA and initiating from 
heterogeneous sites in the first terminal repeat of the EBV genome (Sadler and Raab-Traub, 
1995a). This distinct promoter is not dependent on EBNA2, and therefore allows LMP1 
expression in epithelial cells such as nasopharyngeal carcinoma cells, in the absence of 
EBNA2 protein.  
 
LMP1 is generally considered to be an oncogenic protein. In single gene transfer 
experiments under heterologous promoters, LMP1 has transforming effects in continuous 
rodent fibroblast cell lines (Baichwal and Sugden, 1988, Moorthy and Thorley-Lawson, 
1993, Wang et al., 1985). In Rat-1 cells, expression of LMP1 alters cell morphology, and 
enables cells to grow in low serum medium and leads to loss of contact inhibition so that 
cells heap up in monolayer culture (Wang et al., 1985). Expression of LMP1 in the B 
lymphocytes of transgenic mice predisposes them to develop lymphomas late in life 
(Kulwichit et al., 1998).  
.  
LMP1 expression also has significant effects on growth of epithelial cells and can inhibit 
differentiation and cause morphological transformation (Dawson et al., 1990, Fahraeus et 
al., 1993). LMP1 expression in epithelial cells induces epidermal growth factor receptor 
(EGFR) expression (Miller et al., 1995). In B and epithelial cells LMP1 can induce anti-
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apoptotic factors A20 and Bcl2 (Henderson et al., 1991, Laherty et al., 1992, Rowe et al., 
1994). As a mimic of activated CD40, LMP1 can suppress virus reactivation by inhibiting 
transcription of a viral immediate early gene BZLF1, and may therefore contribute to EBV 
latency (Adler et al., 2002). 
 
LMP1 expression in EBV-negative BL cells or B cells induces a number of phenotypic 
changes in the cell, including upregulation of activation markers CD21, CD23, CD30, 
CD39, CD40 and CD44 and of cell adhesion molecules ICAM1, LFA1 and LFA3 and can 
even restore antigen processing function to BL cells (Wang et al., 1990a, Peng and 
Lundgren, 1993, Huen et al., 1995, Rowe et al., 1995). It is thought to do this by mediating 
signal transduction pathways that lead ultimately to the activation of transcription factors, 
such as nuclear factor kappaB (NF-κB) and activating protein-1 (AP-1) (Huen et al., 1995, 
Laherty et al., 1992, Mitchell and Sugden, 1995, Kieser et al., 1997, Eliopoulos and Young, 
1998, Hatzivassiliou et al., 1998). The domains of LMP1 required for NF-κB activation are 
the C-terminal activating regions, CTAR-1 (residues 194-232) and CTAR-2 (residues 351-
386) (Huen et al., 1995). LMP1 protein mimics a constitutively active tumour necrosis 
factor (TNF) receptor, CD40, promoting B cell proliferation by interaction with signalling 
molecules such as TNF receptor-associated factors (TRAFs) and TNF receptor-associated 
death domain protein (TRADD) through the CTAR regions (Mosialos et al., 1995, 
Devergne et al., 1996, Gires et al., 1997, Izumi and Kieff, 1997, Kilger et al., 1998). 
CTAR1 and CTAR2, play critical roles in the transforming phenotype of LMP1 (Liebowitz 
et al., 1992, Izumi et al., 1997, Izumi and Kieff, 1997, Kaye et al., 1999). Deletion of 
CTAR1 showed it to be essential for primary B cell transformation (Kaye et al., 1999, 
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Izumi et al., 1997); deletion of CTAR2 did not fully abrogate transformation but severely 
impaired growth of the resulting LCLs (Izumi and Kieff, 1997). 
 
1.10.7 LMP2A and 2B 
Two integral membrane proteins, LMP2A and LMP2B are initiated from promoters 3kb 
apart in the EBV genome and generated by alternative splicing (Sample et al., 1989). 
Transcription of the LMP2 genes occurs across the TRs and therefore requires 
circularisation of the viral genome (Kieff and Rickinson, 2007). The first exons of LMP2A 
and LMP2B are the only unique exons and all other eight exons are the same to both. The 
5′ exon of LMP2B is noncoding, whereas the 5′ exon of LMP2A encodes a 119-amino-acid 
cytoplasmic domain which is implicated in cell signalling (Beaufils et al., 1993).  LMP2A 
has been reported to localise to the same site in the plasma membrane as LMP1 in latently 
infected B lymphocytes (Longnecker and Kieff, 1990), whereas other studies report a 
distinct intracytosolic pattern of LMP2 distribution (Lynch et al., 2002). 
 
LMP2 has been extensively mutated in EBV recombinants and the experiments showed that 
LMP2 does not effect EBV transformation of primary B cells into LCLs or LCL survival 
(Rochford et al., 1997, Kim and Yates, 1993, Longnecker et al., 1993, Longnecker et al., 
1992, Speck et al., 1999). 
 
1.10.8 EBERs 
The EBV-encoded RNAs are small nuclear non-polyadenylated RNAs, and are the most 
abundant EBV RNAs in latently infected cells (Arrand and Rymo, 1982). EBER1, 166 
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nucleotides in length, is transcribed by RNA polymerase II and III, and EBER2, 172 
nucleotides in length, is transcribed by RNA polymerase III (Arrand and Rymo, 1982, 
Arrand et al., 1989, Rosa et al., 1981, Howe and Shu, 1989, Howe and Shu, 1993).  The 
EBERs localize to the cell nucleus, where they are complexed with the cellular proteins La 
and EBER-associated protein (EAP) (Fok et al., 2006a, Fok et al., 2006b, Toczyski et al., 
1994, Toczyski and Steitz, 1993, Toczyski and Steitz, 1991, Lerner et al., 1981) . 
 
EBER-knockout EBV recombinants are not impaired for primary B cell transformation 
(Swaminathan et al., 1991) and furthermore, no differences were detected in the growth of 
the resulting LCLs or in the permissivity of these cells for lytic replication following 
induction. However, in contrast, it has also been shown that EBERs significantly contribute 
to the efficient growth transformation of B lymphocytes by enhancing the growth potential 
of transformed lymphocytes (Yajima et al., 2005). The EBERs have also been shown to 
confer resistance to interferon gamma (IFNγ) induced apoptosis when expressed in 
sensitive EBV-negative BL subclones of Akata-BL, Daudi-BL and Mutu-BL (Nanbo et al., 
2002), and more recently, it was suggested that EBERs confer resistance to Fas-mediated 
apoptosis by blocking PKR pathway in human epithelial Intestine 407 cells (Nanbo et al., 
2005). 
 
1.10.9 BARTs/CSTs 
The BamHI A rightward transcripts (BARTs) or complementary strand transcripts (CSTs) 
are differentially spliced RNAs detected in BL cells, NPC tumours, latently infected 
lymphocytes from peripheral blood and primary infected B lymphocytes in culture (Hitt et 
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al., 1989, Gilligan et al., 1990, Chen et al., 1992, Karran et al., 1992, Brooks et al., 1993, 
Chen et al., 1999b, Smith et al., 2000). Several putative ORFs have been identified in the 
BamHI A family of transcripts which may encode proteins in latently infected cells. These 
include BARF0, encoded in the 3′ ORF in exon 7; an extension of BARF0, RK-BARF0; 
RPMS1 encoded by an ORF spanning exon 4 and part of exon 5 of some BamHI A 
transcripts; and A73 encoded by an ORF from components of exons 6 and 7 (Sadler and 
Raab-Traub, 1995b, Smith et al., 2000, Fries et al., 1997, Kienzle et al., 1999). 
 
Although the function of these transcripts is not fully understood, the finding that they are 
consistently expressed in all EBV-associated epithelial and B cell tumours and latently 
infected lymphocytes suggests that they may have important roles in viral persistence. 
However, recombinant viruses lacking the DNA that encoded the BARTs are capable of 
efficient transformation of B cells into LCLs, implying the BARTs are dispensable for 
immortalisation (Robertson et al., 1994, Kempkes et al., 1995b). Most of the viral micro 
RNAs (miRNAs) expressed in EBV latent infections are derived from the BARTs (Cai et 
al., 2006, Griffiths-Jones et al., 2006, Grundhoff et al., 2006, Pfeffer et al., 2004). The 
BARTs miRNAs are thought to be derived mainly from introns prior to splicing of the 
BART primary transcription (Edwards et al., 2008). 
 
1.10.10 EBV microRNAs 
It has been shown that EBV expresses several microRNAs (miRNAs) which may have a 
role in gene regulation, by either targeting mRNA destruction or by suppressing translation 
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(Pfeffer et al., 2004). EBV’s miRNAs are encoded in two primary transcripts, the BHRF1 
transcript which also encodes the BHRF1 orf and the BamHI A rightward transcripts which 
are a set of long, alternatively spliced transcripts, whose protein coding capacity remains in 
doubt. The function of the multiple BART miRNA remains to be determined. 
 
1.11 The importance of individual latent genes for transformation: evidence from 
recombinant EBVs 
EBV is very efficient at transforming human resting B cells in vitro, leading to the 
outgrowth of LCLs. Only 11 EBV genes are constitutively expressed in LCLs and much 
effort has been directed towards identifying the genes that are essential for the virus to 
transform cell growth. Whereas molecular genetic and biochemical analyses have revealed 
some relevant biological activities of individual gene products studied in isolation, 
recombinant EBV genetic analyses allow one to look at individual gene function in the 
context of the whole viral genome. Such studies have identified which genes are essential 
for transformation, which are required for optimal transformation and which are 
dispensable. 
 
1.11.1 Marker rescue of its transformation defective P3HR1 EBV genome 
The first genetic analysis was based on marker rescue of the EBV strain present in the 
P3HR1 cell line (the P3HR1 clone 16 cell line, a hetDNA-negative subclone), itself a 
subclone of an Africa BL cell line, Jijoye, that originally carried a transformation 
competent type 2 virus (Cohen et al., 1989, Hammerschmidt and Sugden, 1989). Compared 
with the prototype strain B95.8, P3HR1 is transformation-incompetent and is deleted for a 
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DNA segment that contains the entire EBNA2 exon and the last two exons of EBNA-LP, 
therefore cannot express EBNA2 and can only express truncated EBNA-LP. To generate 
recombinants, the B95.8 DNA restriction fragment EcoRI A containing EBNA2 and 
EBNA-LP and substantial flanking DNA was cloned into a shuttle vector. This shuttle 
vector was introduced into the P3HR1 cell line and the lytic cycle was induced by co-
transfection with the viral transactivating gene BZLF1. The virus stock released from these 
induced cells, which contains both the endogenous P3HR1 virus and recombinants, was 
able to transform B cells. Experiments using shuttle vectors containing mutation in either 
EBNA-LP or EBNA2 identified EBNA2 as an essential gene in B-cell transformation. This 
marker rescue method has since been used to generate more recombinants with sequence 
insertion or deletion within EBNA2 and identified the essential EBNA2 domains (Cohen 
and Kieff, 1991, Cohen et al., 1991, Yalamanchili et al., 1996, Yalamanchili et al., 1994) 
(see detail in EBNA2).  
 
Recombinants that were rescued with wild-type EBNA2 but lacked the BamHI Y1Y2-
coded C-terminal domain of EBNA-LP have been generated by marker rescue of P3HR1 
(Mannick et al., 1991). Such recombinants were competent for transformation but LCL 
growth was severely impaired compared with LCLs transformed with recombinants 
carrying a wild-type EBNA2 and EBNA-LP. These studies indicate that full length EBNA-
LP is not essential for initial transformation but nevertheless is important for efficient 
growth. EBV recombinant molecular genetic analyses of EBNA-LP have focused on the C-
terminal region because mutations in the repeating exons are more difficult to construct.  
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Because of their genetic location adjacent to the P3HR1 deletion, the EBER1 and 2 genes 
or BHRF1 could be deleted or inactivated by foreign DNA insertion and incorporated into 
the DNA construct used to repair the EBNA2 and -LP genes. Each of these shuttle vectors 
was transfected into P3HR1 cells to generate recombinants. EBER-deleted recombinant 
EBV made in this way was equivalent to wild-type EBV in efficiency of transformation and 
competent for lytic replication (Swaminathan et al., 1991). Recombinant virus deleted for 
BHRF1 was likewise transformation competent and replication competent (Marchini et al., 
1991). The recombinants using this approach were limited to genes which could be 
physically linked to the EBNA2-containing DNA segment which is essential for the 
restoration of the ability of P3HR-1 to transform primary B cells.  
 
A subsequent approach using second-site homologous recombination allows the 
introduction of mutations into the EBV genes at distant sites, allowing other 
transformation-associated latent genes to be analysed genetically (Tomkinson and Kieff, 
1992b, Tomkinson and Kieff, 1992a). In this approach, P3HR1 cells were co-transfected 
with EcoRI A DNA fragment, cloned EBV DNA that is mutated in the gene of interest 
(second-site DNA) and the BZLF1 expression vector. To select for second-site 
recombinants, primary B cells are infected with the virus mixture and LCLs that emerge are 
analysed by PCR to identify and recover second-site recombinants from the LCLs where 
the resident P3HR1 sequences at the second sites have been replaced by vectored sequence. 
Studies using this method have revealed that EBNA3A, EBNA3C and LMP1 are essential 
for B-cell transformation whereas EBNA3B, LMP2A and LMP2B are dispensable 
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(Tomkinson and Kieff, 1992b, Longnecker et al., 1992, Tomkinson et al., 1993, Kaye et al., 
1993). 
 
The limitations of this approach were clearly that it was non-quantitative, the read out being 
either the presence or absence of transformed foci. Also it depended on analysis of LCL 
following outgrowth and could not say anything about sequences that might have been 
present in other cells, i.e., sequences required to initiate rather than maintain transformation. 
 
1.11.2 EBV recombinants using B95.8-derived bacterial artificial chromosomes 
A much improved B95.8 based strategy was later developed using a bacterial artificial 
chromosomes (BACs) system. F-factor sequences for propagation in E. coli. and individual 
antibiotic resistance genes for selection in bacteria and in eukaryotic cells were recombined 
into B95-8 DNA to generate an EBV BAC. This DNA can be specifically mutated and 
segregated while maintained as an F-plasmid in bacteria, thus enabling in principle high-
throughput screening of mutation of every EBV gene. Recombinant BAC DNA can then be 
transfected into 293 cells (an adenovirus-transformed epithelial cell line) and lytic cycle 
induced by co-transfection with BZLF1 and BALF4 expressing vectors to generate 
recombinant virus stocks. BALF4, the gene encoding the gp110 envelope glycoprotein was 
required in addition to BZLF1 because B95.8 itself contains a deletion within BamHI A 
fragment which does not remove BALF4, but reduces its level of expression in lytic cycle. 
LMP1 deleted EBV recombinants were generated using this approach. Surprisingly EBV 
mutants which lacked either LMP1’s COOH terminus, the transmembrane domains or the 
entire open reading frame were able to generate proliferating B-cell clones whose sustained 
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growth was dependent on fibroblast feeder cells. These studies show that LMP1 is not 
required for the initial stages of blast transformation, but under normal culture condition, is 
required for sustaining proliferation through autocrine/paracrine growth factors (Dirmeier 
et al., 2003). Likewise using an EBNA-1 deficient EBV mutant virus, transformation was 
not completely abrogated but its efficiency was reduced by 10,000 fold. Very interestingly, 
the transformants carried EBV as an integrated genome thereby dispensing with EBNA1’s 
episomal genome maintenance function (Humme et al., 2003). In order to explore the roles 
of the EBV Bcl-2 homolog proteins, BHRF1 and BALF1, several viral mutants, which 
carry single or dually inactivated alleles of BHRF1 and BALF1 were generated (Altmann 
and Hammerschmidt, 2005). Single BHFR1- or BALF1- mutants were equally capable of 
yielding LCLs but only at a high virus dose. Mutants with both BHRF1 and BALF1 
inactivated failed to generate LCLs from resting primary B cells but were able to generate 
clonal LCLs from pre-activated B cells blasts and maintained their proliferation. These 
studies indicated that either BALF1 or BHRF1 is essential to establish LCLs but are 
dispensable for their continued proliferation.  
 
1.11.3 EBV recombinants based on an Akata-EBV-derived BAC 
Another group developed another system using Akata-derived BACs for generating EBV 
recombinants (Kanda et al., 2004). The Akata cell line is derived from an EBV-positive 
sporadic BL case in Japan. It has a Latency I form of infection but with relatively high 
spontaneous lytic activity that is considerably enhanced after antibody cross-linking of the 
cell surface IgG. The same line has another rare property in that it also can generate EBV-
loss Akata BL clones in vitro. Similar to B95.8-derived BAC, Akata-BAC also contains F-
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factor sequence and individual antibiotic resistance genes for selection in bacteria 
(chloramphenicol resistance gene) and in eukaryotic cells (neomycin resistance gene). 
Instead of using 293 cells, the Akata-EBV-negative cell line is used as a virus-producing 
cell line and production of progeny viruses can be induced by using anti-IgG antibodies. 
 
Recombinants carrying either EBER1 alone or EBER2 alone were generated using this 
system and used to evaluate the contributions of EBER1 and EBER2 to EBV-mediated B-
cell growth transformation (Yajima et al., 2005). These studies showed that the 
recombinant EBV expressing EBER2 alone transformed B cells as efficiently as the 
recombinant expressing both; in contrast, the transforming ability of the recombinant 
expressing EBER1 alone was significantly impaired, similar to the level of the recombinant 
lacking both EBER1 and EBER2. These results showed that EBER2 was important for 
efficient B-cell transformation, while EBER 1 is dispensable.  
 
1.11.4 EBV Recombinants expressing conditionally activated target proteins 
To be able to understand the function of a latent protein not only in initiation of 
transformation but importantly also in maintenance of transformed phenotype, a 4-hydroxy-
tamoxifen (4HT)-dependent mutant estrogen receptor hormone binding domain  
(ERTM) was fused to the target protein to create a conditionally activated target protein. In 
the medium without 4HT, this HT-fused protein would be docked, inactivated and 
destabilized in the cytoplasm. To generate the EBNA3AHT recombinants, type 1 
EBNA3AHT cosmid DNA was transfected into P3HR1 cells, together with EcoRI A DNA 
and the BZLF1 expressing vector. The resultant virus was used to infect resting B cells and 
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LCL clones which contained only type1 EBNA3AHT-expressing recombinant EBV 
genomes were isolated and used for further analysis. These experiments showed that the 
growth of EBNA3AHT-expressing LCLs is 4HT dependent, which indicated that the 
EBNA3A has a critical role in maintaining the proliferation of LCLs (Maruo et al., 2003). 
Using the same principle, the parental Akata BAC was used to construct a recombinant 
EBV that expresses a conditionally active EBNA3C (Maruo et al., 2006). In the presence of 
4HT, LCLs expressed the E3C-HT protein and grew like wild-type LCLs, however, in the 
medium without 4HT, E3C-HT protein slowly disappeared and the LCLs gradually ceased 
growing. Wild-type EBNA3C expression from an oriP plasmid transfected into E3C-HT 
LCLs protected the LCLs from growth arrest in medium without 4HT, whereas expression 
of EBNA3A or EBNA3B did not. These results indicate that EBNA3C has an essential role 
in cell cycle progress and the growth maintenance of LCLs (Maruo et al., 2006).  
 
1.12 Aims of this thesis 
From previous work, we know that recombinant virus with a deletion of the key Cp 
regulatory regions (including the GRE and EBNA2 response element) and the C1 and C2 
exons can transform B cells with wild-type efficiency  and Wp is instead adopted as the 
EBNA promoter and appears to compensate entirely for the lack of Cp.  However, the 
importance of Wp has not been fully studied, because of complication of (i) its existence in 
multiple copies and (ii) the EBNA-LP repeat region is encoded by BamHI W repeats. So in 
practice, if one reduces BamHI W repeat copy number, one is reducing the number of 
available Wp for early transcription and one is reducing the size of the EBNA-LP repeat 
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domains, which itself might affect EBNA-LP’s function. The aim of my thesis is to try and 
answer the following questions regarding the role of Wp in transformation: 
(i) To what extent is the number of W copies important in the initiation of B-cell 
growth transformation and/or the maintenance of the transformed phenotype? 
How many W copies are needed for efficient transformation in vitro? 
(ii) Can we distinguish between an effect of reducing Wp copy number itself and 
knock-on effects from reducing EBNA-LP size? 
(iii) Would a BamHI W deleted virus have any activity in B cells , if the postulated 
function of EBNA-LP to help initiate B cell growth activity were rendered 
redundant by pre-activation of B cells into cycle with a mitogen? 
(iv) Previous studies have shown that an EBV recombinant carrying two Wp copies 
with mutated BSAP binding sites failed to transform B cells and inferred that 
EBV ensured the B-cell specificity of its growth-transforming function by 
exploiting BSAP as lineage-specific activator of the transforming programme. 
Therefore the final question to be addressed in this thesis is whether the 
apparent dependence of EBV transforming function upon BSAP binding sites in 
Wp in a 2W virus is still apparent when one increases the number of W copies. 
 72 
Chapter 2. Materials and Methods 
 
2.1   Cell culture 
2.1.1   Maintenance of Cell lines 
The BL cell lines, Raji, Rael and Namalwa and X50-7 and CD+Oku LCLs were maintained 
in exponential growth at 37°C, 5% CO2 in 25cm2 flasks in RPMI 1640 with L-glutamine 
(Sigma) supplemented with 10% v/v foetal calf serum (FCS) (Cambrex Biosciences), and 
10 µg/ml penicillin and streptomycin (Invitrogen). The HEK 293 cell lines were maintained 
in exponential growth at 37°C, 5% CO2 in 100mm dishes in the same medium. 
To passage the adherent cell lines (293, fibroblasts and L cells), the medium was removed 
and the cells rinsed in 1 x PBS.  Cells were trypsinised with 1 x trypsin (0.5% w/v trypsin, 
0.54 mM EDTA (Invitrogen) at 37oC for 2 minutes. Medium was added to terminate 
trypsinisation, the culture was then split 1 in 5 and topped up with appropriate medium 
(DMEM with L-glutamine supplemented with 10% v/v foetal calf serum (FCS) (Cambrex 
Biosciences), and 10 µg/ml penicillin and streptomycin (Invitrogen)) 
 
2.1.2   Cryopreservation of cells 
Approximately 107 cells were pelleted by centrifugation at 1400 rpm for 5 minutes and 
resuspended in 1ml freezing mix (50% v/v B cell medium, 40% v/v FCS and 10% v/v 
dimethyl sulphoxide (DMSO)). Cells were transferred to cryopreservation tubes and frozen 
overnight at -80ºC in a freezing box surrounded by sponge soaked in isopropanol. Cells were 
then moved to the vapour phase of a -180ºC liquid nitrogen freezer for long-term storage. 
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2.1.3   Recovery of cells from liquid nitrogen 
Cells were thawed quickly in a 37ºC water bath and transferred to a 15ml tube. 10ml pre-
warmed B cell medium was added gradually to the cells dropwise to dilute DMSO. Cells 
were pelleted by centrifugation at 1400rpm for 5 minutes, resuspended in the appropriate 
medium and transferred to 25cm3 flasks and incubated at 37 ºC, 5% CO2. 
 
2.1.4   Preparation of CD19 positive B cells from whole blood 
Blood samples were diluted with an equal volume of 1 x PBS, mixed well and layered onto 
lymphocyte separation medium (Lymphoprep, Axis Shield) slowly and carefully. This was 
then centrifuged at 1800rpm for 30 minutes and slowed without the brake. Unfractionated 
mononuclear (UM) cells, which formed a distinct band at the interface between serum and 
separation medium, were collected and washed three times with 1 x PBS using 
centrifugation at 1600rpm for 10 minutes, 1200rpm for 10 minutes and 1000rpm for 10 
minutes. UM cells were resuspended in RPMI/1% v/v FCS, counted and the number of B 
cells estimated based on the assumption that 5% of UM cells were B cells. CD19 
Dynabeads (Invitrogen), magnetic polymer beads coated in anti-CD19 monoclonal 
antibody, were used to positively select B cells. The required number of CD19 Dynabeads 
(approximately 4 beads per B cell) were added to UM cells at a concentration of 
approximately 1x107 beads per ml and incubated at 4 ºC for 30 minutes with a rocking and 
rolling motion. Beads were exposed to a magnet for 2 minutes and CD19-negative cells 
(non-B cells) were removed from the bead-bound B cells. Beads and bound B cells were 
washed five times in 10ml RPMI/1% v/v FCS with exposure to a magnet for 2 minutes 
each time. To detach cells from the beads, Detachabead CD19 (Invitrogen) was added at a 
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concentration of 10µl per 107 B cells in 100µl of RPMI/1% v/v FCS and incubated at room 
temperature for 45 minutes. After incubation, the cells were separated from the beads with 
3 washes of 8ml RPMI/1% v/v FCS with exposure to a magnet for 2 minutes between 
washes  
 
 2.2 Bacteriology 
 2.2.1 Bacteria growth media 
Lennox Broth (LB): a solution of 2% w/v LB Broth base (Fisher) in deionised water, 
sterilised by autoclaving at 121oC, 15psi for 15 minutes. 
LB-agar: a solution of 1.5% w/v agar (Fisher) in LB, sterilised by autoclaving at 121oC, 
15psi for 15 minutes. 
Preparation of LB-agar plates 
The LB-agar was melted in a microwave, cooled to 50oC with the addition of the 
appropriate antibiotics (see Table 2.1) and poured into petri dishes and left to solidify. 
Plates were stored at 4oC for up to 1 week. Before use the plates were dried in a 37oC 
incubator for 30 minutes. 
Table 2.1 Working concentrations of antibiotics 
 
Antibiotics Working concentration 
Ampicillin 100µg/ml 
Chloramphenicol 15 µg/ml 
Tetracyclin 10 µg/ml 
Kanamycin 50 µg/ml 
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2.2.2  Blue/white colony selection 
Blue/white colony screening is a method which can be used for detection of successful 
ligation in vectors containing the lacZ (B-galactosidase) gene. 80μl of 2% w/v 5-bromo-4-
chloro-3-indoyl-β-D-galactoside (X-gal) and 20μl of 100mM isopropyl thio-β-D-
galactoside (IPTG) were spread onto L-agar/ampicillin plates and left for 30 minutes to 
infuse into the agar before the transformed bacteria were plated out. Transformants 
containing vector only appear as blue colonies while transformants with recombinant 
vectors appear as white. 
 
2.2.3  Bacterial strains 
DH5α (supE44 ΔlacU169 (Φ80 lacZ ΔM15) hsdR17 recA1 endA1 gyrA96 thi-1 relA1) – 
used for standard DNA cloning 
DH10B (Δ (mrr-hsd RMS-mcrBC) mcrA recA1) – used for maintaining BACs 
BJ5183 (recB recC sbcB sbcC endA galK met thi-1 bioT hsdR rpsL(strR)) – used for 
homologous recombination of BACs 
 
2.2.4  Preparation of competent E. coli 
Simple and efficient method (SEM) competent E. coli  
A single colony of the appropriate E. coli strain was picked from an agar plate and cultured 
overnight in 10ml LB in a 37oC incubator with vigorous shaking. 100µl overnight culture 
was then used to inoculate 250ml LB supplemented with 5mM MgCl2 and 5mM MgSO4, 
which was then incubated at 18ºC with gentle shaking until the absorbance at 600nm (A600) 
reached 0.6 (approximately 30 hours of growth). The culture was incubated on ice for 10 
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minutes and transferred to 50ml tubes before being centrifuged at 3000rpm for 10 minutes 
at 4 ºC. The cell pellet was resuspended in 80ml ice cold filtered TB buffer (10mM 
piperazine-1,4-bis[2-ethanesulphonic acid] (PIPES), 15mM CaCl2, 250mM KCl, 55mM 
manganese chloride), incubated on ice for 10 minutes before being centrifuged  at 3000rpm 
for 10 minutes at 4 ºC, and then resuspended in 20ml ice cold TB-DMSO (7%v/v). The 
competent cells were dispensed into 40µl aliquots in 1.5ml Eppendorfs, snap frozen in 
liquid nitrogen and stored at –80oC. 
Preparation of TFB competent cells  
Bacterial cells were seeded into 4ml of LB and cultured overnight in a 37oC incubator with 
vigorous shaking. The overnight culture (100 µl) was then used to inoculate 30ml LB 
which was then incubated at 37ºC with gentle shaking until the absorbance at 600nm (A600) 
reached 0.6. The culture was then transferred to a pre-cooled sterile 50ml tube and 
incubated on ice for 30 minutes followed by centrifugation at 3000rpm for 10 minutes at 4 
ºC. The bacterial pellet was then resuspended in 10ml of ice cold TFB buffer (10mM K-
MES pH6.2 [2-(N-morpholino)ethanesulfonic acid (MES) buffer. Adjust the pH to 6.2 
using concentrated KOH], 50mM CaCl2, 45mM MnCl2, 100mM RbCl2) and incubated for 
30 minutes on ice, followed by centrifugation again as above. The competent cells were 
then resuspended in 2.4ml of ice cold TFB buffer and immediately used as described in 
section 2.2.4 (a).  
Preparation of electroporation competent E.coli 
A single colony of DH10B was picked from an agar plate and cultured overnight in 4ml LB 
in a 37oC incubator with vigorous shaking. The overnight culture (200µl) was then used to 
inoculate 200ml LB and grown at 37ºC with shaking until the absorbance at 600nm (A600) 
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reached 0.7. The culture was incubated on ice for 10 minutes and transferred to four 50ml 
tubes before being centrifuged at 3000rpm for 10 minutes at 4 ºC. The cell pellets were 
washed twice using 50ml ice cold 10% v/v glycerol and centrifugation at 3000rpm for 10 
minutes at 4 ºC. The cells were then pooled and washed again with 30ml 10% v/v glycerol 
and then resuspended in 400µl ice cold 10% v/v glycerol. The competent cells were 
dispensed into 20µl aliquots in 1.5ml Eppendorfs, snap frozen in liquid nitrogen and stored 
at –80oC. 
 
2.2.5  Bacterial transformation 
Heat shock 
The SEM competent cells were thawed on ice and 100-200µl of competent cells were 
removed to a pre-chilled 1.5ml Eppendorf. DNA was added to the competent cells and 
incubated on ice for 20 minutes before being heat shocked at 42 ºC for 2 minutes followed 
by 2 minutes incubation on ice. To allow the cells to recover, 1ml of LB was added and the 
cells were incubated at 37 ºC for 1 hour. The cells were then centrifuged and the 
supernatant tipped off to leave approximately 100µl in which the cells were resuspended. 
The entire volume was then plated out on a LB-agar plate with antibiotics and grown 
overnight at 37 ºC. 
Electroporation 
The electroporation competent cells were thawed on ice before DNA was added. The 
sample was then removed to a pre-cooled 1mm gap cuvette (Geneflow) and incubated on 
ice for 10 minutes. The sample was then electroporated using 25µFD and 1.8kV. The 
eletroporated cells were then removed to a 1.5ml eppendorf with 1ml LB and incubated at 
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37 ºC for an hour to recover. The cells were then centrifuged and the supernatant tipped off 
to leave approximately 100µl in which the cells were resuspended. The entire volume was 
then plated out on a L-agar plate with antibiotics and grown overnight at 37 ºC. 
 
2.3   Preparation of DNA 
2.3.1  Small scale purification of plasmid DNA 
Single colonies were picked from an agar plate using sterile yellow tips and incubated in 
3ml of LB supplemented with the appropriate antibiotic. Cultures were grown overnight at 
37oC with shaking. Next day, 1.5ml of culture was transferred to a 1.5ml Eppendorf and the 
cells pelleted by centrifugation at 13000rpm for 30 seconds. The plasmid DNA was 
extracted using a GFX-Microplasmid Prep. kit (Amersham Biosciences) according to the 
manufacturer’s instructions. The DNA was eluted in a final volume of 50µl elution buffer 
and 5µl of DNA was digested with selected restriction enzymes and subjected to agarose 
gel electrophoresis to confirm that the plasmid was correct.  
 
2.3.2 Alkaline lysis 
For the preparation of DNA from bacteria colonies transformed with recombinant EBV 
BACs, an alternative alkaline lysis method was employed. Transformed colonies were 
picked and spread as a lawn onto ¼ of an agar plate per colony. These were grown 
overnight at 37°C and the following day, the lawn was scraped off using sterile wooden 
tooth picks and gently resuspended into a large microtube containing 200µl of ice cold 
resuspension buffer (25mM Tris-HCl pH 8.0, 10mM EDTA, 50mM glucose) containing 
0.2µl RNaseA. 300µl of freshly made lysis buffer (0.2M sodium hydroxide, 1% SDS) was 
 79 
then added and the microtube gently inverted five times to ensure complete mixing. Lysis 
was then allowed to occur for five minutes at room temperature. Following lysis, 
precipitation of chromosomal DNA, protein and cellular debris occurred by the addition of 
a neutralisation buffer (5M potassium acetate, glacial acetic acid at 115ml per litre) with 
tubes inverted gently several times and then left for 10 minutes on ice. Sample tubes were 
then centrifuged for 20 minutes at 13000rpm and the supernatant transferred to a new tube, 
followed by a second identical centrifugation step. The supernatant was then transferred to 
fresh microtubes and DNA precipitated by the addition of 0.6 volumes of isopropanol and 
incubation on ice for 10 minutes. Precipitated DNA was pelleted by centrifugation for 20 
minutes at 13000rpm, the supernatant aspirated and DNA washed with 70% ethanol. After 
a further 5 minute spin and aspiration of the ethanol, pellets were air dried and resuspended 
in the desired volume of 1X TE buffer. 
 
2.3.3 Large scale purification of plasmid DNA 
A single E.coli transformant was picked from an agar plate and incubated in 5ml LB, 
containing the appropriate antibiotic overnight at 37oC with shaking. Next day 1ml of the 
starter culture was used to inoculate 25ml L-broth (midiprep)/200ml L-broth (maxiprep), 
supplemented with the appropriate antibiotics, and grown overnight at 37oC with shaking. 
Plasmid DNA was purified using the Jetstar Midiprep/MaxiPrep kit (Genomed) according 
to manufacturer’s instructions. DNA was resuspended in 100μl (midiprep)/400μl (maxiprep) 
TE buffer and the concentration determined by spectrophotometry. 
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2.4 Cloning techniques 
2.4.1 Restriction enzyme digestion of DNA 
DNA was digested with specific restriction enzyme in the appropriate buffers (Roche or 
New England Biolabs) at the required temperature. For the digestion of the relatively small 
vectors or inserts, a 20µl reaction consisting of 1µg DNA, 2 units of specific restriction 
enzyme, 1X appropriate buffer was set up and incubated at the optimal temperature for 2 
hours. Double or triple digests were usually carried out in a single reaction in a buffer that 
gave optimal activity for each enzyme with appropriate enzymes that were sufficiently 
optimal in a single reaction buffer.  
 
2.4.2  Agarose gel electrophoresis 
The percentage agarose gel used depended upon the size of the expected DNA product but 
was generally between 0.8% and 2% w/v (Molecular Biology Grade, Eurogentec) in 1X 
TBE buffer (90mM Tris-borate, 2mM EDTA, pH8.0). The DNA solution was mixed with 6 
x gel loading buffer (0.25% w/v xylene cyanol, 0.25% w/v bromophenol blue, 30% v/v 
glycerol) loaded onto the gel alongside a 1kb DNA ladder (Invitrogen) and the DNA 
fragments separated by electrophoresis at 90-120 volts. After electrophoresis the gel was 
stained in a bath of 1 x TBE containing 0.5µg/ml ethidium bromide for 3 minutes and the 
DNA visualised using a UV transilluminator and the fragment sizes determined by 
comparison with the 1kb ladder. 
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2.4.3 Field inversion gel electrophoresis (FIGE) 
BAC DNA digested with EcoRI and HindIII was mixed with 6 x gel loading buffer loaded 
onto a 0.8% agarose gel, alongside a 2kb DNA ladder (Invitrogen). Field inversion gels 
were run for 20 hours in a tank with re-circulating buffer with a FIGE Mapper (Biorad) 
power supply using the following programme: 0.8 sec at 135 V in the forward direction, 0.8 
sec at 90 volts in the reverse direction. After electrophoresis the gel was stained in a bath of 
1 x TBE containing 0.5µg/ml ethidium bromide for 3 minutes and the DNA visualised 
using a UV transilluminator and the fragment sizes determined by comparison with the 2kb 
ladder. 
 
2.4.4 Gel extraction of DNA fragments 
PCR products or restriction enzyme digests were separated by agarose gel electrophoresis. 
The ethidium bromide stained gel was examined on a UV transilluminator and the required 
product band was excised and the DNA extracted using Qiagen Gel Extraction kit 
according to the manufacturer’s instructions. The DNA was eluted from the column in 50µl 
sterile deionised water and stored at –20oC until required.  
 
2.4.5 Conventional DNA PCR 
PCR amplification was used to amplify the desired gene from the plasmids which contained 
the relevant cDNA. A 50µl reaction mix was set up in a 0.5ml thin-walled microfuge tube 
containing 20-40ng DNA, 3.5 units of high fidelity Taq polymerase (Roche), 200μM each 
of dATP, dCTP, dGTP, dTTP , 1μM of the  gene-specific (forward and reverse) primers 
(Alta Bioscience) (see Table 2.2), 1.5mM MgCl2 (ABgene) and 1x polymerase reaction 
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buffer (75mM Tris-HCl pH8.8, 20mM ammonium sulphate ((NH4)2SO4), 0.01% v/v 
Tween20) (ABgene). An Eppendorf Thermocycler was used with a hot start at 94oC for 5 
minutes followed by 30–35 cycles of 30 sec. at 95oC to denature the DNA strands, 30sec. to 
1 minute at 45oC-60oC to allow the primers to anneal to the DNA and 2-4 minutes at 72oC 
to allow extension of the product. The annealing temperature and incubation time at each 
stage varied according to the specific primers and product size of each PCR (see Table 2.2). 
The PCR products were separated by agarose gel electrophoresis. 
 
2.4.6 Ligation 
1µl of insert DNA from gel extraction and 1 µl of restriction enzyme digested vector DNA 
were first run on an agarose gel to estimate the concentration. A 20µl ligation reaction was 
set up consisting of a 3:1 molar ratio of insert DNA to vector DNA, 1x rapid ligation buffer 
and 1µl T4 rapid ligase (Roche) and was incubated at room temperature for 15 minutes and 
then used to transform SEM competent E. coli cells. 
 
2.4.7 Sequencing 
DNA was sequenced using a Big Dye Version 3 sequencing kit (Applied Biosystems). 
Approximately 200ng of plasmid DNA was put into a 20µl volume sequencing reaction 
with 3.2pmol of sequencing primer. 4µl Terminator Ready Reaction Mix (Applied 
Biosystems) and 1 x sequencing buffer (40mM Tris-HCl pH9, 1mM MgCl2). An Eppendorf 
Thermocycler was used to denature the samples at 95oC for 2 minutes followed by 25 
cycles of 95oC for 10 seconds, 50oC for 10 seconds and 60oC for 4 minutes. After PCR 
amplification, the DNA was precipitated by the addition of 64µl 96% ethanol and 2µl 
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0.25M EDTA and incubation at room temperature for 15 minutes. The DNA was pelleted 
by centrifugation at 13000rpm for 20 minutes, washed with 70% v/v ethanol, air-dried and 
resuspended in 10µl HiDi formamide (Applied Biosystems). The samples were subjected to 
automated sequence analysis using a 3700 DNA Analyser (Applied Biosystems) provided 
by the Functional Genomics Laboratory, School of Biosciences, University of Birmingham. 
 
2.5 Generation of recombinant viruses using the EBV BAC system 
2.5.1 Recombination 
Recombination in E. coli BJ5183 
Recombinant virus genomes were generated by using the EBV bacterial artificial 
chromosome (BAC) cloning system (Delecluse et al., 1998). Shuttle vectors with 
homologous regions and modified regions were first made (details are described in chapter 
3) and allelic exchange was performed in E. coli strain BJ5183. 
BACs which either contained 2 copies of BamHI W fragments (2W BAC) or were deleted 
for BamHI W fragments (0W BAC) used as the parental BACs (Tierney et al. 2007. 10µg 
of shuttle vector DNA were first linearised overnight with 20 units of the appropriate 
restriction enzyme in a 100 µl reaction. 10µl of the reaction and 7µl of DMSO were then 
added to 200µl of TFB competent BJ5183 containing the parental BAC which were then 
transformed using the heat shock method (see section 2.2.5 (a)), plated out on a 
tetracycline/chloramphenicol agar plate and grown overnight at 37°C. For screening, 
colonies were picked and spread as a lawn onto ¼ of an agar plate containing appropriate 
antibiotics and grown overnight at 37ºC. DNA was extracted by alkaline lysis mini-prep 
and digested with appropriate restriction enzymes. The whole digest was loaded on to a 
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0.8% w/v agarose gel (Fisher) with 1kb and 2kb ladder (Roche) loaded on both sides, and 
subjected to electrophoresis at 55V for 36 hours. After eletrophoresis, the gel was stained 
with ethidium bromide and the DNA visualised using a UV transilluminator. The fragments 
were compared to control digests with the parental BACs and the fragment sizes predicted 
from maps made with MacVector software (Accelrys).  
 
Recombination was used to remove the tetracycline cassette which was flanked by Flp 
recombination target sites. 50ng of plasmid pcp20 (containing Flp recombinase gene and a 
temperature-sensitive replication origin) and 7µl of DMSO were added to 200µl of TFB 
competent cells containing the tet+ recombinant. The cells were then transformed using the 
heat shock method, recovered at 30ºC and plated out on a chloramphenicol/ampicillin agar 
plate and grown for 1-2 days at 30ºC to allow recombination to occur. Colonies were then 
picked and grown at 37 ºC for 8 hours in 4ml of LB containing chloramphenicol only, 
followed by plating out onto a chloramphenicol agar plate and grown at 42 ºC overnight in 
order to inactivate and discard the pcp20 plasmid. After Flp recombination, colonies were 
screened by restriction enzyme digestion. One correct colony was chosen and DNA was 
extracted by alkaline lysis mini-prep and transformed into the DH10B rec A- stable cell line, 
by electroporation (see section 2.2.5 (b)). 
Recombination using pDK46 plasmid 
pDK is a plasmid carrying the red recombinase under the control of an arabinose-inducible 
promoter, a temperature-sensitive replication origin and ampicillin resistance gene. pDK46 
plasmid was transformed into chemically competent DH10B containing the parental BACs 
(2W or 0W) by heat shock and cells were plated out on a chloramphenicol/ampicillin plate 
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and grown overnight at 30 ºC. A single colony was picked from the plate and cultured 
overnight in 4ml LB at 30 ºC. 200 µl of the culture were then used to inoculate 200ml LB 
supplemented with 20mM L-arabinose. This culture was then grown at 30ºC with gentle 
shaking until the absorbance at 600nm (A600) reached 0.6 and electrocompetent cells were 
made as described in section 2.2.4 (c). 3 µg of linearised shuttle vector was then 
transformed in to the electrocompetent DH10B-BAC-pDK46 cells by electroporation (see 
section 2.2.5 (b)) and cells then recovered in arabinose containing media for 3 hours at 
30ºC, during which time recombination occurred. The cells were then plated out on a 
chloramphenicol/tetracycline plate and grown overnight at 42ºC and pDK46 plasmid was 
lost at this temperature. Colonies were screened as described above. If required the 
tetracycline cassette was removed using flp recombination as described in the previous 
section. 
 
2.5.2 Large scale purification of BAC DNA 
500ml of LB containing the appropriate antibiotics were seeded with E.coli transformant 
either directly from an agar plate for from a glycerol stock of the bacteria and grown 
overnight at 37ºC with shaking. A nucleobond AX BAC 100 kit (Macherey-Nagel) was 
used to purify recombinant EBV BAC DNA according to the manufacturer’s instructions. 
DNA was resuspended in 50µl 1X TE buffer. 
 
2.5.3 Transfection of BAC into 293 cells and clone selection 
One day before transfection, 8x105 293 cells were plated in a 6-well plate so that the cells 
were 60-80% confluent at the time of transfection. BAC DNA (5µg) and 10µl of 
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Lipofectamine 2000 (Invitrogen) were diluted in 250µl of Opti-MEM (Invitrogen) 
separately and incubated at room temperature for 5 minutes, mixed together and incubated 
for further 20 minutes. The complexes were then added to the 293 cells and incubated for 3 
hours before 3ml of RPMI1640 10% v/v FCS were added to the cells. The following day, 
the transfected cells were trypsined from the 6 well-plate and transferred to a 150mm 2 dish 
in 30ml medium containing 100µg/ml hygromycin.  Visible colonies were removed from 
the dish to 96 well plates after 3-4 weeks and the cultures gradually expanded from 96 well 
plates to 100mm dishes while maintaining drug selection. 
 
2.5.4 Preparation and purification of virus stocks 
293 cell clones carrying recombinant EBV genomes were plated into 6-well plates 2 days 
before transfection so that the cells were 60-80% confluent at the time of transfection. 0.5 
µg of BZLF1 expressing plasmid (p509), 0.5µg BALF4 plasmid (pRA) and 6 µl of 
Lipofectamine (Invitrogen) were diluted in 100 µl of Opti-MEM (Invitrogen) and incubated 
at room temperature for 30 minutes before being further diluted with 900µl of Opti-MEM. 
The complexes were then added to the 293 cells and incubated for 3 hours before 1ml of 
RPMI 1640 10% v/v FCS was added. The cultures were then incubated for 72 hours.Virus 
containing culture supernatant was then harvested, centrifuged at 1400rpm for 4 minutes 
and filtered using a 0.45µm filter to remove cellular contaminants.  
 
To concentrate and purify virus stocks, 10.5ml of supernatant was added to a 15ml 
Beckman Polyallomer untracentrifuge tube and underlaid with 1ml Optiprep (Axis Shield) 
diluted 1:1 with dilution buffer (0.85% (w/v) NaCl, 60mM Hepes-NaOH, pH 7.4). Tubes 
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were weighed to balance and centrifuged in a SW40 rotor at 20,000rpm for 2 hours with 
low brake. Most of the supernatant was removed by aspiration and discarded and the 
remaining contents, consisting of 1ml of supernatant and concentrated virus particles on a 
cushion of Optiprep, were then mixed and transferred to 4.9ml Beckman tube and topped 
up with Optiprep diluted 1:3 with dilution buffer and centrifuged in a VTi65 vertical rotor 
at 64,000rpm for 2 hours and 40 minutes with low brake. A self-generated gradient of 
Optiprep formed in centrifugation and a visible virus band was harvested with a syringe and 
needle by tube puncture. The virus stock was stored in aliquots at -80°C. 
 
2.5.5 Quantification of virus titres  
To quantify the virus stock, an equal volume of lysis buffer (100µg/ml proteinase K 
(Roche), 10mM Tris-HCl pH8.8, 1.5mM MgCl2, 50mM KCl, 0.1% (v/v) Triton X-100) 
was added to the viral supernatant and incubated at 55ºC for 1 hour followed by 99 ºC for 
10 minutes to heat inactivate the proteinase K. Q-PCR was then carried out for the EBV 
DNA polymerase gene (BALF5). DNA standards were made from Namalwa, a cell line 
known to contain 2 integrated EBV genomes per cell. Namalwa DNA was diluted to 
132ng/µl which corresponds to 40,000EBV genomes/µl, assuming one Namalwa cell 
contains 6.6pg of DNA and 2 EBV genomes. Serial dilutions were made to give standards 
with 10,000, 4000, 400, 100, 20 and 1 EBV genomes/µl. A 25µl reaction volume was set 
up in the wells of a 96 well Optical Reaction Plate (Applied Biosystems) consisting of 5µl 
virus lysate (or DNA standards), 1x Taqman Universal PCR Master Mix (Applied 
Biosystems), 200nM of each EBV Pol primer, 200nM of EBV pol probe (see Table 2.3). 
Thermocycling and fluorescence detection were carried out in an ABI Prism 7500 
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Sequence Detection System (Applied Biosystems). The samples were heated to 50oC for 2 
minutes, 95oC for 10 minutes to activate the Amplitaq Gold, followed by 40 cycles of 
denaturation at 95oC for 15 seconds and primer annealing and extension at 60oC for 1 
minute. Data were analysed using Applied Biosystems Sequence Detection Software 
version 1.4.  
 
 2.6   Characterization of Infection 
2.6.1 Binding assays 
1x106 primary B cells were exposed to purified virus stocks at an moi 50 for 3 hours at 4ºC, 
then the cells were washed 3 times with cold PBS to remove unbound virus. DNA was 
extracted from the cell pellet using a DNAeasy Tissue kit (Qiagen) according to the 
manufacture’s instructions. The DNA was eluted from the columns in 100µl 1X TE buffer. 
A multiplex Q-PCR allowed amplification of the EBV polymerase (Pol) gene with a FAM-
labelled probe and the cellular gene, β2m with a VIC-labelled probe simultaneously. 
Primers and probes were designed using Primer Express software (Applied Biosystems) 
and are detailed in table 2.3. Namalwa BL DNA, known to contain 2 integrated EBV 
genomes per cell, was included in the PCR as standards. PCR reactions contained 50-100ng 
DNA, 1x Taqman Universal mastermix (Applied Biosystems), 200mM of EBV Pol primers, 
200nM EBV Pol probes (Eurogentec), 60nM of β2m primers and 100nM β2m probes. The 
samples were heated to 50 ºC for 2 minutes, 95 ºC for 10 minutes to activate AmpliTaq 
Gold, followed by 40 cycles of 95 ºC for 15 seconds and 60 ºC for 1 minute. Fluorescent 
signals were detected by an ABI Prism 7500 Sequence Detection System (Applied 
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Biosystems) and data were analysed using Applied Biosystems Sequence Detection 
Software version 1.4.  
 
2.6.2 Internalisation assays 
To assay virus internalisation, 4x106 primary B cells were exposed to purified virus stocks 
at an moi 50 overnight at 37 ºC, then treated with chymotrypsin (2mg/ml) at 4 ºC for 1 hour 
to strip off the viruses bound to the cell surface. 1ml PBS containing 1.25mM PMSF and 
5% w/v BSA was added to the cells to stop further proteolysis. Cells were washed twice 
with PBS and DNA was extracted from the cell pellet as described above and subjected to 
Q-PCR assay as described above to determine the number of internalised genomes per cell. 
 
2.6.3 Quantification of EBV transcripts 
RNA isolation 
To assay viral gene transcription, 10x106 primary B cells were exposed to purified virus 
stocks at an moi 50 overnight at 37 ºC  and 3x106 cells were harvested at 1, 2 and 3 days 
post-infection. Total RNA was isolated from infected cells using a Macherey-Nagel 
Nucleospin II kit (Fisher) according to the manufacturer’s instructions. RNA was eluted in 
a final volume of 50µl and the concentration determined using a Nanodrop ND-1000 
spectrophotometer (Labtech International). RNA was then diluted to the concentration of 
100ng/ µl and stored at -80ºC.  
Reverse transcription  
RNA was reverse transcribed to cDNA to study RNA expression. 200ng RNA were 
denatured by heating at 90ºC for 2 minutes and then plunged into ice. Denatured RNA was 
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reverse-transcribed in a 20μl reaction containing 5 units of avian myeloblastosis virus 
reverse transcriptase (AMV-RT) (Roche), 200μM mix of dNTPs, 1μM of the mix of 3’ EBV 
cDNA primers (Alta Bioscience) (see Table 2.4) and 1x reaction buffer (50mM Tris-HCl 
pH8.5, 30mM KCl, 8mM MgCl2, 1mM dithiothreitol (DTT) (Roche). This mixture was 
incubated at 42ºC for 90 minutes, followed by 5 minutes at 90ºC to heat inactivate AMV-RT. 
cDNA was diluted to a final volume of 40μl and stored at -20ºC.        
Q-RT-PCR to detect EBV transcripts 
Q-RT-PCR was used to detect EBV transcripts. Primers and probe combinations for 
specific transcripts are listed in Table 2.4. All EBV-specific probes were FAM labelled, 
while the GAPDH probe was VIC-labelled, therefore the quantity of the test gene 
transcripts can then be normalised to a cellular control gene (GAPDH).  25ng of cDNA 
from above was tested per well of a 96-well plate in a 25µl reaction containing 1x Taqman 
Universal PCR mastermix (Applied Biosystems), primers and probe (Table 2.4) and 1x 
GAPDH mix of primers and probe (Applied Biosystems). All samples were analysed in 
duplicate. The samples were heated to 50oC for 2 minutes, 95oC for 10 minutes to activate 
the Amplitaq Gold, followed by 40 cycles of denaturation at 95oC for 15 seconds and 
primer annealing and extension at 60oC for 1 minute. Dilutions of cDNA from appropriate 
reference cell lines were included for each PCR in order to generate standard curves (Table 
2.4). 
 
2.6.4 Immunofluorescence cell staining 
1x106 primary B cells were exposed to purified virus stocks at an moi 50 overnight at 37 ºC 
and harvested at 2 days post-infection. Cells were washed twice with PBS and resuspended 
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in 200µl PBS. 5µl of the cells were then spotted onto a 10-well microscope slide (Hendley-
Essex). The slide was left at room temperature for the liquid to dry out before being fixed in 
fixing solution (1:1 methanol/ acetone) at -20oC for 30 minutes. 30µl of 10%v/v heat 
inactivated goat serum (HINGS) were added to each well on the slide and incubated at 
room temperature for 20 minutes for blocking. The blocking solution was then drained off 
and replaced with 30µl of primary antibody (Table 2.5) and the slide was incubated for 30 
minutes at 37oC in a moist plastic box. The slide was then washed twice for 5 minutes in 
PBS in staining jar with magnetic flea. 30 µl of Alexa Fluor 488 conjugated secondary 
antibody (Invitrogen) diluted at 1 in 1000 in10%v/v HINGS were added to each well 
immediately after washing and the slide incubated at 37 oC for 1 hour in a moist plastic box. 
The slide was then washed twice again in PBS and a drop of DABCO solution containing 
DAPI (0.5µg/ml) was added to each well followed by a cover slip gently placed on the slide. 
 
Table 2.5 Primary antibodies used to detect EBV latent proteins by 
immunofluorescence cell staining 
 
Target protein Antibody Origin Dilution 
EBNA2 
EBNA-LP 
PE2 
JF186 
Mouse 
Mouse 
1 in 200 
1 in 10 
 
2.6.5 Western Blotting 
Preparation of protein samples 
Approximately 107cells were harvested, washed twice with PBS and lysed in 200µl urea 
buffer (9M urea, 50mM Tris-HCl pH 7.5). Samples were then sonicated for 20 seconds to 
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disrupt genomic DNA. The concentration of the protein was determined using a Biorad kit 
according to the manufacturer’s instructions. The protein samples were diluted in urea gel 
sample buffer (62.5 mM Tris pH6.8, 4% w/v SDS, 5% β-mercaptoethanol, 0.01% w/v 
bromophenol blue, 5M urea, 10% glycerol) to an appropriate concentration and denatured 
at 100oC for 2 minutes prior to sodium dodecyl sulphate– polyacrylamide gel 
electrophoresis (SDS-PAGE) or frozen at -20 oC. 
SDS-PAGE 
Proteins were separated by SDS-PAGE gels using a Bio-Rad Mini Gel Tank. SDS-PAGE 
gels were made in two phases, according to the method of Laemmli (Laemmli, 1970). 
Resolving gels were made with10% acrylamide (2.5ml H2O, 7.5ml Protogel acrylamide 
mixture, 4.2ml 1.5M Tris-HCl pH8.0, 0.15ml 10% w/v SDS, 0.025ml 10% w/v APS and 
0.015ml TEMED) and poured immediately. 300µl water-saturated butanol were applied 
immediately on top to give a uniform surface. The gel was allowed to set for 45 minutes 
before the butanol was poured off and the gel surface washed three times with distilled 
water. A stacking gel consisting of 4% acrylamide (5.8ml H2O, 1.5ml Protogel acrylamide 
mixture, 2.5ml 0.5M Tris-HCl pH6.8, 0.1ml 10% w/v SDS, 0.05ml 10% w/v APS and 
0.03ml TEMED) was made and pipetted on top of the resolving gel. Gel-forming combs 
were inserted into the stacking gel and the gel left to polymerise for 30 minutes. The gel 
was placed into the Bio-Rad running tanks and submerged in running buffer (25mM Tris-
HCl pH8.3, 192mM glycine, 0.1% w/v SDS). 20µg of protein samples were loaded into the 
wells alongside 6µl SeeBlue® Plus2 pre-stained marker (Invitrogen). The proteins were run 
into the stacking gel at 60V until the bands had passed the stacking gel and run into the 
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resolving gel, after which the voltage was increased to 120V until the samples reached the 
base of the gel.  
 
Western blotting 
After SDS-PAGE, protein samples were blotted onto a nitrocellulose membrane 
(BioTraceTM NT 0.2µm nitrocellulose filters, PALL Life Sciences). A blotting cassette was 
set up in which the gel and the nitrocellulose membrane were sandwiched between pieces 
of 3MM Whatman filter paper and sponges pre-soaked in blotting buffer (25mM Tris-HCl 
pH8.3, 192mM glycine, 20% v/v methanol). The blotting cassette was placed in Bio-Rad 
Trans-blotTM mini-cell blotting chambers, submerged in blotting buffer and protein transfer 
carried out at 11V for 18 hours in a cold room with an ice cooling unit present in the 
blotting chamber. 
 
After 18 hours blotting, the membrane was then removed gently from the cassette and 
washed briefly in distilled water before being stained with Ponceau S stain (1% w/v 
Ponceau S (Sigma) in 3% trichloroacetic acid) for 3-5 minutes to visualise the marker and 
the sample proteins. The membrane was washed twice in PBS with 0.1% v/v Tween80 until 
the stain had been removed and then incubated in blocking solution (5%w/v skimmed milk 
powder in PBS-0.1% Tween) for 1 hour at room temperature with shaking. The membranes 
were finally sealed in plastic bags with 10ml of primary antibody (Table 2.6) diluted in 
blocking solution and incubated with shaking overnight at 4oC. 
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Following incubation, the primary antibody solution was drained off (the antibody was 
stored at –20oC and reused several times) and the membrane washed twice for 10 minutes 
in 1 x PBS-0.1% Tween20. The membrane was then sealed in a bag with the secondary 
peroxidase-conjugated antibody, diluted at 1 in 1000 in blocking solution, and incubated 
with shaking at room temperature for 2 hour. The secondary antibody was then discarded 
and the membrane washed six times for 15 minutes each in 1 x PBS-0.1% Tween20.  
 
Table 2.6 Primary antibodies used to detect EBV latent proteins by Western Blotting 
 
Target protein Antibody Origin Dilution Reference 
EBNA1 
EBNA2 
EBNA-LP 
EBNA3A 
EBNA3C 
LMP1 
LMP2A 
BHRF1 
1H4 
PE2 
JF186 
HG/RS22 
E3CA10 
CSI-4 
14B7 
5B11 
Rat 
Mouse 
Mouse 
Mouse 
Mouse 
Mouse 
Rat 
Mouse 
1 in 50 
1 in 50 
1 in 50 
1 in 50 
1 in 50 
1 in 25 
1 in 50 
1 in 1000 
(Grasser et al. 1994) 
(Young et al. 1989) 
(Finke et al. 1987) 
(Maunders et al. 1994) 
(Maunders et al. 1994) 
(Rowe et al. 1987a) 
(Fruehing et al. 1996) 
Millipore 
 
To visualise the proteins, the membrane was incubated in equal amounts of ECL reagents A 
and B (Amersham) for 1 minute before being wrapped in Saranwrap and exposed to Kodak 
X-Omat AR film in an autoradiograph cassette. Exposure times varied from 10 seconds to 
30 minutes depending upon the strength of the signal. The membrane was washed twice 
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with PBS-0.1% Tween and either wrapped wet in Saranwrap and stored at 4 oC or was re-
probed with an alternative primary antibody after additional blocking. 
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Chapter 3. The role of EBV BamHI W copy number in B cell growth 
transformation 
 
The BamHI W promoter, Wp, is present in each BamHI W repeat in the EBV genome and 
is selectively activated immediately after infection. The number of BamHI W repeats, and 
therefore the number of Wp copies (from 3-12 copies) varies between EBV strains. It has 
been suggested that Wp may be designed to function particularly well in the quiescent 
environment of a resting B cell due to its presence in multiple copies. In previous studies, 
recombinant viruses carrying only two copies of Wp were able to transform B cells in vitro, 
but the transformation efficiency was much lower compared to the parental virus carrying 
11 copies of Wp (Tierney et al., 2007). The first part of this thesis examines the importance 
of Wp copy number for the initiation and/or maintenance of B-cell growth transformation 
and seeks to determine just how many W copies are needed for efficient transformation 
in vitro. 
 
3.1 Generation of recombinant EBV carrying different numbers of BamHI W 
In order to explore the role of BamHI W copy number in B cell growth transformation, a 
panel of recombinant EBV BACs carrying different numbers of BamHI W (nW) were first 
generated (Figure 3.1). A wild-type B95.8 EBV-derived BAC (2089) was used as the 
parental BAC. The 2089 BAC genome contains a GFP-expressing gene, as well as 
chloramphenicol and hygromycin resistance genes for selection in bacteria and eukaryotic 
cells, respectively. 2089 DNA was first transformed into recA+ BJ5183 E coli by 
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electroporation. Transformants were then selected on chloramphenicol agar plates. Due to 
the active recombinase in the BJ5183 cells, recombination occurred between the BamHI W 
fragments resulting in loss of some repeats from the 2089 genome in some transformants. 
This allowed one to generate recombinant EBVs with different numbers of BamHI W 
copies. BAC DNA was isolated from several clones using alkaline lysis miniprep method, 
digested with BamHI restriction enzyme and subjected to gel electrophoresis. The 
restriction profile of BamHI digestion (Figure 3.2A) showed the genome was intact and the 
only difference seen was in the brightness of the 3kb BamHI W band compared to that from 
2089 indicating that some of these clones contained lower numbers of BamHI W copies. 
The DNA from these clones was then digested with EcoRI and HindIII and subjected to 
field inversion gel electrophoresis (FIGE). EcoRI and HindIII cut either side of BamHI W 
region and therefore the digestion profile allows one to determine the number of BamHI W 
copies in the genome. Figure 3.2B shows the EcoRI and HindIII restriction profile of the 
selected clones differing only in the size of the band containing the BamHI W repeat region. 
Recombinant EBVs carrying 0 to 9 copies of BamHI W were selected and DNA of the 
selected clones transformed into the recA- DH10B E coli strain to prevent any additional 
recombination occurring. Transformants were rescreened again and glycerol stocks were 
made from the selected clones and stored at -80ºC.  
 
To generate virus-producing clones, the BAC DNA was purified and transfected into 293 
cells using Lipofectamine 2000 (Invitrogen). Stably transfected clones were selected by 
growth in hygromycin B and gradually expanded to generate cell lines. For each 
recombinant, many clones were grown out and tested for their ability to produce virus. For 
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each recombinant, the best two virus producing clones were selected for further study. To 
produce virus stocks from these cells, lytic cycle replication was induced by co-transfection 
of two plasmids, p509 (Hammerschmidt and Sugden, 1988) and pRA (Neuhierl et al. 2002), 
which express the immediate early transactivator BZLF1 and late viral glycoprotein 
BALF4 (gp110), respectively. Supernatant from cells induced for 72 hours was harvested, 
concentrated and purified by density gradient centrifugation and the virus titre quantified by 
Q-PCR specific for the EBV polymerase gene BALF5. Virus stocks were then stored at -
80ºC. 
 
3.2 Infection of resting B cells with recombinant viruses 
3.2.1 Viral binding and internalisation into resting B cells 
The first set of experiments aimed to examine the very early events following EBV 
infection of primary resting B cells in terms of virus binding and its subsequent 
internalisation using recombinant EBV carrying 0 to 7 copies of BamHI W repeat (0W-
7W). Fresh primary B cells were isolated from buffy coats by CD19-positive selection (% 
purity was consistently greater than 90% by FACS analysis) and exposed to purified virus 
at a multiplicity of infection (m.o.i.) of 50 virus genome copies per cell. To measure the 
amount of each virus initially bound to the cells, B cells were exposed to purified virus for 
3 hours at 4ºC. Unbound virus was washed off and cells harvested for DNA extraction. To 
measure the amount of each virus that had entered the cells, B cells were exposed to 
purified virus for 3 hours at 4 ºC, followed by 18 hours incubation at 37 ºC and treatment 
with chymotrypsin to strip off any virus particles still bound to the cell surface. DNA was 
extracted from the cell samples and subjected to Q-PCR assay for the EBV polymerase 
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gene (BALF5) and cellular gene, β2-microglobulin to determine the numbers of virus 
genomes. Namalwa-BL, containing 2 integrated copies of EBV per diploid cell, was used 
as a reference line. Figure 3.3 shows the result of Q-PCR assays from one representative B-
cell infection experiment measuring the amount of each virus binding (Figure 3.3A) and 
internalising (Figure 3.3B). In this experiment, all viruses bound with similar efficiency 
with between 22 (7W) and 35 (6W) virus genomes binding per cell. The number of virus 
genomes internalised was also similar with between 0.7 and 2.7 genomes per cell. The 
same experiment was carried out 3 times and in each case, the data showed that viruses 
carrying different number of BamHI W copies bound and entered B cells with similar 
efficiency. However, it should be noted that due to differences in the source of blood 
samples (buffy coats or apheresis cones (cones)), and variation between individual donors, 
the absolute number of virus genomes bound/internalised per cell differed in each 
experiment. Therefore, only one representative result is shown here and in future 
experiments. 
 
3.2.2 EBV gene transcription at early time points following B cell infection 
The effect of reducing the number of BamHI W copies on the initiation of EBV gene 
transcription early after infection was then examined by Q-RT-PCR. Freshly isolated 
primary B cells were infected with recombinant nW viruses at an m.o.i. of 50. Total RNA 
was harvested from the cultures of infected cells at 24-hours intervals over 3 days post 
infection, reverse-transcribed into cDNA and subjected to Q-PCR for EBV latent gene 
transcripts and the endogenous control GAPDH. The positions of the primers and probe 
sequences relative to the transcripts are shown in Figure 3.4A. The level of EBV transcripts 
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were normalised to GAPDH to allow for variations in cDNA input, and results are plotted 
relative to a suitable reference cell line assigned an arbitrary value of 1. This experiment 
was carried out 3 times independently and the results from a representative experiment, 
examining the cells infected with 0W-7W over 3 days post infection are shown in Figure 
3.4B. The first two rows of the graphs show that there was no detection of Wp-initiated, 
BHRF1, EBNA2 and Cp-initiated transcripts in cells infected with 0W or 1W viruses. The 
third row of the graphs shows that there was low level of transcripts detected in cells 
infected with 2W virus, while cells infected with 3W-5W virus showed progressively 
increasing level of transcripts. Cell infected with 6W and 7W viruses showed similar level 
of transcripts to 5W. Overall, cells infected with 3W-7W viruses showed similar kinetics of 
transcription; Wp was activated to very high levels within the first 24 hours post infection, 
followed by a rapid and then gradual decline. BHRF1 transcripts peaked within 24 hours 
post infection and then rapidly declined, exactly matching the kinetics of Wp-activity. 
EBNA2 transcripts also showed a pattern with a peak expression within the first 1 or 2 days, 
with higher copy number virus peaking earlier. Cp was activated at very low levels in the 
first 24 hours post infection and gradually increased. In contrast, cells infected with the 2W 
virus showed different kinetics; a lower level of Wp was activated in the first 24 hours, 
followed by a gradual increase up to 48 hours with the same level remaining at 72 hours. 
Both BHRF1 and EBNA2 transcripts showed similar patterns, matching the kinetics of Wp 
activity. Figure 3.5 shows the results from a second similar experiment using 0W-5W 
viruses with time points at 18 hours, 24 hours and 48 hours post infection. Similar patterns 
of Wp-, and Cp-initiated and viral gene transcription were seen confirming the previous 
data. Thus, in conclusion, no viral transcripts were detected in 0W and 1W virus infections; 
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a low level of transcripts was detected with 2W virus, while the overall level of transcripts 
increased progressively from 3W to 5W virus. These results indicate that at least 5 copies 
of Wp are required for optimal activation of Wp and for the subsequent switching to Cp.  It 
should be noted that, in a later B-cell infection experiment (Figure 4.2) using B cells 
isolated from cones rather than buffy coats, B cells infected with 1W virus had some 
detectable Wp-initated, EBNA2 and Cp-initiated transcripts but at levels 10 fold lower than 
2W virus. However in these later experiments, there was still no detectable transcription 
from the 0W-infected cells (Figure 4.2).   
 
3.2.3 EBV protein expression at early time points following B cell infection 
Two of the earliest markers of viral infection in B cells, EBNA-LP and EBNA2 were 
monitored by immunofluorescence cell staining.  B cells were infected with 0W and 2W-
6W at an m.o.i of 50, harvested at day 3 post infection, spotted onto a 10-well slide, fixed 
and stained for EBNA-LP and EBNA2 using monoclonal antibodies (mAbs) JF186 (1/100) 
and PE2 (1/200) respectively (Figure 3.6A). EBNA-LP-positive and EBNA2-positive cells 
(stained red) and the total number of DAPI positive cells (blue) were counted on 4 fields of 
at least 100 cells to determine the percentage of EBV antigen-expressing cells (Figure 
3.6B). In line with the Q-RT-PCR data, no EBNA-LP and EBNA2 were observed in 
cultures infected with 0W and 1W virus and few cells from the 2W infected culture stained 
positive for EBNA-LP and EBNA2 (2.3% and 4.9%, respectively). The percentage of 
EBNA-LP- and EBNA2-positive cells increased by nearly 10 fold with 3W virus (20% and 
27.7%, respectively), and there was a further slight increase with 4W virus (26.6% and 
33.3%, respectively), while 5W and 6W were similar to each other in having significant 
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more antigen staining (68.7% and 47.2%, respectively in 5W and 55.7% and 57%, 
respectively in 6W).  
 
3.2.4 Transformation efficiencies of recombinant viruses 
The ultimate test of a virus’ B-cell-transforming activity requires the analysis of cultures 
for cell proliferation leading to successful LCL outgrowth. To quantitate the transformation 
efficiencies of the recombinant viruses, aliquots of primary B cells were infected with the 
same panel of recombinant nW viruses (0W-7W) at m.o.i.s of 1, 5, 10, 20, 50 and 100. 
Infected B cells were then plated out at 104 cells/well in 96-well plates , grown with regular 
feeding, and after 6 weeks the number of wells showing actively growing transformed cell 
foci were counted. Figure 3.7A shows the results from one such experiment plotted as bar 
charts. The top two graphs show that the 0W and 1W virus failed to transform B cells at 
any of the m.o.i. during the 6 weeks post infection. 2W showed a low level of 
transformation in comparison to 3W-6W; transformation progressively increased from 3W 
to 5W, while 5W, 6W and 7W showed similar transformation efficiency. Figure 3.7B 
shows the data from the same experiment plotted as log (m.o.i.) against number of wells 
transformed, which allows one to determine the m.o.i at which 50% of wells are 
transformed for each nW virus Figure 3.7C shows that for 2W virus, the m.o.i. for 50% 
transformation was 44.8; for 3W and 4W, the m.o.i. was approximately 10 fold lower 
(m.o.i.: 4.4 and 5.0, respectively). For 5W, 6W and 7W, the m.o.i. for 50% transformation 
(0.04, 1.9 and 0.2, respectively) was at least 30-50 fold lower than for 2W. The high m.o.i. 
required for 50% transformation seen in 2W virus indicates that the 2W virus was severely 
impaired for transformation efficiency. 
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Figure 3.8 shows the results from a similar experiment with 0W to 7W viruses at m.o.i.s of 
0.1, 0.5, 1, 5, 10, 20, 50 and 100. As before, no transformation was seen with 0W and 1W 
virus infections, and a progressively increasing level of transformation was seen with 2W to 
5W (optimal transformation efficiency) (Figure 3.8A). Data from the same experiment 
were plotted as log (m.o.i.) against number of wells transformed (Figure 3.8B). In this 
particular experiment, the m.o.i. for 50% transformation with 2W was 90.7, which 
decreased to between 0.2 and 0.5 with the 5W and 7W virus (Figure 3.8C). The overall 
pattern of results was similar to that observed in the first transformation assay (Figure 3.7). 
In conclusion, the 2W virus transformed with significantly less efficiency than any of the 
other W viruses. The 5W, 6W and 7W viruses transformed most efficiently, with 3W and 
4W transforming with an intermediate efficiency. This result correlated with the original 
data from the QRT-PCR assay measurement of Wp- and Cp-initiated transcripts. When we 
tested virus with higher copy number of BamHI W (data not shown), the transformation 
efficiencies for 8W, 9W and 11W (2089), were very similar to 5W, 6W and 7W, indicating 
that 5 BamHI W copies are sufficient for maximum transformation efficiency. Taking 
together the data from Q-RT-PCR, IF staining and transformation assays, we conclude that 
at least five copies of the BamHI W fragment (i.e. five copies of Wp) are required for 
optimal promoter activation and efficient B cell transformation in vitro. 
 
3.2.5 EBNA-LP expression in established LCLs 
B cells transformed by each nW virus were cultured and expanded for several weeks to 
establish LCLs. Figure 3.9 shows the western blot detecting the EBNA-LP expression in 
each established LCL. Unexpectedly, EBNA-LP expressed from 2W-derived LCLs showed 
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sizes equivalent to 2 and 3 repeat EBNA-LP; EBNA-LP from 3W-derived LCLs showed 
the sizes equivalent to 3 and 5 repeat EBNA-LP and EBNA-LP from 4W-derived LCLs 
showed the sizes equivalent to 4, 5 and 6 repeat EBNA-LP. Whereas the sizes of the 
EBNA-LP expressed from 5W-, 6W- and 7W-derived LCLs correlated to the number of 
BamHI W copies in the viruses (5, 6 and 7 repeat EBNA-LP, respectively). 
 
3.3 Infection of pre-activated B cells with recombinant viruses 
In order to determine whether infection of pre-activated human B cells might overcome the 
failure of 0W and the impairment of 2W virus in activation of viral gene transcription in 
resting primary B cells, we repeated the previous experiments in cycling B blasts.  B blasts 
were generated from resting primary B cells by co-cultivation on CD40 ligand-expressing 
feeder cells with medium containing IL4 for 14 days, and then removed from the feeders 
and IL4 containing medium immediately before infection with 0W, 2W, 3W and 5W 
viruses. In parallel, infection of BL41, an EBV-negative Burkitt lymphoma cell line was 
also analysed. This experiment was carried out 3 times independently and Figure 3.10 
shows Q-RT-PCR analysis from one representative experiment comparing Wp-initiated, 
Cp-initiated and EBNA2 transcription on day 2 post infection. As shown previously, 
resting B-cell infection with 0W virus showed no Wp and Cp activities and no EBNA2 
transcription was detected. Infection with 2W virus resulted in very low level of Wp and Cp 
activation and EBNA2 transcription while 3W and 5W virus gave high levels of Wp-
initiated, EBNA2, and Cp-initiated transcription. Overall the same pattern and similar 
levels of gene transcription were seen in infected B blasts and BL41 cells as in resting B 
cells, indicating that the cellular environment of pre-activated cycling B cells could not 
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overcome the failure of 0W and the impairment of 2W virus in initiating the gene 
transcription associated with the growth transformation program.  
 
Transformation assays using B blasts made as above were carried out to determine whether 
the transformation efficiency of 2W virus could be enhanced in pre-activated cycling B 
cells. However, no transformation was ever observed using B blasts made in this way (data 
not shown). Therefore, alternative experiments were then carried out using soluble CD40 
ligand and IL4 in order to determine whether this method of B cell activation could 
enhance the transformation ability of the impaired 2W virus. Resting primary B cells were 
infected with either the 2W or 5W virus at m.o.i.s. of 0.1, 1, 5, 10, 25, 50, 100 in duplicate. 
One set of infected B cells was then plated in soluble CD40 ligand and IL4 containing 
medium at 104 cells/well in 96-well plates; the other set of infected B cells was plated in 
regular medium at 104 cells/well in 96-well plates. Thereafter all cultures were fed weekly 
using medium without CD 40 ligand (CD40L) and IL4, therefore only the virus-
transformed cells could grow out to become LCLs. After 6 weeks, all wells with actively 
growing transformed cell foci were counted and the results plotted against m.o.i. Figure 
3.11A shows the result from the B cell infection without CD40L/IL4 and Figure 3.11B 
shows the result from the parallel assay with CD40L/IL4. In this experiment, 100% of 
transformation was seen down to 25 m.o.i. in 2W infection with or without CD40L/IL4, 
and down to 5 or 10 m.o.i. in 5W infection with or without CD40L/IL4. Data from the 
same experiment were plotted as log (m.o.i.) against number of wells transformed (Figure 
3.11C). Figure 3.11D shows that for 2W virus without CD40L/IL4, the m.o.i. for 50% 
transformation was 11.5, which is similar to the m.o.i for 2W virus with CD40L/IL4 (m.o.i: 
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10.4);  the m.o.i. for 50% transformation for 5W with or without CD40L/IL4 were also 
very similar (0.5 and 0.6, respectively). Therefore, we concluded that there is no significant 
difference in B cell transformation with or without CD40L/IL4 in either 2W or 5W. 
 
3.4 Discussion 
Epstein-Barr virus possesses a unique set of latent genes whose constitutive expression in B 
cells leads to cell growth transformation. This growth transforming program is initiated 
through the activation of a promoter, Wp, which is located within each BamHI W repeat of 
the EBV genome. Early work on Wp regulation from this laboratory using in vitro reporter 
assays identified the presence of three regulatory regions, UAS1, UAS2 and UAS3 and 
identified the transcription factor binding sites in UAS1 and UAS2 (Bell et al., 1998, Kirby 
et al., 2000, Tierney et al., 2007). In order to understand the Wp regulation in the more 
complex setting of the natural virus genome, Tierney et al. subsequently  generated a series 
of recombinant viruses carrying different mutations in the Wp UAS1 and UAS2 regulatory 
regions (Tierney et al., 2007). However, because of the complication of Wp’s existence in 
multiple copies, it was difficult to make mutations in every Wp copy. With previous studies 
showing that viruses carrying only two copies of Wp transformed B cells in vitro (Kempkes 
et al., 1995b, Yoo et al., 1997),  a recombinant EBV BAC with only two BamHI W copies 
was generated and used as the parental construct to generate mutant recombinant EBVs in 
which both copies of W contained the desired mutations (Tierney et al., 2007). 
 
The work in this chapter was prompted by the observation from the above work that 2W 
wild-type virus, though capable of transformation, was less active in this respect than the 
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prototype EBV recombinant 2089, which had 11 wild-type W copies (Tierney et al., 2007). 
In the first section of this work, we tried to understand to what extent the number of W 
copies is important in initiation of B-cell growth transformation and/or maintenance of the 
transformed phenotype and how many Wp copies are required for efficient transformation 
in vitro. 
 
In order to understand the role of Wp copy number in B-cell growth transformation in the 
context of the virus, a panel of EBV recombinant viruses with different numbers of BamHI 
W fragments was initially generated using the B95.8-derived BAC system. The amount of 
virus produced from recombinant BAC containing 293 cells following BZLF1 induction of 
the lytic cycle was found to vary significantly between different 293 clones. In addition, 
variation also occurred between virus batches produced from the same 293 clones at 
different times. Therefore, to be able to compare these nW viruses, it was important to 
equalise the amount of virus in stocks made from each virus induction and to ensure the 
purity of the virus stocks. Measuring the green Raji cells (GFP-positive cells) after 
infection of Raji cells with the virus stocks, called the “green Raji units” assay has been 
used to determine the infectious virion content in some studies (Dirmeier et al., 2003, 
Neuhierl et al., 2002). However, we have observed that recombinant viruses tend to 
gradually lose GFP expression after passage in culture, and produce infectious virion 
without GFP. Therefore, using “green Raji units” may underestimate the virion content. A 
second method using Q-PCR amplification of the EBV polymerase gene (BALF5) to 
determine virion content has been reported (Shannon-Lowe et al., 2005). However, using 
Q-PCR to determine virion content may overestimate by detecting free DNA in the virus 
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prep. Therefore, intact whole virus particles were purified away from empty capsids, 
microvesicles and cell debris using Optiprep (Axis Shield) self-generated gradient 
centrifugation (Moller-Larsen and Christensen, 1998) to ensure the purity of the virus 
stocks before titrating using Q-PCR. 
 
B cells are another key component in this work. As we had no constant source of tonsils 
from which to isolate B cells, we instead used buffy coat as the source. Due to the limited 
amount of B cells we could isolate from the buffy coats, it was impossible to characterise 
the viruses in all aspects (binding, internalisation, viral RNA transcription, protein 
expression and transformation) in a single experiment. Additionally, because of changes at 
the Blood Transfusion Service in Birmingham part way through the work, the source of B 
cells changed from buffy coats to apheresis cones (cones). We observed that the cones 
which were obtained earlier than buffy coats relative to the time of bleeding, produced 
better yields with greater cell viability for infection experiments. As a result of this 
difference in the source of blood samples (buffy coats vs. cones) and of natural variation 
between B cells preparation from individual donors, the absolute values for virus binding, 
internalisation, transcription, protein expression and transformation vary between 
experiments but the overall patterns of results (comparing viruses with different copies) 
remained the same. Therefore, the results from a representative single experiment are 
shown throughout this part of the work. 
 
First, the nW virus preparations were added at equal m.o.i for virus binding and the 
subsequent internalisation assays (Figure 3.3). In the example shown, infection with m.o.i 
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of 50, each nW virus gave a similar number of virus genomes (between 22 and 35 per cell) 
bound and a similar number (between 0.7 and 2.7 per cell) internalised into B cells. Thus, 
approximately 10% of the virus bound to the cell surface internalised, which is a similar 
proportion to that previously reported (Shannon-Lowe et al., 2005). This experiment was 
repeated several times (Figure 3.3 and data not shown).While the absolute values of virus 
binding and internalisation varied between experiments, we generally observed a similar 
level of binding and internalisation for all the viruses within a single experiment. Therefore, 
we believe that there was no significant difference seen between any of the nW viruses in 
their ability to bind and deliver their genome into B cells. With this as background, we 
could then directly compare the viruses for gene expression post infection and subsequently 
for transforming ability.   
 
For this purpose, we focused on two sets of assays looking at early transcription and 
antigen expression (during the first 72 hours post infection) and long-term transformation 
(after 6 weeks culture). The early transcriptional events in B-cell infection were first 
monitored by Q-RT-PCR. Wp-initiated, Cp-initiated and EBNA2 transcripts were 
quantitated by high sensitivity Q-RT-PCR assays that were capable of detecting a single 
expressing cell in a background of 105 negative cells (Bell et al., 2006). Transcripts 
encoding BHRF1, recently described as a latent protein and strongly related to Wp activity 
(Kelly et al., 2009), were also monitored by Q-RT-PCR assays using an LCL generated 
with a lytic cycle-deficient BZLF1-knocked out virus (BZKO) as a standard. The primers 
for all the Q-RT-PCR assays were designed to go across splices (e.g. for EBNA2, the 
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reverse primer and probe are in the YH exon but the forward primer spans the Y2/YH 
junction), thus determining the RNA specificity of the assays.  
 
From the results of the Q-RT-PCR assays, we saw a correlation between the level of Wp-
initiated transcripts and the numbers of Wp copies. There was a trend for increasing Wp 
activity going from 1W to 5W, suggesting that most (if not all) of the Wp promoters in 
these viruses were functional immediately post infection. However, it should be noted this 
does not apply to viruses carrying more than 5 copies of Wp. Beyond 5W, viruses showed 
similar levels of Wp-initiated transcripts, implying they had reached the maximum 
threshold level of Wp usage. This phenomenon may be down to the transcriptional 
interference from upstream Wp-initiated transcripts affecting downstream Wp usage, in a 
manner like that proposed for Cp interfering with Wp usage later in the infection process 
(Puglielli et al., 1996, Yoo et al., 1997, Puglielli et al., 1997).  
 
BHRF1 was originally recognised as a lytic gene but in recent studies, it has been reported 
that BHRF1 transcripts are expressed very early post infection. Furthermore, BHRF1 gene-
deleted virus had lower transforming ability at low m.o.i., suggesting that BHRF1 protein 
(a Bcl-2 homologue) was protecting early infected B cells from apoptosis (Altmann and 
Hammerschmidt, 2005). More recently, it was shown that there was a strong connection 
between Wp activity and BHRF1 transcription, and that BHRF1 expression is also a feature 
of all in vitro transformed cells (Kelly et al., 2009). The results in Figure 3.4 and Figure 3.5 
showed a burst of BHRF1 transcription immediately post infection followed by rapid 
decline, which matched the kinetics of Wp activity as previously reported (Kelly et al., 
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2009). Furthermore, viruses with more copies of Wp also showed more BHRF1 transcripts, 
supporting that view that Wp is driving BHRF1 expression in early infection. 
 
 EBNA2 is encoded by Wp-initiated transcripts immediately post infection (Alfieri et al., 
1991). Figure 3.4 and Figure 3.5 showed that the kinetics of EBNA2 transcription within 
the first 72 hours post infection were similar to the kinetics of Wp activity, viruses with 
higher number of Wp copies showing higher EBNA2 transcripts. EBNA-LP is also 
encoded by Wp-initiated transcripts and EBNA2 and EBNA-LP are the first two viral 
antigens expressed immediately post infection. Expression of these two early viral antigens 
at the single cell level was detected by immunofluorescence cell staining and recorded as 
the percentage of antigen-positive cells. Consistent with the Q-RT-PCR data, no EBNA-LP 
and EBNA2 expression was detected in cells infected with 0W virus and progressively 
increasing level of EBNA-LP and EBNA2 were expressed from 2W to 5W viruses; 
whereas virus carrying more than 5 copies of Wp showed no further increase. 
 
EBNA2, acting either alone or in cooperation with EBNA-LP, then serves to activate the 
alternative EBNA promoter Cp (Yoo and Speck, 2000, Schlager et al., 1996, Jin and Speck, 
1992, Harada and Kieff, 1997), and this leads to the broadening of viral antigen expression. 
Overall, our two experiments (Figure 3.7 and Figure 3.8) indeed showed that the level of 
Wp activity declined after 24 hours post infection as the level of Cp activity increased. 
However, looking closely, with 3W to 7W viruses, Wp activity peaked within the first 24 
hours post infection and was followed by a rapid and then more gradual decline, while Cp 
activity was induced later, becoming apparent by 48 to 72 hours post infection. This 
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promoter-switching phenomenon matched previous observations (Schlager et al., 1996, 
Woisetschlaeger et al., 1991, Woisetschlaeger et al., 1990). However, with 2W viruses, 
different kinetics were observed; the level of Wp-initiated transcripts was less than 20% of 
that in 5W virus. With the low Wp activity in 2W virus, the level of Cp induced was also 
very low and the promoter switching was not apparent within the time scale of the 
experiment. 
 
In the case of 0W, the deletion of all Wp copies means there is no Wp-initiated EBNA2, 
EBNA-LP or EBNA1 products which could potentially activate Cp (Harada and Kieff, 
1997, Jin and Speck, 1992, Nilsson et al., 2001, Schlager et al., 1996, Yoo and Speck, 
2000). As might be predicted, we found that in the absence of Wp, Cp was not activated. 
Therefore, unlike Wp, Cp is dependent on viral factors (possibly EBNA2, EBNA-LP and/or 
EBNA1) for its activation. Since Cp reporter constructs are active when introduced into 
cycling EBV-negative BL cell lines, we wondered whether the pre-activation of normal 
resting B cells into cycle with mitogenic signal (CD40L/IL4) might allow Cp to become 
active in the 0W to 2W viruses (Figure 3.10). In fact, Cp activity remained silent in cycling 
B cells infected with 0W virus, and was not increased with 1W to 2W viruses, suggesting 
that Cp is absolutely dependent on the viral factors.  
 
Note that in the case of the 1W virus, we failed to detect any Wp or Cp activity in B cells 
isolated from buffy coats; however in more recent experiments, with B cells isolated from 
cones, we could detect extremely low levels of Wp and Cp activity (about 100 fold less 
than 5W virus) and an even lower level of EBNA2 transcription (more than 100 fold less 
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than 5W virus). Further work needs to be carried out to address the issue of EBNA-LP and 
EBNA2 protein expression in such experiments (immunofluorescence staining and Western 
Blotting). But clearly, the 1W virus is significantly more impaired than the 2W virus at 
these early times post infection. 
 
Transformation assays were carried out in separate experiments due to the large amount of 
virus and B cells required to set up one whole microtest plate (96 replicate cultures) per nW 
virus per virus dose. However, in general, the transforming ability of the different nW 
viruses was in line with their early transcriptional activities. Thus, 5W-7W viruses 
transformed most efficiently (similar to 2089, data not shown), with 3W and 4W 
transforming with an intermediate efficiency (10 fold less than 5W virus), whereas 2W 
transformed with very low efficiency (approximately 10 fold less than 3W) and no 
transformation was ever seen with 0W and 1W (Figure 3.7 and Figure 3.8). Taken together, 
our data showed that, between 0W and 5W, viruses with more Wp copies had higher levels 
of Wp activity, produced more EBNA-LP and EBNA2 protein and eventually transformed 
B cells more efficiently. Increasing Wp copy number beyond five brought no further 
increase in early latent gene expression or in transforming ability. 
  
As an additional check, LCLs derived from nW virus infections were further analysed by 
Western Blotting. The majority of the EBNA-LP species from the nW LCLS reflected the 
number of BamHI W copies present in the viruses. For example, in Figure 3.9, an EBNA-
LP protein of expected size (ie. 7 W1W2 repeat domains) is the most abundant species in a 
7W-infected LCL, likewise for 6W, 5W, 4W and 3W transformed LCLs. This is consistent 
 114 
with the view that in established LCLs, at least when made with viruses up to 7W copies, 
the dominant EBNA-LP transcript contains all the available W1W2 repeat exons. This 
transcript may of course be initiated at Cp, but a more attractive idea is that it is initiated 
from the most 5’ Wp copy. This would fit with what the earlier studies of Yoo et al. 
showed (Yoo et al., 1997, Yoo et al., 2002), and also with the notion that a small number of 
Wp transcripts remain present in LCLs and may be initiated from the most 5’ Wp copy, the 
other copies having been methylated by this time (Hutchings et al., 2006, Tierney et al., 
2000b). 
 
However note that in several cases, some larger than expected EBNA-LP proteins were 
seen in the gel. Furthermore an unexpectedly larger EBNA-LP (equal to 3 W1W2 repeat 
domain) was detected in the 2W-LCL, despite the fact that during the first few days post 
infection with 2W virus, only an EBNA-LP of the expected size was detected (see later, 
Figure 4.12B). It should be noted that it took several weeks to expand the transformed foci 
from microtest plate wells to flasks before there were sufficient cells for protein analysis. 
Thus it is conceivable that virus recombination had occurred within the culture to generate 
a new virus with more W copies, and if this had a growth advantage, the cells carrying it 
could have eventually taken over the culture.  
 
However, a second possibility is that this larger than expected EBNA-LP protein is 
generated via trans-splicing of the RNA. Thus, during splicing of the primary Cp/Wp 
EBNA-LP transcript, the introns are removed and the coding W1, W2, Y1 and Y2 exons 
are joined together to make the mature mRNA. Normally exons can only be joined together 
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if they are part of the same primary transcript. However in trans-splicing, an exon from one 
RNA molecule can be joined to the exon of a second RNA molecule (Rickman et al., 2009, 
Gingeras, 2009). In this case, W1 and W2 exons from one EBNA-LP transcript could be 
joined to the W1 or W2 exons of a second LP transcript. In theory, this means that a 2W 
LCL could make 3 or 4 repeat EBNA-LP proteins if two RNAs were trans-spliced.  
 
EBV has acquired multiple copies of the BamHI W repeat sequence during evolution. The 
present data suggest that viruses with such multiple repeats have an advantage, namely they 
are more capable of driving EBNA-LP/EBNA2 expression immediately post infection 
because at least below 5 Wp copies, all Wp copies are active. Indeed, the ladder of EBNA-
LP species seen in the early stages of EBV supports the notion that transcription initiates 
from multiple copies of Wp (Finke et al., 1987, Rooney et al., 1989). Previous studies have 
shown that virus isolated from infected individuals by B cell transformation contained 3 to 
12 copies of Wp (Allan and Rowe, 1989). Since we now know that this will select for 
viruses with ≥ 5 Wp copies, these in vitro isolates may not reflect the true range of viruses 
in vivo. It would be interesting to determine how many BamHI W repeats are found in 
naturally occurring virus genomes in ex vivo assays. However, with current techniques this 
is not possible since it would require large amount of viral DNA. Another possible 
approach is to study the monoclonal virus genomes captured in EBV positive malignancies. 
In fact, we know that BL lines carry viruses with greater than 3 W copies (Allan and Rowe, 
1989), but again it might be argued that B cell transforming ability is a prerequisite for BL 
pathogenesis. Therefore, the virus isolates from nasopharyngeal carcinoma (NPC) cells 
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where B cell transforming ability is irrelevant may reflect the situation in natural viruses 
more closely.   
 
The work in this part of the thesis also has implication for all studies using recombinant 
viruses where B cell transformation is the read-out. Clearly recombinant viruses are very 
important tools which allow one to look at individual gene function in the context of the 
whole EBV genome. However, our experiment shows the ease with which the EBV 
genome lost copies of BamHI W during the recombination procedure in bacteria. Therefore, 
it is important that in any further studies with recombinant viruses carrying specific 
mutation/deletion at any site in the genome are carefully controlled for the number of 
BamHI W copies in the mutated virus. At least five copies of BamHI W fragments have to 
be present and ideally when comparing different mutants for transforming ability, they 
should have the exactly same number of W copies. 
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Chapter 4. Rescuing the growth transformation of impaired nW viruses 
 
From the results shown in Chapter 3, it is clear that the number of BamHI W copies present 
in the genome has an effect on EBV induced transformation of B cells. Virus with BamHI 
W deleted or with only one copy of BamHI W failed to transform B cells; virus with two 
copies of BamHI W showed severely impaired transformation ability, while viruses with 
three, four or five copies of BamHI W showed progressively increasing transforming 
ability. However, increasing the BamHI W copy number beyond 5 had no further effect. 
Therefore at least 5 copies of the BamHI W (i.e. five copies of Wp) are required for 
promoter activation and efficient B cell transformation. To some extent this may reflect the 
fact that, with Wp copies reduced in number, Wp transcription is limiting in freshly-
infected B cells. However another consequence of reducing BamHI W copy number is to 
reduce the size of one of the key latent proteins, EBNA-LP, whose repeat sequence is 
encoded by the W1 and W2 exons within each BamHI W repeat; therefore the 2W virus 
can only make an EBNA-LP with two copies of the W1W2 repeat domain. In order to 
distinguish between the effect of reducing Wp copy number itself and the knock-on effects 
from reducing EBNA-LP size, different strategies were used to try and rescue the impaired 
transformation ability of the 2W virus.  
 
4.1 Rescue with helper virus 
One potential strategy to rescue the impaired transformation with 0W, 1W and 2W viruses 
was to use helper virus coinfection. Two viruses, an EBNA2 gene knockout (called E2KO) 
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and a LMP1 gene knockout (called LMP1KO) were kindly provided by Wolfgang 
Hammerschmidt. E2KO virus was made from the parental 2089 recombinant virus by 
deleting the entire coding sequences of EBNA2 (Altmann and Hammerschmidt, 2005) and 
was not able to transform primary B cells. The other helper virus, LMP1KO virus was 
made from the same parental 2089 virus with the deletion of the entire open reading frame 
of LMP1. LMP1KO virus was able to generate proliferating B-cell clones, but was only 
able to sustain their growth with the aid of fibroblast feeder cell layers (Dirmeier et al., 
2003).  
 
4.1.1 B cell infection with E2KO and LMP1KO helper virus 
Initially, Western blot analysis was carried out to characterise the E2KO and LMP1KO 
virus gene expression in resting B cells. Resting primary B cells were infected with E2KO 
and LMP1KO virus separately at an m.o.i of 50 and 1x107 infected cells were harvested at 
1, 3 and 7 days post infection. Protein samples were extracted from the cells and analysed 
by Western blotting using the monoclonal antibodies shown in Table 2.6.  This experiment 
was carried out 2 times and Figure 4.1 shows the results from one representative 
experiment. Firstly, no EBNA2 was ever detected in E2KO-infected B cells, confirming 
that EBNA2 was totally knocked-out in the E2KO virus. In the same cells, EBNA-LP was 
detected as a ladder of bands by one day post infection. Very low levels of BHRF1 were 
also detected by one day post infection and gradually increased during the time course. 
EBNA1, EBNA3A and EBNA3C proteins were also detected in E2KO-infected B cells by 
one day post infection. Surprisingly, LMP1 was also detected starting at three days post 
infection with higher levels detected by seven days post infection.  
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When the LMP1KO virus was used to infect resting B cells in vitro, no LMP1 was ever 
detected, confirming that LMP1 was successfully knocked-out in the LMP1KO virus. 
Considerable levels of EBNA2 and EBNA-LP (a ladder of bands) were detected by one day 
post infection in LMP1KO-infected B cells. Although no BHRF1 was detected, it should be 
noted that the antibody for BHRF1 was poor and by a more sensitive Q-RT-PCR assay, 
very low levels of BHRF1 transcripts could be detected (Figure 4.2). EBNA1, EBNA3A 
and EBNA3C protein could be detected by three days post infection. Western blotting of a 
second repeat experiment with the E2KO and LMP1KO viruses gave similar results (data 
not shown).  
 
In conclusion, E2KO virus expressed a sufficient amount of large EBNA-LP and all the 
other latent proteins tested except EBNA2, while LMP1KO virus expressed sufficient 
amount of large EBNA-LP and EBNA2, along with the other latent proteins tested except 
for LMP1 and maybe BHRF1. Therefore, for our purposes, these two non-transforming 
viruses were very useful as helper viruses because co-infection with the impaired nW 
viruses allowed us to assess the importance of EBNA-LP (with E2KO) and EBNA-LP plus 
EBNA2 (LMP1KO) in B cell transformation. 
 
4.1.2 Coinfection of recombinant nW viruses with helper viruses in resting B cells 
A series of Q-RT-PCR assays were then carried out to track the initial Wp- and Cp-initiated 
transcription and BHRF1 and EBNA2 transcripts. The fresh B cells used in this experiment 
were isolated from cones, infected with recombinant viruses (1W and 2W) with or without 
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helper viruses (E2KO and LMP1KO) and RNA isolated from infected cells harvested at 1, 
2 and 3 days post infection. This experiment was carried out 2 times independently and the 
results from one representative experiment are shown in Figure 4.2. The kinetics of 
transcription in the 2W virus from this experiment were very similar to that previously 
observed (Figure 3.4), however interestingly, unlike the previous experiments, B cells 
infected with 1W in this experiment showed some Wp-initiated, BHRF1, EBNA2 and Cp-
initiated transcripts. This is most likely due to superior quality of B cells isolated from 
cones compared to buffy coats. However, the transcription seen in the 1W virus was 10 fold 
lower than transcription in the impaired 2W virus.  
 
Very high Wp-initiated and BHRF1 transcripts were detected in cells infected with E2KO 
virus alone, and as expected, no EBNA2 transcripts were detected. Interestingly, the level 
of Cp activity in E2KO was low and similar to the level in 2W virus. High levels of Wp-
initiated transcripts were also detected in cells infected with LMP1KO virus alone, however, 
surprisingly, very low levels of BHRF1 transcripts were detected. In addition, high levels 
of Cp-initated and EBNA2 transcripts were detected in LMP1KO virus with kinetics 
similar to those seen with 5W virus (Figure 3.4).  
 
Due to the dominant transcription seen from E2KO and LMP1KO virus, it is difficult to 
distinguish the transcription from the nW virus and the helper virus. However, in this 
experiment, no increase in the level of EBNA2 transcripts was observed in coinfection with 
2W and E2KO viruses in comparison to 2W virus alone. Therefore, we then carried out 
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transformation assays to directly quantitate the transformation efficiencies with or without 
helper viruses.  
 
Primary B cells were infected with the 0W, 1W or 2W viruses at m.o.i.s of 1, 5, 10, 20, 50 
and 100. In parallel, B cells were co-infected with the same nW virus at the same panel of 
m.o.i.s and either the E2KO or LMP1KO helper virus at 50 m.o.i. Controls of B cells 
infected with E2KO or LMP1KO virus alone (50 m.o.i.) were also set up. The infected B 
cells were then plated out at 104 cells/well in 96-well plates, grown with regular feeding, 
and scored after 6 weeks for wells showing transformed foci as previously described. 
Figure 4.3A shows the results from one such experiment plotted as bar charts. The first row 
of graphs shows that the 0W virus failed to transform B cells at any of the m.o.i. with or 
without helper virus during the 6 weeks post infection. The second row of graphs shows 
that 1W virus alone or 1W plus E2KO helper virus failed to transform B cells at any m.o.i. 
However, most interestingly, when LMP1KO virus was used as a helper virus, 21 out of 96 
wells were transformed with 1W virus at 100 m.o.i. (N.B. infection of 1W in this 
experiment was only carried out at 100 m.o.i). The third row of graphs shows that the 
efficiency of transformation with 2W virus was marginally increased by co-infection with 
the E2KO helper virus and significantly increased by co-infection with the LMP1KO helper 
virus. Figure 4.3B shows the same data plotted as a graph of log (m.o.i.) against the number 
of wells transformed, which allowed one to determine the m.o.i.s for 50% transformation. 
The m.o.i for 50% transformation in 2W was 124.4, which decreased to 20.3 with the 
E2KO helper virus and further decreased to 3.3 with the LMP1KO helper virus. These data 
show that use of the E2KO helper virus slightly improved transformation with the 2W virus, 
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but did not aid the 1W virus. However, the LMP1KO virus provided significant help to the 
2W virus and was even able to provide sufficient help to get transformation with a high 
m.o.i. of 1W virus. 
 
 4.2 Repair of 2W virus with a 7 repeat EBNA-LP expressing cassette 
Considerable levels of improvement in transformation efficiency of the impaired nW 
viruses were observed in the previous experiment using E2KO and LMP1KO helper 
viruses. However, it is difficult for us to conclude that the effects were simply from the 
EBNA-LP (E2KO) or EBNA-LP plus EBNA2 (LMP1KO) alone, because of the additional 
latent antigens expressed in these viruses (Figure 4.1). Therefore, we developed a second 
strategy to rescue the impaired nW virus by creating the repaired viruses, 2W-LP and 2W-
EBNA2. 
 
4.2.1 Construction of repaired virus, 2W-LP 
2W-LP virus was created by introducing a cDNA encoding a 7 repeat EBNA-LP protein 
into the 2W virus genome using the BAC cloning system (Delecluse and Hammerschmidt, 
2000). Figures 4.4 - 4.6 show this cloning strategy in three parts, and the data validating the 
construction at each step.  
 
In the first step (Figure 4.4A), plasmid pW3.1LP (Speck et al. 1986) containing EBNA-LP 
cDNA with seven BamHI W repeats was digested with EcoRI. The 1644bp fragment of 
EBNA-LP cDNA was purified from a 0.8% agarose gel and ligated into an EcoRI-digested 
pIRES-GFP vector (Invitrogen) to generate the plasmid, pIRES-LP-GFP. Figure 4.4B 
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shows HindIII and PciI digests of pIRES-LP-GFP, which gave bands of the predicted sizes 
confirming that the construction of the plasmid was correct. 
 
In the second part (Figure 4.5A), PCR with primers containing HindIII and PciI restriction 
sites was used to amplify the SV40-promoter and hygromycin resistance gene from 2089. 
The PCR product was then purified and digested with HindIII and PciI before being ligated 
into a HindIII/PciI-digested pCP16 vector, containing a tetracycline resistance cassette to 
generate a plasmid called pCP16-HygR. Figure 4.5B shows EcoRI/HindIII digests of 
pCP16-HygR, which gave bands of the predicted sizes confirming that the construction of 
the plasmid was correct. 
 
In the third and final part (Figure 4.6A), to generate the LP-shuttle vector, pCP16-HygR 
plasmid was digested with SmaI and PciI and the 4016bp fragment containing the 
tetracycline and hygromycin resistance cassettes was gel purified, blunt-ended with Klenow 
polymerase and ligated into pIRES-LP-GFP vector, which had been linearised with AflII 
and blunt-ended with Klenow. Figure 4.6B shows XbaI, HindIII/XbaI and FspI/HindIII 
digests of the LP-shuttle vector, which gave bands of the predicted sizes confirming that the 
construction of the plasmid was correct. 
 
To confirm the LP-shuttle vector was capable of expressing EBNA-LP, the EBV-negative 
Burkitt’s lymphoma-derived cell line DG75 was transiently transfected with 10µg of LP 
shuttle vector by electroporation and EBNA-LP expression detected by 
immunofluorescence staining. Transfected cells were harvested at 24 hours post infection 
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and stained for EBNA-LP using JF186 antibody. Representative EBNA-LP stains (red) and 
DAPI counterstains (blue) of the same fields are shown in Figure 4.7A. To also confirm 
that the EBNA-LP expressed from the LP-shuttle vector was the correct size, protein was 
extracted from the cells from the same transfection experiment, and subjected to Western 
blotting. EBNA-LP was detected using JF186 and the size confirmed as 66kDa equivalent 
to 7 copies of the EBNA-LP repeat (Figure 4.7B). 
 
After confirmation of the integrity of the LP-shuttle vector, homologous recombination was 
used to introduce the EBNA-LP cDNA into the 2W BAC genome with the hygromycin 
resistance gene and CMV promoter region acting as the homologous regions on either sides 
of the cDNA (Figure 4.8). The LP-shuttle vector was linearised by digestion with FspI 
which cuts at a single site in the vector, outside of the EBNA-LP and homologous regions. 
The linearised DNA was then transformed into rec A+ BJ5183 E coli. containing the 2W 
BAC plasmid. Recombinants were selected on chloramphenicol/tetracycline agar plates and 
were screened by BamHI restriction enzyme digestion. A correct clone was identified and 
the BAC DNA was then transferred into a rec A- DH10B E coli. strain for propagation and 
maintenance. The BAC DNA was then re-checked by restriction enzyme digestion with 
EcoRI and HindIII in addition to BamHI. Figure 4.9 shows these restriction profiles of 
BamHI, EcoRI and HindIII digests in comparison to the parental 2W BAC, which 
confirmed the construction of 2W-LP BAC was correct. The complete 2W-LP BAC was 
then transfected into 293 cells and stably transfected clones were selected with hygromycin 
B, expanded and screened for virus production as previously described.  
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4.2.2 Infection of resting B cells with 2W-LP repaired virus 
To analyse the effect of additional expression of EBNA-LP on infection of primary B cells, 
a series of binding assays, transcription assays, IF cell staining assays and transformation 
assays were then carried out comparing the 2W-LP virus with the 2W, 3W and 5W viruses. 
This experiment was carried out 3 times independently and Figure 4.10 shows the result of 
Q-PCR assays from one representative experiment measuring the amount of each virus 
initially bound to the cells and the result demonstrated that all the four viruses bound to B 
cells with equal efficiency.  
 
Next, a series of Q-RT-PCR assays (Figure 4.11) was then carried out to track the Wp-
initiated, BHRF1, EBNA2 and Cp-initiated transcripts from the same B-cell infection 
experiment as the binding assay. It should be noted that one of the primers for detecting 
Wp-initated transcripts is in W0, therefore, only Wp-initiated transcripts (not the inserted 
EBNA-LP cDNA) can be detected. Interestingly, overall, the levels of Wp-initiated, 
BHRF1, EBNA2 and Cp-initiated transcripts were significantly enhanced nearly 10 fold, 
with the 2W-LP relative to the 2W parental virus. The kinetics of the transcription in 2W-
LP virus were similar to 3W and 5W viruses, however, the levels of transcriptions were 
much lower (more than 2 fold lower than 3W virus; about 5 fold less than 5W virus).  
 
EBNA-LP and EBNA2 protein expression was monitored by immunofluorescence cell 
staining. B cells infected with the 2W, 2W-LP and 5W viruses at an m.o.i of 50 were 
harvested at day 3 post infection and stained for EBNA-LP and EBNA2 (Figure 4.12 A). 
The number of antigen positive cells (red) and the total number of DAPI stained cells (blue) 
 126 
were counted on 4 fields of at least 100 cells to determine the percentage of EBV antigen-
expressing cells (Figure 4.12B). In the 2W-infected cells, only 10.9% of the cells were 
EBNA-LP positive, whereas in the 2W-LP infected cells, 26.7% of the cells were EBNA-
LP positive, which is similar to the percentage in 5W-infected cells (28.2%). In the 2W-
infected cells, only 5.2% of the cells were EBNA2 positive, whereas in the 2W-LP infected 
cells, 15.5% of the cells were EBNA2 positive, which is lower than the percentage in 5W-
infected cells (26.6%). These results suggested that the increased level of EBNA-LP is 
likely due to the expression from the EBNA-LP cDNA introduced into the repaired virus 
and more importantly, the increased levels of the antigen expression in the 2W-LP virus 
correlate to the increased levels of transcription seen in the Q-RT-PCR data.  
 
To further analyse the expression of EBNA-LP and EBNA2, we then carried out western 
blotting to detect these two proteins in 2W and 2W-LP infected B cells at 3 days post 
infection. EBNA-LP equal to the size of 2 copies of EBNA-LP was detected in 2W infected 
cells (Figure 4.12C). A higher level of EBNA-LP was detected in 2W-LP infected cells, but 
surprisingly its size was not what we expected.  The majority of the EBNA-LP was a size 
corresponding to protein containing 2 repeats, while a low level of EBNA-LP 
corresponding to protein containing 3 or 4 repeats. In addition, a higher level of EBNA-2 
was also detected in 2W-LP infected cells compared to 2W virus (data not shown). Taken 
together, observation from IF staining matched the data from the western blotting; more 
EBNA-LP and EBNA2 were expressed in 2W-LP infected cells than in 2W infected cells. 
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To directly quantitate the transformation efficiency of the 2W-LP virus compared to the 
2W parental virus, transformation assays were carried out as previously described. This 
experiment was carried out 3 times independently and Figure 4.13A shows the results from 
one representative experiment plotted as bar charts. The relative transformation efficiencies 
of 2W and 5W were similar to those previously observed (Figure 3.7A and Figure 3.8A). 
Interestingly, 2W-LP virus showed higher levels of transformation than 2W virus, however, 
the levels were still lower than 3W and 5W viruses. When the m.o.i. for 50% 
transformation was calculated (Figure 4.13B and C), 2W-LP had an m.o.i. of 29.7 
compared to 44.8 for 2W, representing less than 2 fold improvement in transformation 
efficiency. However, this was still well below the transformation efficiency of 3W (4.4 
m.o.i) or 5W (0.04 m.o.i.).  
 
Taken together, these results indicate that expression of EBNA-LP from another promoter 
within the virus genome enhances Wp/Cp-initiated transcription, latent protein expression 
and transformation efficiency but did not to restore these to anywhere near wild type levels. 
 
4.3 Repair of 2W virus with an EBNA2 expressing cassette 
From the previous data, we concluded that producing a truncated EBNA-LP with only 2 
copies of the W1W2 repeat is unlikely to be the sole reason of the defect in 2W virus. It is 
also likely that in 2W virus, the 2 copies of Wp are insufficient to achieve optimal Wp-
initiated transcription in freshly-infected resting B cells and therefore insufficient to 
produce enough EBNA2 to activate the Cp and LMP promoters and push the resting B cell 
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into cell cycle. To further address this issue, another repaired virus, 2W-EBNA2 was 
created. 
  
4.3.1 Construction of repaired virus, 2W-EBNA2 
2W-EBNA2 was made by inserting EBNA2 cDNA driven by CMV promoter into the 2W 
BAC genome. To generate this virus, the EBNA2-shuttle vector was first constructed by 
replacing the EBNA-LP cDNA in the previously described LP-shuttle vector with an 
EBNA2 encoding cDNA (Figure 4.14A). Plasmid pSG5-EBNA2 (Cohen et al., 1992) 
containing the entire EBNA2-coding region of EBV strain W91, was digested with AvrII 
and BglII, and the 2542bp fragment containing the EBNA2 cDNA and the β globin intron 
from pSG5 was gel purified from a 0.8% agarose gel. The LP-shuttle vector was digested 
with NheI and BamHI (which create compatible overhangs for ligation to AvrII and BglII 
digested DNA ends, respectively) and subjected to an agarose gel electrophoresis to 
separate the backbone vector from the EBNA-LP cDNA fragment. The backbone vector 
(9265bp) was then purified and ligated with the AvrII/BglII EBNA2 containing fragment to 
generate the EBNA2 shuttle vector. Figure 4.14B shows the BamHI/FspI and XbaI digest 
of the EBNA2 shuttle vector, which gave bands of the predicted sizes confirming the 
construction of the shuttle vector was correct. 
 
To confirm that the EBNA2 shuttle vector was capable of expressing EBNA2, DG75 was 
transiently transfected with the EBNA2 shuttle vector, pSG5 (negative control) and pSG-
EBNA2 (positive control) and EBNA2 expression was detected by immunofluorescence 
cell staining as previously described. Representative EBNA2 stains (red) and DAPI 
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counterstains (blue) of the same fields are shown in Figure 4.15, confirming that the shuttle 
vector could express EBNA2.  
 
After confirmation of the integrity of the EBNA2 shuttle vector, homologous 
recombination was used to introduce the EBNA2 cDNA into the 2W BAC genome with the 
hygromycin resistance gene and CMV promoter regions acting as the homologous regions 
on either sides of the cDNA (Figure 4.16). Instead of using the rec A+ BJ5183 E.coli strain 
to carry out the recombination, we used the 2W containing DH10B (rec A-) bacteria 
transformed with a pDK46 plasmid, which contains the λ-red recombinase under the 
control of an arabinose-inducible promoter and a temperature-sensitive replication origin. 
These bacteria were grown at 30ºC in medium containing L-arabinose to induce the 
expression of the recombinase before being made electrocompetent. The EBNA2 shuttle 
vector was linearised by digestion with FspI which cut at a single site in the vector and 
electroporated into the 2W/pDK46 containing DH10B. Recombinants were selected on 
chloramphenicol/tetracycline agar plates, grown at 42ºC to induce loss of the pDK46 
plasmid and screened by BamHI restriction enzyme digestion. A correct clone was 
identified and the BAC DNA was then re-checked by restriction enzyme digestion with 
AvrII, EcoRI and NheI in addition to BamHI. Figure 4.17 shows these restriction profiles 
of BamHI, AvrII, EcoRI and NheI digests in comparison to the parental 2W BAC, which 
confirmed that the 2W-EBNA2 BAC was correct. The complete 2W-EBNA2 BAC was 
then transfected into 293 cells and stably transfected clones were selected with hygromycin 
B, expanded and screened for virus production as previously described.  
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4.3.2 Infection of resting B cells with 2W-EBNA2 repaired virus  
To analyse the effect of additional expression of EBNA2 on B-cell transformation, a 
preliminary experiment was carried out for binding (Q-PCR), antigen expression (IF 
staining) and transformation efficiency (transformation assays) comparing the 2W-EBNA2 
virus with the 2W, 2W-LP and 5W virus. First, Figure 4.18 shows the result of Q-PCR 
assays measuring the amount of each virus initially bound to the cells. In this particular 
assay, approximately 2 fold less 2W-EBNA2 virus bound to B cells compared to 2W, 2W-
LP and 5W viruses.  
 
In the same experiment, infected cells were then monitored for EBNA-LP and EBNA2 
protein expression by immunofluorescence cell staining (Figure 4.19A). EBNA-LP and 
EBNA2 positive cells (red) and the total number of DAPI positive cells (blue) were counted 
on 4 fields of at least 100 cells to determine the percentage of EBV antigen-expressing cells 
(Figure 4.19B). The percentages of EBNA-LP and EBNA2 positive cells in 2W-EBNA2 
repaired virus infected cultures (11.9% and 11.2%, respectively) were even lower than 
those in parental 2W infected cultures (EBNA-LP: 22.2% ; EBNA2: 23.3%). However, 
higher percentages of antigen-positive cells were detected in cultures infected with the 2W-
LP repaired virus (EBNA-LP: 38.2% ; EBNA2: 40.4%) compared to 2W virus, although 
still much lower than for 5W (EBNA-LP: 82%; EBNA2: 68.5), confirming the previous 
result (Figure 4.12A). In this particular infection experiment, more antigen expressing cells 
were detected overall compared to the previous experiments (Figure 4.12A). 
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Transformation assays as the ultimate read out for transformation efficiency were also 
carried out in the same experiment. Figure 4.20 shows the results of the transformation 
assays. Similar transformation efficiencies were observed in 2W and 2W-EBNA2, while 
2W-LP virus showed a higher efficiency, the level was still lower than 5W viruses. Thus, 
the m.o.i. for 50% transformation was 10.8 and 14.2 for 2W and 2W-EBNA2, respectively, 
3.4 for 2W-LP and only 0.5 for 5W virus. 
  
It should be noted that B cells used in this preliminary experiment was isolated from cones, 
and better infection of 2W, 2W-LP and 5W viruses were observed in this experiment 
compared to the previous similar experiment (Figure 4.12 and Figure 4.13.) using B cells 
isolated from buffy coats. Importantly, although the absolute numbers were higher in this 
experiment, the trend we saw in this experiment was exactly the same as in the previous 
experiment. In this preliminary experiment for the 2W-EBNA2 virus, no clear effect was 
observed. However, this could be due to the poor virus binding (Figure 4.18), and 
presumably low internalisation with 2W-EBNA2.  
 
In a subsequent experiment, Western blotting was used to detect the expression of EBNA-
LP and EBNA2 in cells infected with 2W-EBNA2 and 2W viruses. As shown in Figure 
4.21, higher levels of EBNA2 and EBNA-LP expression were observed in cells infected 
with the 2W-EBNA2 virus compared to cells infected with the 2W virus.  
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4.4 Discussion 
The immediate background to these studies was the earlier finding (Chapter 3) that BamHI 
W repeat number had a major influence on EBV B cell transforming function. In particular, 
0W and 1W viruses had no detectable transforming ability, while 2W virus was around 100 
fold less active than the optimum (shown by virus with ≥ 5 W copies) with 3W/4W viruses 
showing intermediate activities. This may reflect the fact that when Wp copies are reduced 
in number below 5, Wp-initiated transcription is limiting in freshly-infected B cells. 
However another consequence of reducing BamHI W repeat number is to reduce the size of 
one of the key latent proteins, EBNA-LP, whose repeat sequence is encoded by the W1 and 
W2 exons within each BamHI W repeat. Thus the 2W virus is predicted to make an EBNA-
LP with two copies of the W1W2 repeat domain. 
 
In order to distinguish between an effect of reducing Wp number itself and the knock-on 
effect from reducing EBNA-LP size, the following approaches were attempted:- 
1. to use the E2KO and LMP1KO as helper virus for EBV with limiting numbers of BamHI 
W repeats 
2. to insert full length EBNA-LP or EBNA2 cDNA into the poorly transforming 2W EBV 
genome. 
 
Helper virus experiments 
Initially, characterisation of the helper viruses was carried out by infecting B cells with 
either the E2KO or the LMP1KO virus alone and monitoring RNA transcription by Q-RT-
PCR (Wp- and Cp-initiated transcripts and BHRF1 and EBNA2 transcripts) and protein 
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expressions by Western blotting (BHRF1, EBNA-LP, 1, 2, 3A, 3C and LMP1) (Figure 4.1 
and Figure 4.2).  
 
In Chapter 3, we had shown that with wild-type virus, Wp activity peaked within the first 
24 hours post infection, followed by a rapid drop and then a more gradual decline, while Cp 
activity became apparent by 48 to 72 hours post infection. Surprisingly, completely 
different kinetics were observed for E2KO infection. Wp activity increased to very high 
level and remained high for at least 72 hours post infection. Likewise a progressively 
increasing level of BHRF1 was detected during the 72 hours time course mirroring this 
sustained Wp activity; and therefore reinforcing the connection between Wp activity and 
BHRF1 first suggested by Kelly et al. (Kelly et al., 2009). At the same time, Cp initiated 
transcription from E2KO virus was detectable from 24 hours onwards but by 72 hours only 
matching the very low level (< 2% of 5W virus) shown by the 2W virus itself. This 
reinforced the previous studies showing that Cp activation requires transactivation by 
EBNA2 (alone or with EBNA-LP) (Harada and Kieff, 1997, Jin and Speck, 1992, Schlager 
et al., 1996, Yoo and Speck, 2000), and that EBNA1 is not sufficient to transactivate Cp in 
the absence of EBNA2 (Nilsson et al., 2001, Schlager et al., 1996). The fact that Wp levels 
remained high up to 72 hours post infection in the absence of significant Cp activation is 
also consistent with the idea of Cp transcript-mediated interference with Wp activity 
(Puglielli et al., 1997, Puglielli et al., 1996, Yoo et al., 1997). 
 
Very interestingly, from the immunoblots, full-length EBNA-LP, EBNA1, EBNA3A and 
EBNA-3C were strongly expressed by the E2KO virus even within 24 hours post infection, 
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while BHRF1 (usually detectable at the protein level in early post infection) was also 
detectable by day 1 and became strongly expressed by day 3-7. Referring to the 
transcription data at the same time points, these proteins detected at one day post infection 
must be being expressed from Wp, rather than Cp; furthermore the same is probably true 
for the proteins at least up to day 3. Unexpectedly, LMP1 was also detected in E2KO virus-
infected cells at 3 days post infection. Although we do not know which promoter was used 
to express LMP1 at this time, recent studies showed that NF-κB can transactivate the LMP1 
promoter (ED-L1 promoter) in the absence of EBNA2 (Johansson et al., 2009, Demetriades 
and Mosialos, 2009). Nevertheless, even though E2KO virus produced all the latent 
proteins except EBNA2 as published, it still never drove the infected B cells into cell cycle 
and failed to induce B-cell transformation (Altmann and Hammerschmidt, 2005, Tierney et 
al., 2007). This emphasises the essential role of EBNA2 in B-cell transformation (Cohen et 
al., 1989, Hammerschmidt and Sugden, 1989, Kempkes et al., 1995c). These results 
showed that, for our purposes, E2KO can be used as a transformation-defective helper to 
try and rescue the impaired 2W virus by providing large amount of a sufficiently large 
EBNA-LP in early infection. 
 
In B cells infected with the LMP1KO virus, just as in wild-type EBV infection, Wp activity 
peaked within the first 24 hours post infection and then gradually decreased, while Cp 
activity was induced later and became apparent by 48 to 72 hours post infection. EBNA2 
transcripts showed similar kinetics to Wp activity. While, by Western blotting, a large 
amount of EBNA-LP and EBNA2 were detected at one day post infection; whereas 
EBNA1, EBNA3A and EBNA3C were detected at three days post infection; this is again 
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typical of the kinetics seen in wild-type EBV infection, the key difference being that no 
LMP1 was expressed (Dirmeier et al., 2003). Also for reasons that are not clear, BHRF1 
transcription was significantly lower for the LMP1KO virus than for the E2KO virus and 
BHRF1 protein was not detectable. Most importantly, in the context of the planned helper 
experiments, the LMP1KO virus made easily detectable levels of EBNA-LP species with 3-
6 W1W2 repeats, which although smaller than the E2KO virus encoded EBNA-LP, should 
still be sufficient for wild-type EBNA-LP activity. Note also that microscopic examination 
of cultures of B cells infected with the LMP1KO virus showed blast transformation and cell 
growth occurring for approximately 2 weeks post infection; after that in the absence of 
fibroblast feeder cells, no LCLs grew out and cultures eventually died (Dirmeier et al., 
2003). Thus LMP1 is not essential for the initiation of B cell growth transformation but is 
essential for continued growth and LCL establishment. On this basis, we predicted that the 
LMP1KO virus would be a better helper than the E2KO virus, providing both EBNA2 and 
a sufficiently large EBNA-LP in trans while itself being non-transforming.    
 
The effect of these helper viruses on 1W and 2W virus infections was first analysed by Q-
RT-PCR. It is difficult for us to draw conclusions from these assays (Figure 4.2), because 
the helper viruses themselves dominate the Wp transcription and (in the case of LMP1KO 
virus) Cp transcription and also EBNA2 transcription. But importantly, the E2KO helper 
virus did not improve EBNA2 transcript levels for the 2W virus above their very low level, 
and its only effect on the 1W virus was to make EBNA2 transcription very weakly 
detectable at 72 hours. In the corresponding experiments, looking at help for transformation, 
the E2KO virus marginally improved transformation efficiency of 2W virus as previously 
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described (Tierney et al., 2007). This 2-fold increase in transformation efficiency may not 
be large enough to be reflected quantitatively in the transcription assays. By contrast, the 
LMP1KO helper virus significantly improved transformation efficiency of 2W, restoring it 
to a level similar to that of 5W virus in earlier work (Figure 4.3 and Figure 3.7) and was 
even able to provide sufficient help to achieve transformation in some wells using high 
doses of 1W virus. These findings are consistent with the hypothesis that sufficient levels 
both of EBNA-LP and of EBNA2 proteins are required to switch on Cp and drive the 
transformation process. 
 
Repaired virus experiments 
As made clear in Figure 4.1, a potential complication of the helper virus approach is that 
the E2KO and LMP1KO viruses also express other EBV latent antigens besides full-length 
EBNA-LP. As an additional approach, therefore, we attempted to repair the 2W virus first 
by introducing a 7 repeat EBNA-LP cDNA driven by CMV-IE promoter into the 2W virus 
genome at a site distant from Wp. Overall, this led to an approximately 2-fold improvement 
in latent gene transcription, latent protein expression and B cell transformation compared to 
the 2W virus. However, this EBNA-LP repaired 2W virus was still less active than the 3W 
virus and much less active than the 5W virus standard. It should be noted that, even though 
the EBNA-LP shuttle vector used during BAC construction did express the expected 7-
repeat EBNA-LP protein, and the 7 repeat sequence had been recombined intact into the 
2W genome, B cells infected with the 2W-LP virus expressed three different sizes of 
EBNA-LP equivalent to 2, 3 and 4 repeat EBNA-LP. Despite this, the EBNA-LP repair had 
the same effect on 2W virus infection/transformation as the E2KO helper virus, which 
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provided full-length EBNA-LP. This suggested that one of the factors limiting 2W virus 
activity was the level of EBNA-LP expression early post infection, and not necessary the 
size of the EBNA-LP protein per se. The fact that neither approach had a large effect on 
2W activity, whereas the LMP1KO virus did have such an effect, indicated that EBNA2 
expression was by far the most critical factor. 
 
Therefore, in another approach to repair the 2W virus, we introduced CMV-driven EBNA2 
into the 2W virus genome. Unfortunately, time did not allow this work to be completed. 
From one preliminary experiment, 2W-EBNA2 showed no increase in EBNA-LP and 
EBNA2 expression by immunofluorescence staining, and a transformation assay carried out 
with the same virus stocks and the same B cells showed no improvement compared to 2W 
virus. However, these results were difficult to interpret, since in this particular experiment, 
there was less 2W-EBNA2 virus binding to B cells than 2W virus. In a subsequent 
experiment using Western blotting, 2W-EBNA2 did show slightly higher level of both 
EBNA2 and EBNA-LP proteins than 2W virus and so more work is required before any 
conclusions can be made. 
 
In this section of work, we tried to explain the impaired transformation ability of 2W virus. 
Was it the result of producing a truncated EBNA-LP which failed to function as a 
transactivator? Or were two copies of Wp insufficient to achieve optimal Wp-initiated 
transcription in freshly-infected resting B cells and therefore insufficient to produce enough 
EBNA-LP and EBNA2 to activate the Cp and LMP promoters and drive the cells into cell 
cycle? By providing additional EBNA-LP either from within the genome or from 
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coinfection with the E2KO helper virus, the impaired transformation ability in the 2W virus 
could not be restored fully to the wild-type virus level. In contrast, with the help of 
LMP1KO virus, which provided not only the high level of wild-type EBNA-LP, but also 
additional EBNA2, the impaired transformation ability of 2W virus was restored to wild-
type levels. These results suggest that while EBNA-LP is important in the initiation of B-
cell growth transformation, its full effect is only seen in the presence of EBNA2. We 
conclude that the viruses with a low number of BamHI W repeats are relatively impaired in 
transforming ability, not because of the size of their encoded EBNA-LP per se but because 
of low Wp-initiated transcription leading to suboptimal levels of EBNA2 and EBNA-LP 
co-expression. This is consistent with the model (described earlier) in which every Wp 
copy is potentially active in the early stages of B cell infection. 
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Chapter 5. The role of BSAP in Wp-regulation 
 
Using electrophoretic mobility shift assays (EMSAs) and reporter constructs, two 
regulatory regions within Wp, UAS1 and 2, and the transcription factors that influence their 
activity have been identified (Bell et al., 1998). UAS2 contains two binding sites for the 
ubiquitous transcription factor YY1 and shows lineage-independent activity in reporter 
assays. By contrast UAS1 contains two binding sites for the B lineage-restricted BSAP 
protein, plus sites for the ubiquitous RFX and CREB/ATF transcription factors, and has B 
cell-specific activity (Bell et al., 1998, Kirby et al., 2000, Tierney et al., 2000a). To 
determine the importance of these regions in the physiological setting of the complete virus 
genome, BAC cloning was used to construct recombinant EBVs carrying two tandemly-
arranged copies of Wp deleted either for UAS1 and/or UAS2 (Tierney et al., 2007). This 
showed that UAS2 was completely dispensable for Wp activation and subsequent B cell 
transformation, whereas UAS1 was absolutely essential for both activities. Subsequently a 
recombinant virus (2WBSAPm) was produced carrying two Wp copies in which both 
BSAP sites were inactivated. Like the UAS1 knockout, this virus showed greatly reduced 
Wp activity in resting B cells and did not transform B cells. Since the 2W virus itself has 
reduced transforming ability relative to the parental 2089 virus, in the third part of this 
thesis, we tried to test whether the apparent dependence of EBV transforming function 
upon BSAP sites in Wp in a 2W virus was still apparent when one increased the 
number of W copies. 
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5.1 Construction of the 5WBSAPm BAC 
Having previously shown that 5 copies of the BamHI W are required for optimal 
transformation (Chapter 3), a recombinant virus carrying five copies of the BamHI W 
repeat in which both BSAP sites were inactivated was made. To generate this 5WBSAPm 
virus, an engineered 5WBSAPm shuttle vector was constructed in two parts. In the first part 
(Figure 5.1), a new shuttle vector was made by introducing a multiple cloning site (Reeves 
et al.) into pBS 5’3’ (Tierney et al., 2007) between the sequences homologous to the 
BamHI C and BamHI Y fragments (i.e. sequences that are naturally 5’ and 3’ of the 
BamHIW repeats in EBV). Three pairs of oligonucleotides containing different multiple 
restriction sites (which do not cut within the BamHI W fragment) were first generated. 
Each pair of oligonucleotides was incubated at 95ºC for 5 minutes, cooled down gradually 
to allow annealing to each other. The first double stranded oligonucleotide was then ligated 
into BamHI-digested pBS5’3’ vector to generate pBS 5’-MCS1-3’. The second double 
stranded oligonucleotide was then ligated into BsrGI/NotI digested pBS 5’-MCS1-3’ vector 
to generated pBS 5’-MCS1+2- 3’. Finally, the third double stranded oligonucleotide was 
ligated into SbfI/NheI digested pBS 5’-MCS1+2- 3’ to generate the final MCV vector 
(Figure 5.1). 
 
In the second part of the cloning strategy (Figure 5.2), five BamHI W fragments with both 
BSAP sites inactivated (BSAPmW) were amplified from pBS 5’-BSAPmW-3’ (Tierney 
et al., 2007) by PCR with primers containing restriction sites present in the MCS. These W 
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fragments were then digested with the appropriate restriction enzymes and cloned 
sequentially into MCS vector to generate the final 5WBSAPm shuttle vector.  
To generate the 5WBSAPm BAC, homologous recombination was used to introduce the 
five copies of mutated BamHI W (5xBSAPmW) into the 0W BAC genome with the 
BamHI C fragment and BamHI Y fragment acting as the homologous regions on either side 
of the 5xBSAPmW (Figure 5.3). The 5WBSAPm shuttle vector was linearised by digestion 
with AhdI which cuts at a single site in the vector outside of the 5WBSAPm and 
homologous regions. The linearised DNA was then transformed into rec A+ BJ5183 E coli. 
containing the 0W BAC plasmid. Recombinants were selected on 
chloramphenicol/tetracycline agar plates and were screened by EcoRI/HindIII restriction 
enzyme digestion. A correct clone was identified and the BAC DNA was then transformed 
into the rec A- DH10B E coli. strain for propagation and maintenance. The BAC DNA was 
then re-checked by restriction enzyme digestion with ScaI, which cuts within one of the 
mutated BSAP binding sites. Figure 5.4 shows these restriction profiles of BamHI, 
EcoRI/HindIII and ScaI digests, with the red arrows indicating the bands containing the 
BamHI W repeats and blue arrows indicating the bands predicted difference between 
5WBSAPm and 5W BAC. After confirming the integrity of the construct, 5WBSAPm 
BAC was then transfected into 293 cells to generate the virus producing cell line.  
 
5.2 Infection of resting B cells with 5WBSAPm virus 
To characterise this virus, a series of binding assays, transcription assays, IF cell staining 
assays and transformation assays were then carried out comparing the 5WBSAPm virus to 
the 5W virus and the previously published 2WBSAPm virus (Tierney et al., 2007).  
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Figure 5.5 shows the result of Q-PCR assays from one representative experiment measuring 
the amount of each virus initially bound to the cells and the result demonstrated that 
5WBSAPm virus bound to B cells with equal efficiency as 5W virus. This experiment was 
carried out 2 times independently and similar results were observed in each experiment. 
 
Q-RT-PCR analysis of Wp-initiated, BHRF1, EBNA2 and Cp-initiated transcripts from one 
preliminary experiment is shown in Figure 5.6. In line with the previous studies (Tierney at 
al. 2007), no transcription was detected in the 2WBSAPm virus. Interestingly both Wp and 
Cp activity and BHRF1 and EBNA2 transcripts were detected in 5WBSAPm infected cells. 
However, in comparison to 5W virus, the level of transcription was much lower with 
5WBSAPm.  
 
EBNA-LP and EBNA2 protein expression were monitored by immunofluorescence cell 
staining. B cells infected with the 2W, 2WBSAPm, 5WBSAPm and 5W viruses at an m.o.i 
of 50 were harvested at day 3 post infection and stained for EBNA-LP and EBNA2. 
EBNA2/EBNA-LP positive cells (red) were counted against the total number of DAPI 
stained cells (blue) on 4 fields to determine the percentage of EBV antigen-expressing cells. 
As shown in Figure 5.7, 22.2% cells were EBNA-LP positive and 23.3% were EBNA2 
positive in the culture of 2W infected cells, while as expected, no EBNA-LP or EBNA2 
were detected in 2WBSAPm infected cells. A higher percentage of cells was found to 
express EBNA-LP and EBNA2 in cultures infected with the 5W virus (EBNA-LP: 82% ; 
EBNA2: 68.5%) compared to 5WBSAPm virus (EBNA-LP: 36.4% ; EBNA2: 43.4%).  
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To directly quantitate the transformation efficiencies of the 5WBSAPm virus compared to 
the 2W, 2WBSAPm and 5Wvirus, transformation assays were also carried out in the same 
experiment. Figure 5.8A shows the results of the transformation assays plotted as bar charts. 
No transformation was observed in the 2WBSAPm virus, which confirmed the observation 
in the previous studies (Tierney et al., 2007). In line with previous data (Chapter 3), 2W 
virus showed lower level of transformation efficiency compared to 5W virus. Most 
interestingly, similar transformation efficiencies were observed in 5WBSAPm virus in 
comparison to the 5W virus. Figure 5.8B shows the data from the same experiment plotted 
as log (m.o.i.) against number of wells transformed. For 2W, the m.o.i. for 50% 
transformation was 4.4 and was higher than the m.o.i for 5W (m.o.i: 0.09) virus and for 
5WBSAPm virus (m.o.i: 0.05).  
 
5.3 Discussion 
In this phase of work, we were trying to address the importance of B-cell specific 
transcription factors binding within Wp in the context of viral infection. In particular, 
sequences upstream of Wp have been shown to be important for Wp-initiated transcription 
(Puglielli et al., 1997, Ricksten et al., 1988, Woisetschlaeger et al., 1989) and, in some 
cases, Cp-initiated transcription (Ricksten et al., 1988). Bell et al. have identified the 
presence of three regulatory regions: UAS1 which exhibits B-cell-specific activity, and 
UAS2 and UAS3 which exhibit cell lineage-independent activity (Bell et al., 1998). 
Subsequently, it was shown that UAS2 contains two YY1 sites and UAS1 contains CREB, 
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RFX and two BSAP binding sites (Kirby et al., 2000, Tierney et al., 2000a) and of these 
factors, only BSAP is B-cell specific. 
In the literature, two studies have shown the importance of the regulatory regions of the Wp 
promoter for B-cell growth transformation (Tierney et al., 2007, Yoo et al., 2002). In the 
previous studies, Yoo et al. attempted to make recombinant viruses with a 200bp deletion 
(from -369 to -169 bp) upstream of the first copy of Wp (Wp1), that removed both YY1 
sites in UAS2 and BSAP binding site D in UAS1. To achieve this, a combination of two 
constructs, one to repair the EBNA2 deletion, and the other containing two copies of 
BamHI W fragment with the 200bp deletion in the first copy, were transfected into the non-
transforming EBV strain P3HR1, along with a BZLF1 gene expression vector to induce 
virus replication. The resulting heterogeneous virus stock was then used to infect primary B 
cells. All LCLs which arose from this infection were screened and analysed to determine 
where the mutant Wp recombined within the BamHI repeat.  Among all the 253 LCLs, 
most LCLs were immortalised by recombinant viruses harbouring the 200bp deletion 
downstream of Wp1 (ie. in Wp2 or Wp3) and only a single LCL was immortalised by a 
recombinant EBV harbouring the deletion upstream of Wp1. The very poor transforming 
ability of virus with this deletion in the first Wp copy, considered to be the most active in 
an LCL, suggests that this region of Wp is essential for B-cell growth transformation (Yoo 
et al., 2002). The limitations of this study were firstly that it relied on growth 
transformation as the read-out and secondly that wild-type BamHI W repeats were still 
present in the recombinant viruses generated. 
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In the later study, the B95.8 based system was used to generate a series of recombinant 
viruses containing two copies of BamHI W fragments in which either the UAS1, UAS2 or 
UAS1 and UAS2 regions of Wp had been deleted or the BSAP-binding sites in UAS1 had 
been mutated (Tierney et al., 2007). This approach had the advantage that pure virus stocks 
containing the desired mutation in both BamHI W repeats could be made in the absence of 
any wild-type BamHI Ws. In addition, this virus could be used to directly infect resting B 
cells and look at early EBV transcription and gene expression in addition to the late B-cell 
transforming ability. Recombinants with UAS1 deleted failed to initiate viral transcription 
and transform B cells, while deletion of UAS2 had no detectable effect on the virus’s 
transforming function. Most importantly, recombinants with mutation of the two BSAP 
binding sites in UAS1 also lost all detectable transcriptional and transforming activity. 
During lymphocyte ontogeny BSAP is first expressed at the multipotent pro-B-cell stage 
and actually drives the final commitment to the B-cell lineage (Matthias and Rolink, 2005). 
Our hypothesis is that the UAS1-binding protein, BSAP/Pax5 is a key determinant of the B 
cell lineage specificity of EBV’s growth transforming programme.  
 
However, it should be noted that the previous BSAP mutant virus only contained two 
copies of BamHI W fragments, and the work presented in this thesis (Chapter 3) and 
previous studies (Tierney et al., 2007) have shown that 2W virus itself is impaired for its 
transformation ability. Therefore, in order to further investigate the importance of the Wp 
BSAP binding sites in B-cell-transformation, we constructed a mutant virus carrying five 
BamHI W repeat fragments with mutant BSAP binding sites in every repeat (5WBSAPm). 
This was based on our previous results showing that five copies of BamHI W were 
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sufficient for optimal transformation efficiency. Therefore the mutation could be tested in a 
virus genome which was approximately 100 times more efficient than 2W virus itself. To 
achieve this, linkers containing multiple cloning sites were introduced into a shuttle vector 
to allow us to sequentially clone in BamHI W fragments containing the mutated BSAP 
binding sites. Importantly, this system allows one not only to introduce any desired 
mutation into every BamHI W copy, but also to generate viruses carrying different numbers 
of mutated BamHI W repeats.   
 
In preliminary experiments, 5WBSAPm virus showed a significant reduction of Wp- and 
Cp-initiated transcription and BHRF1 and EBNA2 transcription in comparison to 5W virus. 
We also observed less expression of EBNA-LP and EBNA2 with 5WBSAPm virus by IF 
staining relative to the expression with 5W virus. Unexpectedly, however, in a separate 
transformation assay, 5WBSAPm virus showed similar transformation efficiency to 5W 
virus. These results suggest that mutation of the BSAP binding sites may have an effect on 
viral transcription. It is possible that the effect of mutation in the BSAP binding sites is 
more subtle in the context of a 5W virus than in the poorly transforming 2W virus. 
Unfortunately, the limited data obtained are insufficient for us to make any conclusion at 
present. Work is still currently progressing to test out the effects of BSAP mutation in the 
whole spectrum of 2W, 3W, 4W and 5W viruses using the constructs made during this 
thesis.  
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Chapter 6. Final discussion and future work 
 
As a B lymphotropic virus, EBV’s biology is closely entwined with the biology of B 
lymphocytes. To establish and maintain persistence in vivo, EBV uses different 
transcription programmes at different stages of the virus lifecycle, which may be dependent 
on the differentiation stages of the host cell. We believe that the virus initially activates and 
drives the growth of newly infected B cells, using the growth transformation programme. 
Wp/Cp initiated transcripts, characteristic of this latency III growth transformation 
programme,  have been detected in the peripheral blood mononuclear cells (PBMC) of 
infectious mononucleosis (IM) patients undergoing primary infection (Tierney et al., 1994) 
and EBNA2 expression (Cp or Wp driven) has also been detected in tonsillar B cells from 
IM (Niedobitek et al., 1997a). In vivo infection of host cells most likely involves a very low 
dose of virus. Therefore it is essential that the virus drives the infected cell into cycle to 
amplify the pool of infected cells in the host, before the host immune system is activated. 
Our hypothesis is that the multiple copies of Wp serve to initiate high levels of viral gene 
transcription in the context of a quiescent cell, thus producing high levels of EBNA-LP and 
EBNA2 which then activate both additional viral and cellular promoters, which in turn 
drives the cell into cell cycle.  
  
The work described in this thesis uses in vitro model of primary B cell infection. Using 
recombinant EBV viruses carrying different numbers of BamHI W repeats, we have shown 
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that virus with more BamHI W repeats (ie. more copies of Wp) had a higher level of Wp 
activity, produced more EBNA-LP and EBNA2 protein and transformed B cells more 
efficiently. The virus requires at least 2 copies of the BamHI W repeat to be able to initiate 
the growth transforming programme in B cells in vitro, and at least 5 copies of BamHI W 
for optimal transformation. These in vitro studies support the notion that in the quiescent 
environment of a resting B cell, a high level of Wp-initiated transcription is required to 
initiate the growth transformation programme and to achieve this the virus has acquired 
multiple copies of BamHI W repeats, and therefore multiple copies of Wp promoter, during 
virus evolution.  
 
This hypothesis has been reinforced by the observation that large internal repeat regions, 
homologous to BamHIW are present in other lymphocryptoviruses. For example, the Old 
World rhesus LCV contains an IR1 comprised of 5.7 copies of a 3072bp repeat sequence 
and the New Word LCV, marmoset LCV prototype contains an IR1 comprised of 7.5 
copies of a 2912bp repeat sequence (Rivailler et al., 2002a, Cho et al., 2001). Most 
importantly, the Wp sequence in the rhesus LCV is more than 80% identical to the EBV 
Wp (Peng et al., 2000a), and the Wp sequence in the marmoset LCL is more than 60% 
identical to the EBV Wp (Rivailler et al., 2002a). The existence of this conserved promoter 
containing, large internal repeat both in the genome of the New World and Old World 
LCVs and in EBV in man, suggests that the amplification of the BamHI W fragment 
occurred early in primate evolution and is an essential component of the virus. 
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Wp activation and the B cell growth transforming programme are clearly important during 
the early stages of B cell infection. However the transforming programme is not compatible 
with the establishment of a persistent latent infection in vivo as most of the genes expressed 
in latency III are targets of the host immune system. The virus must therefore down-
regulate expression of most of its latent genes to become immunologically silent, and as 
such only the EBER and BART RNAs are detectable in the PBMCs of healthy virus 
carriers (latency 0). Studies have suggested that methylation and chromatin re-modelling of 
the EBV genome are involved in transcriptional silencing (Hutchings et al., 2006). 
However at present there is no in vitro model for this latency 0 form of infection. 
 
 It would be instructive therefore, to use an animal model to study the role of the BamHI W 
repeats and Wp during primary infection and the establishment of persistent infection. 
Using an animal model, we could analyse virus transcription immediately after infection; 
samples obtained from IM patients, who are already displaying symptoms of infection, 
represent later time points of infection where the immune response has already been 
activated. Also by using our nW viruses, we could compare the virus ability to initiate the 
growth transformation programme and also the ability on establishing persistence in the 
host. There are two options of animal model systems we could possibly use. The first is the 
mouse model that partially reconstitutes the human immune system component after 
engraftment of hematopoietic progenitor cells (HPC) (Strowig et al., 2009, Ishikawa et al., 
2005). Purified virus particles could then be injected in to the humanised mice 
intraperitoneally, and samples would then be collected and analysed post infection. 
Alternatively, we could choose the rhesus macaques model using rhLCV BAC (Chen et al., 
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2005a). The identical repertoire of lytic and latent infection viral genes in the rhLCV and 
EBV genomes provides important genetic validation that rhLCV is an accurate animal 
model for EBV infection (Rivailler et al., 2002b, Wang, 2001). To use this system, we 
would need to generate the “nW” virus containing different numbers of the 3072bp motif, 
homologous to the BamHI W repeat using the rhLCV BAC system.  
 
In our in vitro model, we observed that virus required at least two copies of the BamHI W 
repeat to initiate the growth transformation programme. It should be noted that, the in vitro 
infection was carried out with high dose of virus stocks, therefore in the more complicated 
host environment and with much lower virus dose, it is even more essential for virus to 
establish the growth transformation programme to be able to establish persistence. Thus, 
virus may require more than 2 copies of BamHI W (ie. two copies of Wp) to initiate 
sufficient level of transcription and to transform the cells. In the animal model experiments, 
after infection, samples (saliva, tonsil, blood etc.) would be collected from different time 
points post infection to carefully monitor the activity of the viral growth transformation 
programme, including promoter usage, viral antigen expression at the early and later time 
points. The virus load in the host could also be used as a read-out for the efficiency of the 
virus infection. This animal model could provide us a clearer picture of the role of the 
BamHI W repeat and multiple Wp copies in the growth transformation programme in vivo 
in primary infection and persistence. 
 
From our previous experiments of using the E2KO helper virus or the 2W-LP to provide 
additional EBNA-LP, we could only marginally improve B cell transformation with the 
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impaired 2W virus. Furthermore, by coinfection with the LMP1KO helper virus, which 
provided both EBNA2 and EBNA-LP, we could improve the transformation ability to 
optimal level. Therefore, we concluded that the key function of high level Wp-initiated 
transcription was to produce sufficient level of both EBNA-LP and EBNA2 expression 
which then serves to activate Cp and other viral promoters, along with cellular promoters 
for subsequent stages of the growth transformation programme.  
 
To further test our hypothesis, it would therefore be instructive to construct a single 2W 
virus repaired for both EBNA2 and EBNA-LP expression. This could potentially be done 
in several different ways. We could repair the 2W-LP by placing the EBNA2 encoding 
cDNA downstream of the IRES sequence following the LP cDNA, or vice versa, we could 
replace the EBNA-LP cDNA downstream of the IRES in the 2W-EBNA2 virus. However it 
is likely that in using either of these approaches that the gene downstream of the IRES 
would be expressed at a lower level than the upstream gene. An alternative method would 
be to construct an entirely new construct in which we were able to express these two 
proteins independently from a single promoter using the “self-cleaving” 2A (T2A) peptide 
sequence placed between EBNA-LP and EBNA2. If our hypothesis is correct, we would 
then expect this repaired virus (2W-EBNA-LP/EBNA2) to achieve optimal transformation 
in resting B cells.  
 
 
The studies presented in this thesis provide some insight into the mechanism EBV uses to 
achieve the growth transformation programme in the quiescent environment of a resting B 
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cell. EBV initiates the growth transformation programme through the activation of a 
multimerised promoter, Wp, which is solely dependent on cellular transcription factors for 
its activation (Bell et al., 1998, Kirby et al., 2000, Tierney et al., 2000a). Transcription from 
the multiple Wp copies, which are all active immediately post-infection, produces large 
amounts of EBNA-LP and EBNA2, which activate viral and cellular promoters and drives 
the infected cell to proliferate, thus increasing the population of infected cells. Activation of 
a host immune response against the latent gene products expressed in this growth 
transforming programme will ultimately select for EBV infected cells which have down 
regulated viral expression (latency 0) and a stable virus/host balance will be established.  
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